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ABSTRACT 
 
 
P53 is a central component in most cellular stress responses and acts against cancer 
on multiple levels. It acts as a hub in the response to a range of environmental and 
intracellular stresses, such as ultraviolet radiation and other DNA-damaging agents, hyper-
proliferation and hypoxia. The p53 biological activities include cell cycle arrest, DNA-repair, 
various forms of programmed cell death (PCD) and senescence. P53 activity is under the 
control of multiple and complex regulatory mechanisms and is mediated by a large variety 
of downstream mediators. All these modulators and mediators of p53 function form a 
complex regulatory network often referred to as the p53 pathway (reviewed in Horn & 
Vousden, 2007). Through the use of classical biochemical approaches such as transfection 
studies, new players in this p53 pathway are still discovered on a regular basis. More than 
hundred are known today. A critical step in the functional characterization of these new 
putative modifiers is the assessment of their physiological relevance in vivo. To this end, the 
generation of mutant mouse lines is a vital experiment. Using such an approach the aim 
was to establish the genetic and functional relationship between some of these players and 
p53. 
One promising p53 modulator was the GTPase nucleostemin (NS). NS was shown by 
another group to be a new putative p53-interactor and is expressed preferentially in the 
nucleoli of neuronal and embryonic stem cells and several cancer cell lines (Tsai & McKay, 
2002). To assess the physiological role of NS in vivo, a NS mutant mouse line was 
generated. The mutation proved lethal around embryonic day 4, as a result of a proliferation 
defect. NS is not required to maintain pluripotency, nucleolar integrity, or survival of the 
embryonic stem cells and does not seem to play a role in ribosome biogenesis. However it 
does control the proliferation rate of stem/progenitor cells in vivo. Importantly, this 
phenotype was not rescued on a p53-deficient background. Based on these observations, it 
is concluded that NS controls proliferation of stem cells in vivo independently of p53. 
The second protein studied in the context of this thesis is Ptprv, a protein tyrosine 
phosphatase shown in our laboratory to be strongly up-regulated in Mdm4-mutant embryos 
(Martoriati et al. 2005). Indeed Ptprv basal levels are very low in unstressed cells and are 
strongly up-regulated following p53 activation and/or at high cell density. To study the role 
of Ptprv as a mediator of p53 function, Ptprv-null mice and cells were characterized. Ptprv is 
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shown to be a key mediator of p53-induced G1 cell cycle arrest but is dispensable for p53-
induced apoptosis.  
The third protein studied is Translationally Controlled Tumor Protein (TCTP), which 
functions as an anti-apoptotic protein and was shown to be (indirectly) down-regulated by 
p53 (Bommer 2004; Tuynder et al. 2002). Consistent with the latter, TCTP steady state 
protein levels were shown to dramatically decrease in irradiated primary thymocytes 
concomitantly with the onset of apoptosis. Loss of TCTP expression in mice leads to 
increased spontaneous apoptosis during embryogenesis and causes lethality at around 
E6.5-7.5. Moreover, it was demonstrated that tctp is not haplo-insufficient in the control of 
apoptosis. Based on this and data from another laboratory a model was proposed in which 
TCTP antagonizes apoptosis by inhibiting Bax function (in regulating the mitochondrial 
membrane permeability during apoptosis), thereby controlling the balance between the pro- 
and anti-apoptotic members of the Bcl2-family. 
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INTRODUCTION 
 
 
1.  The p53 protein 
P53 is a central component in most cellular stress responses and acts against cancer 
at multiple levels. Since its discovery in 1979, p53 has been studied intensively, resulting in 
over 40.000 publications on its various functions and complex regulation. P53 is of crucial 
importance in the prevention of cancer development and may provide a powerful tool for 
human therapy, possibly eliminating the need for destructive radio- or chemotherapy. Still, 
after almost thirty years of intensive research, the exact mechanisms by which p53 impedes 
cell cycle progression and suppresses tumorigenesis are far from clear. Given the 
complexity of p53 regulation it would be impossible to mention all identified p53 regulators 
and downstream mediators here. Therefore only a selection of key modulators will be 
discussed in this introduction. To provide a better context for the new putative interactors, 
some background information will also be given on nucleolar function, embryonic 
development, stem cell biology and the role of protein tyrosine phosphatases in cell 
adhesion. 
 
TABLE 1: Some stresses that activate the p53 pathway: 
Type of stress examples 
radiation UV-radiation 
 ionizing radiation 
DNA damage mismatch errors 
 single- or double strand breaks 
 shortened telomeres 
cellular deprivation hypoxia 
 glucose starvation 
 depletion of ribonucleoside triphosphates 
insufficient ribosome biogenesis   
cell spindle damage (faulty chromosome segregation)  
heat and cold shock  
altered/denatured proteins   
nitric oxide  
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1.1. The ‘classic’ p53 biological functions  
The p53 pathway is activated in response to many stress types that interfere with DNA 
replication, chromosome segregation and cell division, as well as oncogene expression 
(Table 1).  Upstream mediators detect those signals and almost immediately (in minutes to 
an hour) upregulate the concentration and activity of the p53 protein. P53 acts mainly as a 
transcription factor, activating numerous target genes (see chapter 3), but can also repress 
the expression of genes (Innocente et al. 1999; Krause et al 2000; Manni et al. 2001; Taylor 
et al.1999; Taylor et al. 2001), or act via direct protein-protein interaction. These activities 
contribute to the two best-described p53 functions, namely cell cycle arrest and induction of 
apoptosis, but can also control senescence, genetic stability, and inhibition of angiogenesis 
(Fig. 1). P53 can stop the cell cycle at the G1/S regulation point to allow for DNA repair (it 
can itself activate DNA repair proteins like p48 and p53R2), but if the damage is too 
extensive it can initiate apoptosis. Some oncogenes can also change the p53-response 
from cell cycle arrest to apoptosis. Inactivation of tumor suppressor genes retinoblastoma 
(which leads to activation of E2F-1) or APC (which activates β-catenin-TCF4) are known to 
activate p53. Alternatively, the mutational (hyper)activation of oncogenes like Myc or Ras 
also leads to p53 activation (through induction of p19 ARF). How p53 makes the choice 
between life and death is yet unknown. 
P53 regulates a large number of genes, that directly or indirectly affect other signal 
transduction pathways in the cell (reviewed in Levine et al. 2006). Some of these target-
genes are apparently transcribed in all tissues, following many different types of stress 
(p21, cyclin G, MDM2, GADD45), while others are more stress- or tissue specific (PTEN, 
TSC2). P53 induction of G1/S cell-cycle arrest is mostly attributed to the transcriptional 
upregulation of p21WAF1 and to the transcriptional repression of c-myc. The role of p53 in 
G2/M cell-cycle arrest in response to DNA damage is more complex, involving multiple 
targets that can interfere with cell cycle progression (Cyclin-B, Cdk1/cdc2, cdc25C) or the 
mitotic machinery (Topoisomerase II, B99/Gtse-1, and Map4). Cell cycle control is achieved 
through the cyclic change in cyclin-dependent kinase (Cdk) -activity. Cdk levels are mostly 
constant, but cyclins undergo a cycle of synthesis and degradation each cell cycle. Since 
Cdks only have kinase activity when bound to a cyclin, the cyclic assembly of cyclin-Cdk 
complexes results in changes in the phosphorylation of intracellular proteins that initiate or 
regulate the major events of the cell cycle, like DNA replication, mitosis, and cytokinesis. In 
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vertebrate cells there are four classes of cyclins, each specific to a certain stage of the cell 
cycle and associating with one of four Cdks: G1-cyclins (cyclin D), G1/S-cyclins (cyclin E), 
S-cyclins (cyclin A) and M-cyclins (cyclin B). Cyclin-Cdk complexes are regulated by the 
binding of Cdk inhibitor proteins (CKIs), primarily during G1 and S phase. P21 is a CKI that 
binds G1/S and S-phase Cdks. Gadd45, 14-3-3sigma and Reprimo all inhibit G2/M 
progression by inhibiting Cdk1/cdc2-cyclin B complexes (reviewed in Taylor & Stark, 2001), 
although Reprimo was not observed to bind Cdk1/cdc2 or cyclin B and its mechanism of 
action is unknown (Ohki et al. 2000). In the category of p53-target genes that interfere with 
the mitotic machinery, both Map4 and B99 associate with the microtubule network. 
Overexpression of B99 causes G2 arrest (Utrera et al., 1998), possibly by interfering with 
microtubule rearrangements that are required to enter mitosis, such as spindle formation. 
Topoisomerase II, an enzyme that creates and reseals double-strand breaks, to allow 
torsional strain to be removed from chromatin, is required during the G2/M transition to form 
highly condensed mitotic chromosomes (reviewed in Withoff et al. 1996). P53 was found to 
repress the promoter of topoisomerase II (Sandri et al. 1996; Wang et al. 1997), which 
leads to G2 cell cycle arrest (Anderson & Roberge, 1996). 
The large number of apoptotic p53-target genes can be divided in those functioning in 
the intrinsic apoptotic pathway (Bax, Noxa and Puma) and those acting through the 
extrinsic, death receptor pathway (Fas, killer/DR5). In addition to its function in 
transcriptional regulation, the p53 protein can move out of the nucleus and directly interact 
with proteins in the mitochondrial membrane. This way it can inhibit antiapoptotic Bcl-2 
proteins (Bcl-2 and Bcl-xL) and activate proapoptotic multidomain Bcl-2 proteins (Bax and 
Bak), leading to outer mitochondrial membrane permeabilization (Schuler & Green 2005), 
cytochome c release, activation of caspases and apoptosis (Murphy at al., 2004; reviewed 
in Chipuk & Green 2006).  
INTRODUCTION                                                                                                                                                               . 
 10 
p53 
activation 
p53 
regulation 
stress 
Target 
genes 
γ-IR 
DSB 
UV 
SSB 
genotoxic 
drugs 
Telomere 
erosion 
Spindle 
damage 
ATP  
depletion 
Oncogenic 
stress 
cell cycle arrest               apoptosis        metabolism enhanced
      excretion  
? 
Mdm4
NS
ARF
other E3 
 ligases 
P21/WAF1, 
14-3-3s,  
Ptprv? 
Bax, IGF-BP3, Fas, 
killer/DR5, Noxa, 
p53AIP1, Puma, 
PERP, Apaf1, 
CABC1, etc 
TCTP?
TSAP6 TIGAR 
SCO2
ATM, ATR, 
CHK2, CHK1 
MDM2 
p53 
Fig. 1: The p53 pathway is triggered by DNA-damaging stress or oncogenic signals. This 
activates several proteins upstream of p53 that can enhance the its stability (like ATM, ATR, 
CHK2, CHK1) and/or modify the activity of p53 regulators. P53 induces the transcription of its 
master regulator Mdm2, which cooperates with Mdm4 to inhibit p53 activity and cause its 
degradation. The feedback between p53 and Mdm2 is modulated by ARF, which can be 
activated by oncogenic signals. When p53 accumulates, it can induce transcription of many 
target genes, repress others and/or act via protein-protein interaction, leading to a different 
outcome depending on the cellular context and the nature of the stimulus (adapted from 
Levine et al. 2006 & The TP53 Web Site at http://p53.free.fr/p53_info/p53_Pathways.html). 
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        In unstressed cells p53 is inactivated by its negative regulator, the ubiquitin ligase 
Mdm2, an interaction that is modified by Mdmx and p19 ARF (see chapter 2.1). Upon DNA 
damage or other types of stress, the p53 protein is phosphorylated at a number of serine 
and threonine residues by two groups of protein kinases that transduce stress signals 
(Levine et al. 2006). The MAPK family kinases (JNK1-3, ERK1-2, p38 MAPK) respond to 
several types of stress, such as membrane damage, oxidative stress, osmotic- and heat 
shock. The second group (including ATR, ATM, Chk1, Chk2, DNA-PK and CAK) responds 
to several forms of DNA damage caused by genotoxic stress. This phosphorylation of p53 
disrupts its binding of Mdm2 (and p300). Other proteins, such as Pin1, then induce a 
conformational change in p53 which prevents Mdm2-binding even more. Mdm2 itself is also 
a target of p53 transcriptional activation, thereby forming a negative feedback loop that is 
the core of p53 regulation. In fact, a large number of p53-responsive genes form positive or 
negative feedback loops with the p53 pathway (p21, WIP-1, SIAH-1, PTEN, TSC-2, IGF-
BP-3, cyclin G, p73delta N, COP-1 and PIRH-2). After p53 is phosphorylated, trancriptional 
coactivators (like p300 or PCAF) acetylate p53, exposing the DNA binding domain of p53, 
allowing it to activate or repress specific genes. 
 
1.2. New p53 biological functions  
A recently discovered function of p53 that depends on its transcriptional activity is the 
regulation of respiratory and glycolytic pathways. Cancer cells down-regulate their aerobic 
respiratory activity and preferentially use glycolytic pathways to generate energy. It was 
found that p53-loss is associated with a decrease in oxygen consumption and mitochondrial 
cytochrome oxidase c activity as well as an increase in lactate (Matoba et al. 2006). Sofar 
two transcriptional targets of p53 have been shown to be involved in this process: 
Cytochrome c Oxidase 2 (SCO2) and TP53-induced glycolysis and apoptosis regulator 
(TIGAR; Matoba et al. 2006; Bensaad et al. 2006).  
Another recent discovery is the role of p53 in the 'suntan' response. The ability to tan is 
directly related to the synthesis of melanin by melanocytes, typically found in the basal layer 
of the epidermis of vertebrate skin. Melanin production requires induction of α-melanocyte-
stimulating hormone (αMSH), one of the cleavage products of pro-opiomelanocortin 
(POMC). P53 potently stimulates the POMC promoter in response to UV and consequently 
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skin pigmentation, providing a novel mechanism by which p53 protects keratinocytes from 
UV-radiation induced DNA mutations (Cui et al. 2006). Interestingly, αMSH was shown to 
have a function in nucleotide excision repair as well (Böhm et al. 2005). 
Part of the p53 response to stress is to produce secreted proteins that can 
communicate with adjacent cells, which may not be damaged themselves. P53 stimulates 
the excretion of proteins that regulate growth factors (IGF-BP3) and inhibit proteases that 
alter the extracellular matrix (PAI-1, maspin), which can lead to a block of angiogenesis 
(thrombospondin) or cell migration (review by Nakamura, 2004). The excretion of soluble 
(signaling) molecules typically follows one of two routes of cellular export. The majority of 
secreted proteins translocates via an ER/Golgi-dependent pathway, whereas a smaller 
number is secreted via exosomes. These small vesicles are formed by inward budding of 
the endosomal membrane, turning the endosome into a multivesicular body. When a 
multivesicular body fuses with the plasma membrane the exosomes are released outside 
the cell (Denzer et al. 2000). In cells undergoing stress the p53 pathway stimulates 
exosomal excretion. Possibly these exosomes can fuse with adjacent cells, which might 
affect gene expression patterns in those cells (Yu et al. 2006) or activate an immune 
response.  
 
1.3. The p53 protein structure 
The p53 locus is an 11-exon gene located on mouse chromosome 11 (in humans it is 
found on chromosome 17p13.1), and encodes for a 393 amino acid protein (Fig. 2). The 
protein contains a tetramerization domain (residues 226 to 354). The need for 
tetramerization makes p53 susceptible to dominant negative regulation, since one 
anomalous subunit can distort the whole tetramer (Eliyahu et al. 1984; Kraiss et al. 1988). 
When functioning as a transcription factor p53 binds to a double 10-amino acid consensus 
site. This process depends on the central DNA binding domain (or core domain). Other 
functional domains of p53 include the N-terminally-located transactivation domain, a 
proline-rich domain and a basic domain (also called regulatory domain). The transactivation 
and basic domains are involved in the regulation of protein stability and transactivation 
function. These regions are subjected to specific and regulatory post-translational 
modifications such as phosphorylation, acetylation, ubiquitination, neddylation, sumoylation 
and methylation (Toledo & Wahl, 2006). 
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1.4. The p53 tumor suppression function and cancer therapy 
In most human tumors p53 function is compromised either though mutations of the p53 
gene itself or aberrant expression and/or functional dysregulation of key p53-modulators 
and/or mediators (Levine, 2000). In the inherited Li-Fraumeni syndrome one of the TP53 
alleles is mutated, leading to increased cancer-susceptibility (Iwakuma et al. 2005). Most 
mutations occur in exons 4-9 encoding for the DNA binding domain of p53 (Hainaut & 
Hollstein, 2000). These missense-, contact- or conformational mutations are found in 
roughly 50% of human tumors. In keeping with the human genetic data, p53-null mice are 
viable but highly tumor prone. They all develop lymphomas and/or sarcomas only a few 
months after birth (Donehower et al. 1992; Jacks et al. 1994). Interestingly, restoration of 
p53 expression in a p53-null tumor causes it to regress (Martins et al. 2007; Ventura et al. 
2007; Xue et al. 2007), proving that established malignancies are still vulnerable to p53s 
tumor-suppressive abilities.  
To prevent p53 from interfering with normal cell function its levels and activities are 
kept in check by a network of negative regulation, which when perturbed can lead to 
cancer-formation. Under normal conditions p53 protein levels are undetectable in most 
tissue types (MacCallum et al. 1996), while p53 transcript can readily be discerned, 
indicating that the protein is subject to post-translational regulation. The proteins involved in 
this regulation will be described below. Of the 50% of tumors that are p53 wild type, almost 
Fig.2: Structure of the p53 locus and protein.  A) The mouse p53 locus situated on 
chromosome 11.  B) The p53 protein, containing a transactivation domain, proline-rich 
domain, DNA-binding domain, tetramerization domain (oligo), C-terminal basic domain and 
several nuclear import and -export signals (* and #, respectively). (adapted from the p53 
Knowledgebase; http://p53.bii.a-star.edu.sg/index.php). 
1 234 10 56 7 89 11 
A 
B 
ATG                                                                         TAA 
#
  prolin DNA-binding domain oligo trans- activation 
#
*                 *  * 
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all have mutations in such regulators, rendering the p53-pathway inactive (Vousden & Lu 
2002). It is therefore of great importance to gain insights into the molecular mechanisms 
involved in this regulation since this may lead to the discovery of new putative targets for 
cancer therapies allowing p53 reactivation (Bullock & Fersht 2001). An example of such a 
therapeutic approach is nutlin-3; Treatment with this antagonist of MDM2, a key negative 
regulator of p53, is proving successful against various cancer types (Vassilev et al. 2004). 
 
2. Regulation of p53 protein levels 
 
2.1. Key regulators 
Given the strong inhibitory effects of p53 on cell growth, it is essential to keep its 
function in check, especially during embryonic development (Vousden & Lane 2007). 
Multiple negative control mechanisms exist to oversee p53’s activity, stability and 
subcellular localization. The many modifications of the p53 protein (phosphorylation, 
ubiquitination, etc.) lead to differences in the final conformation of p53 that influence its 
protein-protein interactions, co-activator choice and affinity to target promoters, and so 
contribute to the selection of genes to induce (Vousden 2000; el-Deiry et al. 1998). The 
levels of the p53 protein are predominantly regulated by its proteolytic turn-over (it has a 
half-life of 6–20 min), regulated by ubiquitination. Ubiquitin is a small peptide that is 
attached to proteins in short chains and serves as a targeting signal for the proteasomal 
protein-degrading machinery (Ciechanover & Iwai 2004). Several enzymes are required in 
the ubiquitination process of which only the E3 ligases are substrate-specific (Chowdary et 
al. 1994; Maki et al. 1996). An E3 ubiquitin ligase shown to be of crucial importance is 
Mdm2, the master regulator of p53. Mice lacking Mdm2 exhibit early embryonic lethality, 
which is rescued on a p53-null background, demonstrating that the lethality is due to a 
failure to restrain p53 function (Jones et al. 1995; Montes de Oca Luna et al. 1995; 
Iwakuma & Lozano 2003; Moll & Petrenko, 2003). Our laboratory has provided clear genetic 
evidence for a role of Mdm2 in keeping p53 at low levels in vivo (Boetsen et al. 2006; 
Francoz et al. 2006; reviewed in Marine et al. 2006). In addition, biochemical evidence 
suggests that Mdm2 may also promote the translocation of p53 to the cytoplasm, thereby 
removing it from its site of action. Both p53 and MDM2 proteins can shuttle between the 
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nucleus and the cytoplasm which changes their activity and regulation (what factors control 
this cellular localization is unknown). Additionally the binding of MDM2 to p53 blocks the 
interaction of p53 with the transcriptional apparatus and thus may interfere with its 
transactivation ability. DNA strand breaks and other UV-induced lesions release the block 
on p53 by initiating a series of phosphorylation events that perturb the p53-MDM2 
interaction. In addition Mdm2 function is antagonized by p19ARF, a nucleolar protein which 
is expressed specifically in cells undergoing oncogenic stress (reviewed in Sherr & Weber 
2000). Clear genetic evidence indeed suggest that ARF acts upstream of p53 to regulate 
positively its activity upon for instance overexpression of the Myc oncoprotein. Like p53-KO 
mice, ARF-deficient mice are highly tumor prone (Kamijo 1997 & 1999).  
As in the case of Mdm2, depriving mice of the structural homologue Mdm4 also leads 
to embryonic lethality, which is rescued on a p53-null background (Migliorini et al. 2002; 
Parant et al. 2001; Marine & Jochemsen 2005). Mdm4 does not cause p53 degradation by 
itself, but rather acts as a co-factor for Mdm2 in this process. However recent data from our 
laboratory highlight a Mdm2-independent role for Mdm4 in the regulation of p53 
transcriptional activity as well, suggesting that these two related proteins exert non-
overlapping functions and cooperate in vivo to keep p53 in check in absence of stress 
signals (Francoz et al. 2006; reviewed in Marine et al. 2006). Mdm2, but not Mdm4, is a 
direct p53 transcriptional target, forming a negative feedback loop with p53, allowing for 
tight control (Barak et al. 1993; Wu et al. 1993). Besides the negative feedback loops, 
positive ones also occur. For example the kinase Dapk1 was shown to activate p53-
dependent apoptosis, and is itself a transcriptional target of p53 (Martoriati et al. 2005). 
Recently several putative p53- E3 ligases have been reported to be regulated by p53 
as well. For instance; Cop1 was shown to bind and ubiquitinate p53 in vitro and in vivo 
(Dornan et al. 2004). Its expression is induced following DNA-damage in a p53-dependent 
manner. Moreover, just like Mdm2, Cop1 is an ATM-substrate. This kinase plays a critical 
role in maintaining genetic stability, and mutations lead to the Ataxia-Telangiectasia 
disorder, which is also characterized by high incidence of leukemia and lymphoma in 
childhood (Lavin & Shiloh. 1997). The kinase activity of ATM increases after exposure to 
ionizing radiation (causing double-strand breaks) and can directly bind to and phosphorylate  
p53. (Banin et al.1998;  Canman et al.1998). ATM-mediated phosphorylation of Cop1 in 
response to DNA damage leads to Cop1 degradation (Dornan et al. 2006). Similar 
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biochemical evidence has been reported for another ubiquitin ligase protein, Pirh2 (Leng et 
al. 2003). However, the biological relevance of these findings is still unclear and should be 
resolved by genetic experiments. 
It becomes increasingly clear that the nucleolus, beside being a ribosome-producing 
factory, plays a key role in the stabilization/activation of p53 following stress. Rubbi and 
Milner (2003) demonstrated that DNA damage fails to stabilize p53 unless the nucleolus is 
also disrupted, while nucleolar disruption can cause p53 stabilization in the absence of DNA 
damage. Accordingly, several nucleolar proteins have been shown to physically interact 
with p53 and/or indirectly regulate p53 function. One of them is the GTPase nucleostemin. 
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2.2.  Nucleostemin is a putative p53-modulator 
2.2.1. Introduction nucleostemin 
Nucleostemin (NS) was discovered in 2002 as part of a subtractive library between rat 
neuroepithelial stem/ precursor cells and differentiated neurons (Tsai & McKay 2002). NS 
was not found in differentiated cells and the only adult tissues with high levels of NS mRNA 
are the testis and placenta (Liu et al. 2004; Sijin et al. 2004). In the mouse cerebral cortex 
NS protein is strongly expressed around embryonic day 8.5 and declines considerably after 
E10.5. NS was also found in several stem cell compartments, tumor tissues and cancer cell 
lines, suggesting a role for NS in the regulation of the proliferation of cancer cells (Table 2).  
Neuroepithelial precursors can continue to proliferate in vitro for a period of time after NS 
expression is lost. This indicates that NS downregulation may lead to cell cycle exit rather 
than occur as the consequence of cellular differentiation and cell cycle withdrawal (Tsai & 
Mckay 2002; Bernardi & Pandolfi 2003). Therefore it was suggested that NS expression is 
not simply a reflection of the proliferative state but characteristic of a multipotential state.  
 
TABLE 2: Cells and tissues expressing NS protein. 
stem cells cancer cell lines (tumor) tissue 
 p53 WT p53-mutant  
embryonic stem (ES) cells HepG2 H1299 gastric adenocarcinoma 
neuroepithelial progenitors LTEP-a-2 Saos-2 liver cancer 
bone marrow mesenchymal stem cells OS-732 SGC-7901 bladder carcinoma 
hematopoietic stem cells HeLa (low) SW480 pancreatic cancer 
 U2OS U937 esophagus squamous carcinoma 
 HEK293  benign tumor tissues 
   benign hyperplastic tissues 
 
NS knockdown in neural progenitors or U2OS-cells by siRNA led to an increased 
percentage of noncycling cells. Surprisingly, forced overexpression of wild-type NS also 
resulted in cell cycle exit or apoptosis. This phenotype was partly p53-dependent. Indeed, 
overexpression of NS GTP-fusion proteins caused an increase in apoptosis in p53-wild type 
U2OS-cells but not in p53-null Saos-2 cells.  NS was shown to interact physically with p53, 
both in GST pull-down assays and by co-immunoprecipitation of the endogenous proteins 
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(Tsai & McKay 2002). Although it is not clear from these experiments whether NS acts as a 
positive or negative regulator of p53 function, a possible function for NS could be to restrain 
p53 growth-suppressive activity in stem and cancer cells. The binding of NS to p53 in the 
nucleoplasm could cause inhibition of p53 growth-suppressive function, which would be 
released upon cell differentiation when NS is downregulated. 
 
2.2.2. Stem cells & cancer 
Stem cells are present throughout embryonic development and small pools are 
maintained in most organs of the adult organism, including the nervous system, bone 
marrow, epidermis, skeletal muscle, and liver. This “set-aside” population of cells is 
believed to be responsible for maintaining homeostasis within individual tissues in adults. 
Embryonic stem (ES) cells derived from the inner cell mass of mammalian blastocysts grow 
rapidly and infinitely in vitro by symmetrical self-renewal, producing two identical stem cell 
daughters upon division (Burdon et al. 2002). At the same time they maintain pluripotency, 
the ability to differentiate into cell types derived from all three germinal layers: ectoderm, 
mesoderm and endoderm (Evans & Kaufman 1981; Martin et al. 1981). These abilities offer 
the possibility of growing replacement organs in vitro and treating degenerative diseases 
such as Parkinson’s disease and diabetes (Smith et al. 1998), which gave rise to the 
intense interest in stem cell research. A stem cell-specific protein like NS may play an 
important role in the expansion of stem cells in culture; therefore drugs that could stimulate 
NS activity may facilitate the maintenance and propagation of these cells.  
The number of stem cells and their decision to differentiate must be tightly controlled 
during embryonic development and in the adult to avoid premature aging or tumor 
formation. Different somatic stem cells share the properties of self-renewal and multi-
developmental potential, suggesting the presence of a common cellular machinery. Stem 
cells and cancer cells have similar abilities, illustrated by the incidental development of 
tumors when ES cells are transplanted into mice. During tumor formation from differentiated 
cells a fraction was shown to revert to a stem cell-like state with unlimited self-renewal 
capacity (Beachy et al. 2004). In accordance, stem cell lines have been derived from a 
cancer known as teratocarcinoma (Hanaoka et al. 1991). The similarity of stem and cancer 
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cells makes it important to identify new stem-cell specific proteins like NS and elucidate 
their role in control of self-renewal /commitment to differentiation. 
P53 mRNA was shown to be present in the stem cell population, and its level of 
expression remained unchanged throughout differentiation. It has been suggested that ES 
cells lack the p53-dependent G1/S checkpoint and fail to undergo p53-dependent apoptosis 
in response to DNA damage although p53 is present in these cells. It was proposed that 
p53 is maintained in the cytoplasm through a yet to be defined molecular mechanism 
(Aladjem et al. 1998; Hong & Stambrook 2004; Corbet et al. 1999). Possibly NS could play 
a role in sequestering p53 away from its site of action, by transporting it to the nucleoli.  
Alternatively the binding of NS could directly inhibit p53 from binding its target genes. In 
either case downregulation of NS during differentiation would release this block and allow 
p53 to function. 
 
2.2.3. Early embryonic development 
As NS is highly expressed in stem cells and possibly involved in maintaining 
pluripotency of these cells, it can potentially be important during early embryonic 
development. This paragraph briefly describes the early stages of mouse embryonic 
development (A scheme of embryonic developmental is given in supplements 1 and 2). 
At E3.5, blastocyst embryos are composed of an outer layer of cells that form an 
epithelium, the trophoectoderm, descendants of which are restricted to generation of the 
trophoblast components of the placenta. The interior cells (inner cell mass or ICM) develop 
into pluripotent progenitors of nontrophoblast extraembryonic tissues and all fetal cell types, 
including germ cells (Papaioannou et al. 1982). Several proteins are known to be specific to 
ES-cells, including the proteins LIF, gp130, Stat3, Oct3/4 , Sox2, FoxD3 and Nanog, which 
are required to maintain pluripotency in ES cells (Niwa et al. 2000; Avilion et al. 2003; 
Hanna et al. 2002; Kafienah et al. 2006). Both transcription factors Oct4 and Sox2 are 
required for proper ICM formation, which is achieved by inhibiting trophoblast formation 
(Fig. 3). Loss of Oct4 in blastocysts leads to terminal differentiation of the inner cell mass 
into trophoblast lineages (Nichols et al. 1998), while over-expression of Oct4 causes 
differentiation into endoderm lineage (Nichols et al. 1998; Niwa et al. 2000). Clearly precise 
Oct4 dosage is required for cell fate decisions (Niwa et al. 2002). Nanog is required at a 
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slightly later stage of development, where it suppresses parietal-visceral endoderm 
formation. Ablation of Nanog also results in differentiation to endoderm-like cells (Chambers 
et al. 2005; Mitsui et al. 2003) as well as loss of self-renewal. Over-expression of Nanog 
augmented the selfrenewal capacity of ES cells in the absence of LIF (Mitsui 2003). Oct4, 
Nanog, and FoxD3 form a negative feedback loop to maintain their expression in pluripotent 
ES cells (Fig. 3; Pan et al. 2006; Chickarmane et al. 2006). Possibly NS could be part of 
this regulation loop in ES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.4. The nucleostemin protein structure 
The Mouse NS gene is located on chromosome 14 and consists of 15 exons. The 
cDNA contains an open reading frame of 1617 nucleotides, coding for a 538 amino acid 
protein of 61 kD. NS is conserved throughout evolution and found in all vertebrate species 
tested. The human homologue was isolated after estrogen-induced expression in breast 
cancer cell lines and shares about 80% identity with the mouse sequence. The protein 
contains a N-terminal basic region, a coiled-coil domain, two GTP-binding consensus motifs 
(G4 & G1), a C-terminal acidic domain and an intermediate region between the G1 motif 
and the acidic domain (Fig. 4). Additionally several nuclear localization sequences were 
Fig. 3: Signaling during early embryogenesis.  A) Model of lineage-deciding signaling; The relative 
expression of Oct4 and Cdx2 determines the formation of ICM and trophectoderm of the blastocyst, 
while a similar regulation loop between Nanog and Gata6 segregates epiblast and primitive 
endoderm within the ICM (reproduced from Wang & Dey, 2006).  B) Transcriptional network of ES-
cell genes (adapted from Chickarmane et al. 2006). 
A B
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found in the N-terminal part of NS (Tsai & McKay 2002). Although coiled coil domains are 
known to be involved in protein-protein interactions, for NS the region involved in binding 
p53 seems to be the basic domain, since deletion of this region significantly reduced p53 
binding.  
 
 
 
 
 
 
 
 
 
 
 
 
NS is a member of the YRG (YlqF Related GTPases) and TRAFAC (Translation factor-
related) family of GTPases. These proteins contain a central GTPase domain with a circular 
permutation of the G motifs compared to the canonical organization of GTPases (based on 
the small GTPase Ras), resulting in the relocation of the G4, G5, and G6 subdomains from 
the C- to the N-terminal side of the protein (Daigle et al. 2002; Leipe et al. 2002). All known 
GTPases have a conserved mechanism of action, core structure and sequence motifs. 
They are described as molecular switch proteins because the binding and hydrolysis of 
GTP results in conformational changes that make them switch between the active GTP- 
and inactive GDP-bound form. GTP binding proteins are found in all domains of life and are 
involved in essential processes such as cytoskeleton control, vesicular trafficking, 
intracellular signal transduction, cell cycle progression and protein translation (Bourne et al. 
1991; Sprang 1997; Kjeldgaard et al. 1996). Many YRG family members show functional 
conservation in relation to rRNA maturation (Reynaud et al. 2005). This is true for the 
closest family members for NS in vertebrates, Gnl2 (NGP1) and Gnl3l (Meng et al. 2006). 
Suppression of GNL3L expression leads to reduced cell growth and apoptosis (Du et al. 
2006). 
Fig. 4: Structure of the NS locus and protein. The mouse NS locus is found on 
chomosome 14. The protein contains a basic region, a coiled-coil domain (CC), two 
GTP-binding consensus motifs (G4 & G1), an intermediate region, a C-terminal acidic 
domain (A) and several nuclear localization sequences (*). (adapted from Tsai & McKay 
2002).  
ATG                  TAA 
               
1                      2        3   4   5       6                  7     8    9      10   11 12 13     14   15 
basic CC G4 acidic G1 intermediate 
*  *          *     * 
A 
B 
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2.2.5. Nucleolar function 
The nucleolus has long been known as the nuclear compartment where the rRNA-
genes reside and ribosomes are assembled. It is typically divided into 3 regions that have 
been defined by their ultrastructural appearance and by their roles in ribosome synthesis. 
These regions are 1) the fibrillar centers, which are the sites of the repeated rRNA genes; 
2) the dense fibrillar component, which surrounds the fibrillar centers and into which the 
nascent rRNA extends and some of its processing occurs; and 3) the granular component, 
where ribosome assembly steps are completed. Ribosome production starts with rRNA 
transcription and the formation of the 90S ribosomal precursor particle that separates into 
40S and 60S pre-subunits. The pre-60S ribosomes undergo a series of RNA processing 
reactions that begin in the nucleolus and finish in the cytoplasm after export of the 
ribosomes through the nuclear pore complex (Venema & Tollervey 1999; Milkereit et al. 
2001; Fatica & Tollervey 2002; Nissan et al. 2002; Tschochner & Hurt 2003). Several 
putative GTPases are known to be associated with pre-60S ribosomes on their journey from 
the nucleolus to the cytoplasm and are thought to play a role in rRNA processing and/or 
60S ribosomal subunit export (Nissan et al. 2002; Tschochner & Hurt 2003). This does not 
mean that they are just 'housekeeping' genes. Nucleolar proteins are increasingly 
recognized as possible regulators of cell growth and proliferation, either by controlling 
ribosome biosynthesis or by mediating p53 functions (Olson 2004). NS could have a similar 
dual role. Mammalian cells quickly adjust the rate of ribosome synthesis based on the 
availability of nutrients and growth-promoting mitogens. Cells that exit the division cycle and 
enter into a quiescent state greatly limit ribosome production and overall protein synthesis. 
Links between cell proliferation control and ribosome biogenesis have been demonstrated 
experimentally, but how this is ultimately coordinated remains unclear (Pardee et al. 1989; 
Eichler & Craig 1994; Du & Stillman 2002; Sulic et al. 2005).  
The nucleolus participates in the regulation of p53 in multiple ways. When cells are 
exposed to stress, MDM2 is sequestered in the nucleolus by tumor suppressors ARF and 
PML (Weber et al. 1999; Berbardi et al. 2004) and possibly ribosomal proteins L11 (Lohrum 
et al. 2003; Bhat et al. 2004) and L22 (Jin et al. 2004), which inhibits Mdm2s block on p53 
activity. ARF in turn is stabilized by nucleolar protein NPM, which also directly enhances 
p53 activity and stability, much like nucleolin (Bertwistle et al. 2004; Brady et al. 2004; 
Takagi et al. 2005; Saxena et al. 2006). As mentioned before, the study by Rubbi and 
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Milner suggests that nucleolar disruption may be a requirement for p53 activation, 
independent of DNA-damage. Many stress signals that activate p53 also cause nucleolar 
disruption, but how nucleolar disruption activates p53 is unclear. Hypothetically nucleolar 
disruption could cause the release of specific nucleolar factors that stabilize p53 in the 
nucleoplasm, possibly including the nucleolar proteins mentioned above (Olson 2004). 
Alternatively the disruption may cause p53 to exit the nucleus. Ribosomal subunits are 
transported from the nucleus to the cytoplasm by efficient cellular mechanisms and it has 
been proposed that p53 uses these same “route” for its own nuclear export (Sherr & Weber 
2000). Disruption of the nucleoli may interfere with this export mechanism, thereby 
preventing the proteasomal degradation of p53.  
 
2.2.6. Nucleostemin localization 
Electron microscopy showed that NS did not concentrate in the fibrillar centers of 
nucleoli, where the rRNA genes are situated, suggesting that it does not participate in the 
transcription or early processing of rRNA (Politz 2005). NS was mostly found in the granular 
component, where ribosomes are assembled, although a substantial part was localized in 
the peripheral regions of the nucleolus, suggesting that NS is not associated with nascent 
ribosomes. This observation therefore suggests that NS is not involved in ribosome 
synthesis. 
Small amounts of NS can also be found in the cytoplasm, especially under stress 
conditions (Huang et al. 2007; Ma et al. 2007). The exchange of molecules between 
nucleus and cytoplasm occurs through nuclear pore complexes (NPCs), either by passive 
diffusion or by active transport. Proteins exceeding 45-50 kDa need to be actively 
transported into the nucleus, and therefore require a NLS. The transport can be facilitated 
by nuclear transport receptors (NTRs) like importin-beta, which continuously shuttle 
between nucleus and cytoplasm. The NTRs bind their substrate in either cytoplasm or 
nucleus, translocate through NPCs, release their substrate and finally recycle back to their 
original compartment (Nigg et al. 1997; Gorlich et al. 1996 & 1997; Corbett et al. 1997; 
Palmeri et al. 1999; Truant et al. 1999). Like many other GTPases of the YRG-family, NS 
rapidly cycles between the nucleolus and the nucleoplasm. Most nucleolar proteins do not 
share a consensus targeting nucleolar localization signal (NoLS) and may temporally 
INTRODUCTION                                                                                                                                                               . 
 24 
associate with other subnuclear organelles, such as the Cajal bodies, paraspeckles, and 
promyelocytic leukemia (PML) nuclear bodies (Bernardi et al. 2004; Fox et al. 2002; 
Sleeman et al. 2003). Nucleolar association can be due to ribosome, chromatin or protein–
protein interaction. NS contains a NLS that prevents nucleolar accumulation, which is 
dynamically controlled by the GTP-binding domain. NS enters the nucleolus in a GTP-
bound form, mediated in part by its basic domain (without this domain the mutant protein 
diffuses to the nucleoplasm). When NS is in the GTP-unbound state, its nucleolar targeting 
ability is suppressed by the intermediate-domain, and upon dissociation of GTP in the 
nucleolus the NS protein is released into the nucleoplasm (Tsai & McKay 2005; Meng et al. 
2006 & 2007).  
The p53-regulators Mdm2, ARF, NPM and nucleolin also shuttle between the 
nucleolus, nucleoplasm and/or cytoplasm. GTP-controlled localization of some nucleolar 
proteins might indirectly affect the distribution of other proteins. NPM, for example, does not 
contain any obvious GTP binding motives, but its dynamic retention is affected by 
alterations in cellular GTP levels. NS localization is directly controlled by a GTP-binding and 
could hypothetically influence the localization of NPM and other proteins. Whether the GTP-
bound or non-GTP-bound NS represents the active form and what NS binds to in the 
nucleolus remains to be determined.  
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3. The mediators of p53 activities 
 
3.1. Key mediators 
As mentioned above, one of the best-studied p53 functions is its ability to drive 
transcriptional activation of numerous target genes that, in turn, will execute an appropriate 
response. This response is largely dictated by the type of stress activating the p53 pathway 
and also appears to be cell-context specific. In absence of stress, the p53 pathway is in an 
“off” state and only becomes fully activated when a cell is damaged. Left unchecked such a 
cell is likely to accumulate mutations and become cancerous. The p53 pathway protects the 
organism by transiently arresting the cell cycle and prompting repair or alternatively by 
killing the cell. The ability to "choose" between life and death suggests that the p53 pathway 
is able to sense whether or not recovery from DNA damage has been successful, however 
it is not clear how p53 makes this choice (Vousden & Lu 2002). It may be that different cell 
types exhibit different sensitivity to p53; Cells may simply stop dividing unless a certain 
threshold level of p53 is reached, at which point the cells undergo apoptosis. The target 
gene profiles vary greatly according to the type of the initial stimulus, its intensity and the 
cell type (Zhao et al. 2000). There are likely hundreds of physiological p53 responsive 
genes, but so far direct roles in mediating the p53 response have only been shown for a 
small group.  
p53 stimulates a host of apoptotic genes, particularly those involved in the 
mitochondrial apoptotic pathway (the intrinsic pathway) such as Bax, Noxa, Puma and 
Apaf-1, as well as genes involved in the death receptor pathway (the extrinsic pathway) 
including Killer/DR5 (a TRAIL receptor), Fas (a secreted membrane protein) and Pidd. 
Together these proteins activate caspase 8 and Bid to release cytochrome c. This then acts 
with Apaf-1 to activate caspase 9 and then 3, resulting in apoptosis. For several other p53-
regulated genes, known to be involved in apoptosis,  the mechanism of action is not clear 
(Perp, scotin, some PIGS, p53 AIP). Critical importance in vivo has only been established 
for few of these genes, including Puma and Noxa (Jeffers et al. 2003; Villunger et al. 2003). 
A more recently discovered p53-responsive gene is TSAP6 (tumor suppressor activated 
pathway 6). The transmembrane protein TSAP6 is up-regulated upon p53 induction and 
can promote different types of activities related to apoptosis, cell cycle regulation and 
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vesicular trafficking. TSAP6 overexpression selectively enhances the presence of specific 
proteins in exosomes in a dose- and time dependent manner (Amzallag et al. 2004). 
Among those p53 target genes involved in cell cycle inhibition, the most studied gene 
encodes for the cyclin-dependent kinase inhibitor (CDKI) p21/CIP/WAF1 (el-Deiry et al. 
1993). This negative cell cycle regulator binds the G1-S/CDK and S/CDK protein 
complexes, which inhibits their function in the G1/S transition of the cell cycle. Indeed p21-
null fibroblasts are defective in p53-mediated G1 arrest in response to DNA damage or 
nucleotide depletion. However, in contrast to p53-null cells, this defect is only partial. P53-
deficient MEFs divide more rapidly, reach a higher saturation density than WT cells and are 
virtually immortal (Harvey et al. 1993), whereas the fibroblasts derived from p21-null mice 
enter senescence and have a lifespan similar to WT cells (Brugarolas et al. 1995; Deng et 
al. 1995; Pantoja & Serrano 1999). In addition, p21-null cells respond to oncogenic Ras by 
accumulating p53, and by decreasing their proliferation rate (Pantoja & Serrano 1999), 
suggesting that p21 is not the only critical mediator of G1 arrest. 
Lately researchers have become increasingly convinced of the importance of non-
coding RNAs such as micro-RNAs in various cell processes. Micro-RNA expression 
patterns of tumor cells proved different compared to normal cells (Iorio et al. 2005; Volinia 
et al. 2006), and recently the miR-34 family members were identified as direct p53-targets 
(Bommer et al. 2007; Chang et al. 2007; He et al. 2007; Raver-Shapira et al. 2007; Tarasov 
et al. 2007). Expression of the 3 members of this family was induced by DNA-damage or 
oncogenic stress in a p53-dependent manner, with a magnitude comparable to that of p21. 
This induction caused the downregulation of hundreds of mRNAs, many of which are cell 
cycle regulators, and resulted in growth arrest and (mild) apoptosis. The miR-34s could 
provide the link between p53 and those proteins known to be regulated by p53 through an 
unknown mechanism (He et al. 2007).  
While many genes are involved in the p53 response, no single gene product can 
mediate its effects in full. Their expression and individual functions contribute to a 
coordinated series of events and additional contributions from other responsive genes are 
likely to be important. There are still multiple proteins in the p53 pathway that need to be 
further characterized. One such protein is Ptprv, a protein tyrosine phosphatase shown to 
be strongly up-regulated in Mdm4-mutant embryos and a mediator of p53-induced cell cycle 
inhibition (Martoriati et al. 2005). 
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3.2. Ptprv, a putative mediator of p53 
3.2.1. Ptprv 
Ptprv was first discovered in the bone and testis of rats and therefore called 
osteotesticular protein tyrosine phosphatase, or OST-PTP. The mouse ortholog was 
discovered in the epiblast of early mouse embryos, leading to the name embryonic stem-
cell phosphatase, or ESP. Rat and mouse Ptprv share 87% identity (Mauro et al. 1994) and 
are expressed in a stromal compartment of the bone marrow called the bone collar, which 
contains both multipotential mesenchymal progenitor cells and maturing osteoblasts. Ptprv 
mRNA is up-regulated in differentiating cultures and down-regulated in late stage 
mineralizing cultures. The Ptprv promoter contains potential binding sites for osteoblast-
specific transcription factors and appears to be a marker of mesenchymal potential. In 
addition to its important role during skeletogenesis (Lathrop et al. 1999; Chengalvala et al. 
2001; Maduro et al. 2002; Wheeler et al. 2002; Yunker et al. 2004; Kawaguchi et al. 2005), 
Ptprv also plays a part in spermatogenesis. Its expression appears to be tightly regulated 
during the differentiation of the germ cell to mature sperm, but while relatively few proteins 
are differentially expressed in bone, numerous protein kinases, phosphatases and nuclear 
transcription factors show differential expression during germ cell differentiation, which 
could mean that Ptprv is of less importance during this process (Mauro et al. 1994). The 
expression in ES and progenitor cells is suggestive of a role for Ptprv in the maintenance of 
pluripotency. Ptprv mRNA is down-regulated during ES cell differentiation; however it is re-
expressed in particular differentiated cell types at a later stage (Lee et al. 1996). 
 
3.2.2. Ptprv structure 
Ptprv is one of 21 genes coding for receptor protein tyrosine phosphatases (RPTPs; 
see supplement 3 for an overview; Alonso et al. 2004). Mouse Ptprv localizes to 
chromosome 1 and is composed of 35 exons (Lathrop et al. 1999). The mRNA contains a 
single open reading frame of 5065 nucleotides encoding a transmembrane PTP of 1689 
amino acid residues (molecular mass of 185 kDa). The extracellular domain of Ptprv is 
made up of 10 fibronectin type III repeats and the cytoplasmic segment contains two PTP 
domains, one of them enzymatically inactive (Fig. 5) (Lee et al. 1996). 
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3.2.3. PTPs and cancer 
 Phosphorylation of tyrosine residues is a central feature of many cellular signaling 
pathways, including those affecting apoptosis, growth, differentiation, and cell cycle 
regulation (Neel & Tonks 1997), making Ptprv a plausible candidate for driving p53-induced 
cell cycle arrest. Protein tyrosine phosphorylation is antagonistically controlled by protein 
tyrosine kinases (PTKs) and phosphatases. RPTPs family members have been implicated 
in intracellular-signal transduction by regulating the Src and JAK family kinases (Irie-Sasaki 
et al. 2001).  
Several RPTP genes have been implicated in cancer. Analysis of PTPs in colorectal 
cancers, for instance, identified inactivating mutations in PTPRF, PTPRG and PTPRT. One 
of them, PTPRT, inhibited cell proliferation in human cancer cells (Wang et al. 2004). 
Genetic inactivation of DEP-1, another RPTP frequently deleted in human cancers 
(Ruivenkamp et al. 2002), induces a vascular phenotype characterized by enlarged, 
oversized vessels with abnormally high endothelial cell proliferation (Takahashi et al. 2003). 
Overexpression of DEP-1 in mammary carcinoma cell lines and in thyroid carcinoma cells 
suppresses the transformed phenotype, so DEP1 acts as a tumor suppressor (Keane et al. 
1996; Trapasso et al. 2000). Ptprv may play a similar role in inhibiting cell proliferation and 
tumor suppression. Its 70-100 fold induction in Mdm4-mutant embryos strongly argue a 
function in the p53 suppressor pathway. 
 
Fig. 5: Structure of the Ptprv locus and protein. A) The mouse Ptprv locus on 
chromosome 1.  B) The Ptprv protein contains an extracellular domain consisting of 10 
fibronectin type III repeats (F), a transmembrane domain (T) and two  cytoplasmic PTP 
domains (PTPI and PTPII). PTPII is enzymatically inactive (adapted from Lee et al. 
1996).  
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3.2.4. RPTPs and cell-cell adhesion  
The capacity for cells to regulate proliferation in the context of cell-cell contact is 
fundamental for the organization and maintenance of specialized tissues in multicellular 
organisms. When cultured in vitro, contact inhibition causes primary cells to stop growing at 
a certain density, whereas transformed cells continue to grow. Loss of contact-inhibition is 
an important event in tumor-formation and metastasis. In vertebrates several types of cell 
junctions exist (Fig. 6). Adherens-junctions, tight junctions and desmosomes link the 
cytoskeletons of neighboring cells, whereas gap junctions are channels connecting the 
cytoplasm. Tight junctions form a virtually impermeable barrier to fluid, whereas 
desmosomes leave a wide intercellular space. Adherens junctions are composed of three 
major proteins: cadherins, β-catenin and α-catenin. The cadherins are transmembrane 
proteins that form homodimers in a calcium-dependent manner with other cadherin 
molecules on adjacent cells. The 
catenins form a complex with the 
intracellular portion of cadherin 
molecules and α-catenin was long 
believed to bind to the cadherin-β-
catenin complex and so serve as a 
bridge between the cadherins and the 
actin cytoskeleton (Harrington et al. 
2000). 
 
 
Fig. 6: Different types of cell junctions in 
mammalian cells. Adherens-junctions, tight 
junctions and desmosomes link the 
cytoskeletons of neighboring cells, whereas 
gap junctions are channels connecting the 
cytoplasm. Adherens junctions are composed 
of cadherins and catenins. The cadherins form 
homodimers with other cadherin molecules on 
adjacent cells. The catenins form a complex 
with the intracellular portion of cadherins and 
may serve as a bridge between the cadherins 
and the actin cytoskeleton (adapted from 
Alberts et al. 2002). 
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However this view has recently been challenged because a quaternary complex of 
cadherin-β-catenin-α-catenin-actin could not be found in vitro (Yamada et al. 2005). The 
importance of these cell-cell contacts is evident in cells lacking E-cadherin. E-cadherin 
downregulation decreases the strength of cellular adhesion within a tissue, resulting in an 
increase in cellular motility (Handschuh et al 1999; Vleminckx et al 1991). This can allow 
cancer cells to invade surrounding tissues. β-catenin also plays an important role. The 
majority of β-catenin associates with E-cadherin at the cell membrane, but a small fraction 
can translocate to the nucleus to activate LEF/TCF transcription factors, in response to Wnt 
signaling (Anders et al. 2006; Perez-Pinera et al. 2006). β-catenin activity leads to 
increased proliferation, which is inhibited by sequestration of the protein at adherens-
junctions. Phosphorylation of β-catenin by the serine/threonine kinase GSK-3β is known to 
trigger its degradation, perturbing adherens junction protein complexes and cell–cell 
adhesion. RPTPs like DEP-1 and Ptprv can antagonize this process and so influence both 
cell proliferation and motility, as well as play a role in contact inhibition. Compared to sparse 
cell cultures, there are many more cell junctions in dense cultures, which are made up of 
more dephosphorylated components (Pallen & Tong, 1991; Gaits, 1995). This 
dephosphorylation causes a decrease in signaling of the Src, Ras–MAPK and PI 3-kinase-
Akt pathways, resulting in inhibition of cell proliferation (Ponniah et al 1999;  Kellie et al. 
2003;  Jandt et al. 2003).  
The p53-pathway interacts with several signaling pathways (reviewed in Oren 2003). 
P53 was found to interact directly with GSK-3β, which boosts the activity of both proteins. In 
the absence of Wnt signals, GSK-3β serine-phosphorylates β-catenin, targeting it for 
degradation by the ubiquitin-proteasome system (Nakamura et al, 1998).  Only when β-
catenin is phosphorylated at two specific serine residues does the β-TrCP ubiquitin ligase 
recognize it as a substrate (Kitagawa et al, 1999; Winston et al, 1999; Wu et al, 2003) and 
will β-catenin be ubiquitinated by β-TrCP in combination with the Skp1-Cullin1 ubiquitin-
conjugating complex (Fuchs et al, 1999; Kitagawa et al, 1999; Winston et al, 1999). So by 
enhancing GSK-3β activity, p53 stimulates the degradation of β -catenin. In addition, 
hyperactive β-catenin causes activation of p53 by elevating the production of ARF, forming 
a negative feedback-loop between p53 and β-catenin. Ptprv-induction by p53 could 
theoretically add another level of regulation. The binding of β-catenin to cadherins is 
regulated by phosphorylation of three critical tyrosine residues. Phosphorylation of tyrosine 
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residue 142, 654 or 489 results in the release of β-catenin from cadherin (Ozawa & Kemler, 
1998;  Roura et al, 1999;  Rhee et al, 2002), therefore (over)expression of tyrosine kinases 
like Src, Fer, EGFR and c-Met leads to downregulation of E-cadherin-mediated cell 
adhesion (Lilien et al, 2002). To maintain β-catenin in a dephosphorylated state, several 
tyrosine phosphatases also associate with the cadherin complex  (Xu et al, 2002). If β-
catenin would prove to be a substrate of Ptprv as well, p53 activation would stimulate the 
retention of β-catenin at the plasma-membrane, that way stimulating cell adhesion and 
inhibiting β-catenin transcriptional activity in the nucleus (in addition to stimulating its 
degradation in the cytoplasm). 
  
 
 
. 
 
 
 
 
3.2.5. PTP regulation & isoforms 
Despite the similarity of Ptprv function to other RPTPs in cell adhesion, Ptprv is the 
only RPTP shown to be transcriptionally activated by p53 so far. Although the p53MH 
algorithm predicted the presence of multiple p53-binding sites in the Ptprc, Ptpre, Ptprg and 
Ptpro loci in both the mouse and human genome, induction of these genes could not be 
detected following p53 activation (experiments performed by others in the lab). It seems 
that Ptprv is the only member of this family that is regulated by p53. Interestingly, the 
mouse Ptprv cDNA contains several potential transcription factor-binding sites such as AP-
2 and NFkappaB in the 5' UTR. The Ptprv promoter also revealed many potential regulatory 
elements with relevance to gene regulation in bone (e.g. osteocalcin specific element 2; 
Morrison & Mauro 2000).  
In proliferating osteoblasts as well as the adult testis (Mauro et al. 1994; Maduro et al. 
2002) a smaller alternative 4.8-5.0-kilobase transcript of Ptprv was found, encoding an 
isoform lacking one or both of the phosphatase domains. Evidence of such PTP isoforms 
  p53      Mdm2      ARF 
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has also been reported for the RPTPβ/ζ and PTPRQ (Andersen et al. 2004). RPTPβ/ζ 
appears to have an extracellular splice variant encoding a soluble protein lacking the PTP 
domains This protein, named phosphacan, is thought to be a brain proteoglycan which 
interacts with neural CAMs and modulates neurite outgrowth (Levy et al. 1993; Maurel et al. 
1994). By analogy, the smaller transcript of Ptprv may be a soluble protein involved in 
intracellular signaling events during bone and spermatocyte formation. 
RPTPs exhibit broad structural variation in their extracellular part, but little is known 
about their ligands. Ptprv may be activated by various extracellular signals. For example 
RPTPβ/ζ is deactivated by the binding of its ligand, the cytokine pleiotrophin. RPTPβ/ζ- 
depletion leads to loss of cell–cell adhesion and can even induce a morphological 
epithelial–mesenchymal transition (Perez-Pinera et al. 2007). Interestingly, inactivation of 
RPTPβ/ζ also causes increased phosphorylation of the protein tyrosine kinase ALK 
(anaplastic lymphoma kinase). When RPTPβ/ζ is inactivated by PTN, the normally auto-
phosphorylated sites in ALK can no longer be dephosphorylated by RPTPβ/ζ, leading to 
auto-activation of ALK (Perez-Pinera et al. 2007). Of note, constitutively expressed ALK can 
form a fusion protein with NPM, which can lead to the formation anaplastic large cell 
lymphomas, possibly by reduced NPM-Mdm2 interaction, which leaves Mdm2 free to inhibit 
p53 activation. 
 
3.2.6. Ptprv & metabolism 
Although Ptprv-/- mice are viable, fertile and anatomically identical to wild-type mice 
(no skeletal abnormalities), crosses between Ptprv+/- mice never yielded more than 20% of 
Ptprv-/- pups. The perinatal lethality was higher in pups born form Ptprv-/- mothers than in 
those from Ptprv+/- mothers, indicating the lethality was caused, at least in part, by a 
humoral abnormality (Lee et al. 2007). In humans PTP family members are linked to 
diabetes and obesity, a key feature of which is insulin resistance. Several cytoplasmic and 
receptor-like PTPs have been implicated in the regulation of insulin signaling, including 
PTP1B (Andersen et al. 2004). People suffering from obesity or diabetes are known to have 
abnormal bone metabolism and show elevated PTP1B activity in skeletal muscle and 
adipose tissue. PTP1B activation causes Jak2 activation, followed by phosphorylation of 
Stat3, which then activates the transcription of target genes involved in energy homeostasis 
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(Cook et al. 2002). PTP1B knockout mice have increased insulin sensitivity and resistance 
to obesity (Elchebly et al. 1999; Zabolotny et al. 2002; Cheng et al. 2002; Klaman et al. 
2000). Similarly, mice lacking Ptprv were shown to have increased pancreatic beta-cell 
proliferation, insulin secretion, insulin sensitivity and energy expenditure, protecting them 
from obesity and glucose intolerance (Lee et al. 2007). This effect depends on γ-
carboxylation of osteocalcin, a protein known to induce cyclinD1 and insulin, since removing 
one osteocalcin allele from Ptprv-deficient mice corrects the metabolic phenotype. These 
observations show that Ptprv is capable of regulating energy metabolism through its 
regulation of bone formation and suggest that pharmacological inhibition of Ptprv could help 
people suffering from obesity and diabetes. 
 
3.3. TCTP, a putative mediator of p53 
 
3.3.1. TCTP functions 
Another protein involved in the p53 pathway as a putative downstream mediator is the 
translationally controlled tumor protein (TCTP). The protein was discovered in the early 80s 
in serum-stimulated cells and sarcoma ascites tumor cells (Thomas et al. 1981; Yenofski et 
al. 1982) and plays an important role in cell cycle progression and malignant transformation. 
TCTP is expressed in mitotically active tissues, whereas expression levels are low in 
postmitotic tissue like brain (Thiele et al. 2000). It is considerably up-regulated during the 
entry of cells into the cell cycle and in response to growth signals and cytokines. TCTP 
synthesis precedes that of transcriptionally regulated proteins, implying that TCTP 
transcripts accumulate in resting cells and can be rapidly translated into the protein when 
cells require it (hence the name). TCTP protein levels are adapted in response to a wide 
range of cellular conditions, including stress conditions such as starvation, heat shock, 
heavy metals, calcium stress or proapoptotic/cytotoxic signals (Bommer et al. 2002; Bonnet 
et al. 2000; Xu et al. 1999; Oikawa et al. 2002; Sinha et al. 2000; Gachet et al. 1999). The 
protein has been shown to have anti-apoptotic activity in cultured cells (Graidist et al. 2004; 
Li et al. 2001; Liu et al. 2005; Tuynder et al. 2002; Yang et al. 2005; Zhang et al. 2002). 
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Knock-down of TCTP by anti-sense or siRNA techniques resulted in slow growth, cell cycle 
exit and increased apoptosis (Kamath et al. 2003; Tuynder et al. 2002; Zhang et al. 2002).  
In addition TCTP was shown to have an extracellular function as a histamine release 
factor, leading to the name ‘histamine releasing factor’ (HRF; MacDonald et al. 1995). 
TCTP is excreted by erythroid, leukemic cells and bronchial epithelial cells. This process is 
partially under the control of p53, through its induction of TSAP6, which leads to exosomal 
excretion of TCTP and other proteins. TCTP is implicated in immune responses and has 
been shown to trigger the release of histamine from eosinophils, basophils and mast cells, 
as well as stimulate interleukin-4 and interleukin-8 production (Bheekha-Escura et al. 2000; 
MacDonald et al. 2001). 
 
3.3.2. TCTP, cancer & p53 
A screen for differentially expressed genes between tumor cells and their revertant 
counterparts revealed that TCTP was significantly down-regulated in cells with a 
suppressed malignant phenotype. Depletion of TCTP expression was found to cause 
reversion of transformed cells to a more normal phenotype even in the presence of wild-
type p53 (Tuynder et al. 2002 & 2004), highlighting a putative oncogenic function for TCTP. 
Consistent with this view, TCTP protein levels were significantly amplified in a variety of 
human tumor tissues (Deng et al. 2006; van de Sande et al. 2006; Chung et al. 2000). Not 
only does TCTP contribute to tumorigenesis, consistently increased levels of TCTP could 
also render cells resistant to etoposide, a drug commonly used in chemotherapy to induce 
apoptosis (Sinha et al. 2000). Interestingly, in one report p53 activation was shown to cause 
a decrease in TCTP protein levels (Tuynder et al. 2002), suggesting indirect regulation of 
TCTP by the p53 pathway. Given the many functions of TCTP, both intra- en extracellularly, 
it is clear that perturbations of TCTP levels could have various important consequences for 
cell growth and survival, making it a protein of interest for many research-groups. 
 
3.3.3. TCTP structure & expression 
The murine tctp gene is located on chromosome 14 and consists of five introns and six 
exons, preceded by strong promoter with activity comparable to viral promoters (Thiele et 
al. 1998). Sequence alignment of TCTP sequences from more than 30 different species 
                                                                                                                    INTRODUCTION 
 35 
reveals a high degree of conservation over a long period of evolution. Mammalian genomes 
contain substantial numbers of intron-less, processed TPT1 pseudogenes (13 in mice). 
Transcription of the functional gene produces two mRNAs, which differ only in the length of 
their 3-UTR (Thiele et al. 2000) and can be found in untranslated mRNP particles 
(Chitpatima et al. 1988). The encoded hydrophilic protein of 18 to 23 kDa contains a β-
stranded ‘core’ domain, tubulin-binding region and Ca2+-binding domain (Fig. 7; Gachet et 
al. 1999; Kim et al. 2000).  
 
 
 
 
 
 
 
 
 
 
 
Due to a significant similarity to the core domain of the mammalian suppressor of Sec4 
(Mss4 = Dss4 in yeast), a small chaperone reported to bind to the nucleotide-free form of 
Rab proteins, TCTP was initially grouped in one protein family with Mss4 (Thaw et al. 
2001). TCTP is ubiquitously expressed in all eukaryotic organisms and in more than 500 
tissues and cell types investigated so far, so TCTP expression is not tumor-specific. 
However expression levels vary widely, depending on the cell/tissue type (Thiele et al. 
2000) and on the developmental stage (Gnanasekar et al. 2002; Rao et al. 2002). In 
proliferating yeast (S.cerevisiae) for instance TCTP may be expressed at a 100,000 copies 
per cell, which is higher than actin with 60,000 copies per cell (Norbeck & Blomberg 1997). 
The majority of publications describe TCTP as a cytoplasmic protein, but nuclear 
localization has also been reported (Li et al. 2001). In fission yeast, the latter has been 
found to be associated with cell stress (Inoki et al. 2005). 
 
Fig. 7: Structure of the tctp locus and protein. A) The mouse tctp locus on chromosome 
14.  B) The TCTP protein contains overlapping tubulin- and Ca2+-binding regions (light- 
and dark-grey) (adapted from Bommer 2004).  
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3.3.4. Mechanism/interactions 
In mammalian cells TCTP is a tubulin-binding protein that associates with microtubules 
during most of the cell cycle, including the metaphase spindle. Overexpression of TCTP 
results in microtubule stabilization and alteration of cell morphology (Gachet et al. 1999). 
Mitotic spindle functions are regulated by several protein kinases, including the polo-like 
kinases, and during mitosis TCTP is phosphorylated by Plk1. This further implicates TCTP 
in cell cycle-related activities (Yarm et al. 2002). In yeast TCTP is translocated from the 
cytoplasm to the mitochondria upon induction of apoptosis, establishing a functional link 
between microtubules and mitochondria, which may be needed for correct localization of 
mitochondria during cell division (Rinnerthaler et al. 2006). The cell growth regulatory 
function of TCTP is related to its guanine nucleotide dissociation inhibitor (GDI) activity for 
elongation factors EF1A and EF1Bβ. During peptide elongation GTP-bound EF1A recruits 
the aminoacyl-tRNA to the programmed ribosome. Upon correct codon–anticodon 
interaction GTP hydrolysis is triggered and subsequently EF1A is reactivated by EF1Bα or 
EF1Bβ-induced GDP-GTP exchange. TCTP stabilizes the inactive GDP-bound form of 
EF1A and blocks its activation by EF1Bβ (Cans et al. 2003), thereby slowing down the 
elongation process. This was suggested to improve the efficiency of protein synthesis by 
reducing the number of mistakes made (“skipping”) and so stimulate proliferation.  Another 
important observation implicating TCTP in cell growth was recently made in Drosophila 
genetics (Hsu et al. 2007). In Drosophila as well as mammals the Ras-homolog Rheb 
activates the TOR pathway, which is required for growth and proliferation. The study shows 
that TCTP activates Rheb by its GEF activity (it replaces the GDP bound to Rheb with a 
GTP). In doing so TCTP is antagonistic to tumor-suppressor genes TSC1 and TSC2, which 
are known to negatively regulate Rheb activity in mammals. The TSC-TOR pathway is 
conserved in many eukaryotes and the function upstream of TOR places TCTP in a 
strategic position for regulating cell growth in mammals. In addition to its function in 
proliferation, TCTP has been shown to interact with several anti-apoptotic proteins. TCTP 
interacts with Bcl-XL, a protein critical role for cell survival, and stabilizes Mcl-1, a member 
of the Bcl2-family that is required for many developmental processes (Graidist et al. 2004; 
Liu et al. 2005; Zhang et al. 2002; Yang et al. 2005).  
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TCTP shows structural homology to Mss4, a protein known to interact with Rab-
proteins. Mss4 preferably associates with nucleotide-free Rabs, but also binds the GDP-
bound form. It can quickly release GDP from Rab8, but the recruitment of GTP is much less 
efficient, therefore Mss4 can be viewed as an exchange factor as well as a chaperone for 
nucleotide-free GTPases (Itzen et al. 2006). Rab GTPases are thought to play an important 
role in intracellular vesicular transport (Balch et al. 1990; Pfeffer et al. 1992; Ferro-Novick & 
Novick 1993; Simons & Zerial 1993). Active GTP-bound Rabs interact with effectors that 
make transport vesicles competent for docking and fusion with the cell membrane (Shirataki 
et al. 1993; Brennwald et al. 1994), so Mss4 can influence vesicular exocytosis by 
activating Rabs. Since TCTP is an excreted protein, it might be functionally linked to Rab-
proteins as well, despite some structural differences between TCTP and Mss4. Since TCTP 
also displays GEF-activity for Rheb (Hsu et al 2007), this seems plausible and should be 
further studied. 
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4. Aims 
 
An increasing number of proteins that either modulate and/or mediate specific p53 
activities are being identified through the use of genetic functional screens, various 
biochemical approaches or gene expression profiling. However, the physiological relevance 
of most of these putative p53 modifiers very often remains elusive. The mouse as a model 
system allows the establishment of clear genetic and functional interactions between p53 
and such molecules, as exemplified for instance by the Mdm2, Mdm4 or ARF KO studies 
(Marine et al. 2006; Kamijo et al. 1999). In this thesis three mutant mice lines will be 
described. Based on transfection studies, NS was proposed to prevent p53 activity, through 
direct physical interaction, in stem cells and cancer cells. Here a NS-deficient mouse line 
will be used to gain new insights into the physiological role of NS in stem and cancer cells, 
and in particular to assess its contribution to the regulation of the p53 pathway in vivo. Ptprv 
is a putative p53-target based on its high level of expression in Mdm4–null embryos 
(Martoriati et al. 2005). By using Ptprv-mutant mice, a possible role for Ptprv as a mediator 
of p53-biological activities and in tumor suppression will be investigated. TCTP has also 
been implicated as an important player in the p53 pathway as a putative downstream 
mediator. Again a knock-out mouse line will be used to determine the importance of this 
oncogene during embryonic development. 
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RESULTS 
 
5. Results Nucleostemin 
 
5.1. Nucleostemin expression pattern 
NS is considered a marker of stem/progenitor cells. It was first reported to be 
expressed in the developing mouse brain until E12,5, while in the adult NS was only 
detected at relatively high levels in testis and various stem cell populations (Tsai & McKay 
2002, Sawada et al. 2006, Kafienah et al. 2006, Klima et al. 2007). To further define the NS 
expression profile, specific RT-PCR, Western blotting and immunofluorescence methods 
were developed. RT-PCR analyses show that the NS mRNA is present at low levels in 
several adult tissues, including brain, kidney and skeletal muscle. Moreover, the high level 
of NS expression in testis was confirmed (Fig 8A).  
Fig 8: NS is expressed in various adult tissues. A) NS mRNA is most strongly expressed in the 
testis, but was also clearly present in the brain and kidney.  In other tissues very little NS was 
detected (RT-PCR on lysate of WT mice).  B) Low levels of NS protein could be found in all 
organs tested. C) Illustration of the difference in household genes used as loading control. 
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       After several unsuccessful attempts, finally a specific commercially available NS 
antibody (Chemicon #AB5689, #AB5691) was identified. Surprisingly, this antibody 
detected low levels of NS expression in practically all tissues (Fig 8B). During development 
NS protein is expressed very early on; At E3,5 clear NS nucleolar staining is detected in 
both the inner cell mass and the trophoblast (Fig 9A). High levels of NS were also detected 
in undifferentiated cultured ES cells, kept in a pluripotent state by addition of LIF in the 
culture medium (Fig 9A, Fig 10A+B). Induction of neuronal differentiation by addition of 
retinoic acid (ATRA) to the cultured medium (and removal of LIF) caused a significant 
decrease in NS levels, as shown by immunofluorescence and Western blot (Fig 10A+B). In 
agreement with the published data, NS expression is high in E7,5 embryos (Fig 9B), 
however, NS staining could still be detected in several regions of 3-week old brains that 
contain differentiated neurons (Fig 9C). In skin sections the strongest NS expression 
colocalized with p63, a marker of the basal cell layer (Fig 9E). So while NS is indeed 
preferentially expressed in proliferating stem/progenitor cells in vivo, it is not exclusive to 
this compartment and can be found in differentiated cells as well.  
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NS has also been reported to be expressed at high levels in a number of cancer cell 
lines. Here the high levels of NS expression reported for the U2OS osteosarcoma cell line 
were confirmed. NS was mainly found in the nucleoli of these cells and colocalized with 
NPM expression (Fig. 9D). Moreover, Ns protein expression in several hundreds of human 
primary tumors and normal tissue was examined by tissue micro-array (in collaboration with 
Maria Capra, Milan, IEO-IFOM, Italy). No consistent increase of NS expression in tumors 
was observed as compared to normal adjacent tissue. Some tumor-samples showed 
Fig 9: NS expression in stem cells, tissue and cancer cell line. A) NS protein in E3,5 embryo and B) 
ES-cells: Stem cells show strong staining in vivo and in vitro. C) Strong nucleolar staining in a E7,5 
embryo. D) NS staining in the brain (dentate gyrus) of a 21-day old pup is weak but distinguishable.  
E) Staining of NS and NPM in U2OS cells. The two proteins colocalize in the nucleoli. F) NS staining 
in adult skin colocalizes with p63 (G) in the basal layer. Magnification = 40x (E), 200x (A1), 400x (A2, 
B, C) or 600x (D).
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elevated NS-levels, but so did a few normal tissues (Table 3 + Fig. 11). Overall, NS 
expression seemed to vary between all samples, whether cancerous or normal. 
 
 
TABLE 3: NS protein levels in normal- and tumor tissues  (TMA performed at the IEO-IFOM, Italy). 
Organ Type # Positive # Low # Negative 
Bladder Primary tumor (9) 0 0 9 
  Normal bladder (5) 0 0 5 
Breast Primary tumor (24) 2 4 18 
 Normal breast (14) 3 6 5 
Colon Primary tumor (27) 4 1 22 
  Normal colon (23) 1 3 19 
CNS Primary tumor (19) 8 4 7 
Larynx Primary tumor (22) 10 4 8 
  Normal larynx (12) 10 0 2 
Lung Primary tumor (19) 1 0 18 
 Normal lung (12) 0 2 10 
Skin Primary tumor, Melanoma (20) 2 2 16 
  Normal: Nevus (11) 2 2 7 
Ovary Primary tumor (29) 9 2 18 
 Normal ovary (5) 2 3 0 
Stomach Primary tumor (14) 2 4 8 
  Normal stomach (14) 0 1 13 
Kidney Primary tumor (16) 0 0 16 
 Normal kidney (13) 0 0 13 
Prostate Primary tumor (20) 7 3 10 
  Normal prostate (16) 1 4 11 
Soft tissue Primary tumor, Sarcoma (23) 10 0 12 
Germ cell tumors Primary tumor, Seminoma (3) 0 1 2 
  Normal testis (2) 0 0 2 
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Fig 11: A tissue micro-array did not reveal a consistent increase in NS expression in tumors 
compared to normal adjacent tissue (performed by M. Capra at the IEO-IFOM, Italy). Sometimes 
stronger staining was observed in more tumor samples, but often the tumor- and corresponding 
normal tissue had similar expression levels. Sometimes NS was even higher in normal tissues. 
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Tumor 
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Fig 10: Some NS remains after differentiation. A) NS staining in LIF-maintained ES-cells and 
ATRA-differentiated neuronal type cells. B) Matching western blot. Although less apparent in 
the immunofluorescent staining, there was a clear decrease in NS protein levels upon 
differentiation. Magnification = 400x. 
NS 
 
 
vinc 
ES
 
neuron
A B
undiff    diff 
RESULTS NUCLEOSTEMIN                                                                                                                                            . 
 48 
5.2. A nucleostemin-null mutation results in early embryonic lethality 
In order to assess the physiological function of NS, it was decided to generate a NS 
mutant mouse line. To this end, an ES cell clone with a specific gene trap event in the NS 
locus was used. The gene trap vector had integrated into the intron between exons 1 and 2, 
285 base pairs downstream of exon 1 (Fig 12B). This vector (Rosaβgeo) contains a splicing 
acceptor site (SA), the β-geo selection/reporter cassette, and a transcriptional stop element. 
The mutant allele is expected to drive the expression of a fusion protein that encodes the 
first four amino acids of the NS open reading frame and the β-galactosidase reporter. The 
expression of the fusion transcript is under the control of resident NS regulatory element. 
Interestingly, ubiquitous lacZ expression in E9.5 - E15.5 heterozygous embryos indicate 
that the NS promoter is active in virtually all embryonic cells at these stages, although levels 
begin to decrease in the differentiated parts of the brain at E15.5 (Fig. 13). Evidently NS 
expression is not restricted to stem/progenitor cells.  
Fig 12: Generation of the NS-deficient mice.  A) NS locus and the RosaBetaGeo trapping vector 
used (see http://tikus.gsf.de/ggtc/info/protocols/vectors.php for more information). B) Resulting 
mutated locus.  C) PCR genotyping strategy. 
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A PCR genotyping strategy was designed to distinguish between wild type and gene trap 
alleles (Fig 12C). Mice that are heterozygous for the gene trap mutation are viable and 
fertile. Wildtype and heterozygous animals were born at the expected Mendelian ratio, 
indicating that loss of one copy of the NS gene did not cause severe developmental 
defects. However, matings between heterozygous animals produced no homozygous 
mutant offspring, indicating a recessive lethal phenotype (Table 4). Harvesting whole 
embryos between E10,5 and E17,5 also yielded no homozygous mutants, therefore earlier 
stages were examined. Most of the H/E-stained sections of E5.5 or 6.5 embryos showed 
normal morphology (Fig 14A), but 5 out of 42 deciduas were found to be empty. This 
observation suggested that the NS-null embryos die shortly after implantation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 13: NS transcription is ubiquitous during early embryonic development. 
Whole-mount LacZ staining on embryos resulting from NS+/- intercrosses. NS 
transcription is high in E9,5 embryo and declines in differentiation tissues like the 
forebrain at E15,5. 
 E9,5 +/-                E13,5 +/-                 E15,5 +/-              E15,5 +/+ 
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TABLE 4. Genotyping analysis of progeny from NS heterozygous intercrosses. 
No. of embryos 
Stage No. of litters Total +/+ +/- -/- Abnormal 
E3-3.5 13 151 NDa ND 43b (28) 43 (28) 
E3-3.5 7 60 14 30 16 (26) 16 (26) 
E5.5-7.5 11 97 ND ND ND (0) 5  (5) 
E9.5-10.5 7 45 19 26 0  (0) 0  (0) 
E12.5-13.5 6 57 17 40 0  (0) 0  (0) 
E15.5-17.5 2 14 8 6 0  (0) 0  (0) 
F2 49 342 127 215 0  (0) 0  (0) 
a ND, not determined. 
b As determined by lack of immunoreactivity to the NS antibody. 
 
 
 
At E3.5-E4.5, about 25% of embryos showed various degrees of morphological 
deterioration and were distinguishable from their littermates (Fig. 14B). PCR genotyping 
confirmed that these smaller embryos were NS-deficient embryos (Fig 14C), whereas the 
embryos with proper blastocyst morphology were either NS+/+ or +/-.  
                                                                                                 RESULTS NUCLEOSTEMIN 
 51 
The mutant embryos could also be identified by immunofluorescence, which could 
readily detect NS protein expression in cells from both ICM and trophoectoderm in wild-type 
blastocysts. In contrast, NS-mutants are not immunoreactive to the anti-NS polyclonal 
antibody (Fig. 14D). Thus, this NS gene trap mutation leads to absence of detectable levels 
of NS protein expression and results in peri-implantation lethality.  
Fig 14: NS-loss leads to early embryonic lethality. A) Absence of embryonic tissue in decidua 
resulting from NS+/- intercrosses. B) A typical litter of E,5 embryos resulting from NS+/- 
intercrosses (after superovulation). C) PCR genotyping of one litter of E3,5 embryos; The 
blastocysts were either NS wildtype or heterozygous, the smaller embryos are NS-/- mutants. 
D) NS immunostaining; The blastocyst stage-embryos were positive for NS staining, whereas 
the smaller embryos were usually NS-negative.  
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RESULTS NUCLEOSTEMIN                                                                                                                                            . 
 52 
5.3. The proliferation rate of nucleostemin-/- ES cells is reduced in vivo   
NS-mutant embryos appeared smaller than wild-type and heterozygous littermates 
(Fig. 15A+B). This could reflect a reduced number of cells in mutant embryos. To address 
this in a quantitative manner, E3-3.5 embryos from heterozygous intercrosses were 
collected, fixed immediately, stained for NS and counterstained with DAPI, so that the 
number of nuclei and their morphology could be ascertained. At E3.0, NS- embryos 
contained roughly half as many nuclei as the NS+ embryos (p<0,05), a difference that 
became more pronounced at E3,5 (p<0,001). Whereas the number of cells in NS+ embryos 
clearly increased between E3 and E3.5, the number of cells in the mutant embryos showed 
no significant difference (Fig 15B). This trend continued when E3.5 embryos were 
explanted in culture overnight. At E4,5 the NS- embryos seemed to have stopped growing 
(or died) and never hatched out of their zona pellucida, in contrast to their NS+ littermates. 
 
 
 
 
To explain this apparent difference in cell number there are two possibilities: The reduction 
can be due to increased cell death or to a reduction in proliferation ability. Apoptotic cells 
can be recognized by the nuclear condensation and fragmentation of their nucleus, but 
neither could be found in the NS mutant embryos (Fig 14D, 15A). A hallmark of apoptosis is 
the cleavage of caspase 3, which then continues to cleave many other proteins. To confirm 
n=24 n=10 n=26 n=11
+/+ or +/- -/-
Dapi 
NS 
E3,5
A B
Fig 15: NS -/- mutants have a reduced cell number.  A) NS immunostaining; Examples of NS-
positive and NS-negative E3,5 embryos. B) Count of DAPI-stained nuclei of NS-positive and 
negative embryos at E3,0 and E3,5.  
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that apoptosis was not the 
reason for the reduced cell 
numbers, the embryos were 
stained with an antibody against 
cleaved caspase 3. NS+ and 
NS- embryos showed very few 
(if any) caspase-positive cells 
(Fig 16). This implies that NS-
deficiency does not cause loss 
of cell viability.  
 
Although most of the NS 
mutant nuclei exhibited a 
regular morphology, they were 
somewhat enlarged. The 
formation of micro or macronuclei often occurs as a result of mitotic errors and is frequently 
associated with mutations in mitotic checkpoint genes or genes involved in the G2 DNA 
damage checkpoint (Uren et al. 2000; Liu et al. 2000; Takai et al. 2000; Artus et al. 2006). 
The occurrence of enlarged nuclei in NS-mutant embryos therefore suggests that NS-
deficiency is associated with a defect in mitosis. To determine the effect of the NS-/- 
mutation on the ability of the embryos to proliferate, E3,5 embryos were cultured overnight 
in the presence of BrdU. The NS+ embryos showed strong incorporation of this DNA label, 
whereas the NS-mutants incorporated very little BrdU (p<0.00001), providing evidence for a 
block in cell cycle progression (Fig 17). To narrow down the timing of this block blastocyst 
embryos were stained with an antibody against phosphorylated histone H3 (on serine 
residue 10), a specific marker of mitosis (Strahl & Allis 2000). The percentage of P-H3-
positive cells is significantly lower (P<0.05) in cells from the NS-mutants than that in either 
their wildtype or heterozygous counterparts (Fig 18), indicating that the mutant cells are not 
blocked in mitosis. Together, these observations suggest that the majority of the cells from 
NS-null blastocysts are arrested during the G1 phase of the cell cycle or at the G2/M 
boundary. For the cells with enlarged nuclei arrest at the G2/M boundary is probably most 
likely. 
NS           DAPI casp-3 cl        merge 
+/+
or 
+/-
 
 
 
 
 
-/-
Fig 16: NS-deficient embryos do not die due to increased 
apoptosis. Examples of NS-positive and NS-negative E3,5 
embryos; hardly any apoptosis was observed. 
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5.4. Possible causes for reduced proliferation 
As NS is a nucleolar protein, its depletion may result in nucleolar disruption, leading to 
reduced proliferation capacity. To test this possibility, blastocysts embryos were stained 
with antibodies directed against fibrillarin, a protein associated with the fibrillar center and 
dense fibrillar region of nucleoli. The fibrillarin staining was comparable in NS-null embryos 
and control littermates (Fig 19), indicating that NS-deficiency does not cause nucleolar 
disruption.  
 
Fig 17: NS-/- mutants show less cells in S-phase. Embryos were cultured overnight in BrdU-
containing medium. A) Immunostaining for NS and BrdU; Examples of NS-positive and NS-
negative E4,0 embryos. B) Percentage of BrdU stained nuclei of NS-positive and negative 
embryos at E4,0. 
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Fig 18: NS-/- mutants show less cells in G2/M-phase. A) Immunostaining for NS and 
phosphorylated histone 3 (P-H3); Examples of NS-positive and NS-negative E3,0 embryos. B) 
Percentage of P-H3 stained nuclei of NS-positive and negative embryos at E3,0. 
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Since NS was 
originally found in stem 
cells and was down-
regulated before final 
differentiation, it was also 
possible that NS is 
required to maintain 
pluripotency. To deter-
mine if this is the case 
blastocysts were stained 
with antibodies directed 
against Oct3/4. Strong 
Oct4 was observed in the 
NS+ as well as the NS- 
embryos (Fig 20) indica-
ting that NS is not re-
quired for pluripotency of 
the ICM.  
 
5.5. Loss of one nucleostemin allele leads to a slight decrease in proliferation 
Western blots performed using whole embryonic extracts showed that NS expression 
in heterozygous embryos is significantly reduced compared to their WT counterparts. At 
E10,5 the reduction in NS expression was roughly 50%, but as NS expression decreased 
towards the end of gestation the difference between the two genotypes became less 
pronounced (Fig 21B). A similar pattern could be observed in MEF-cells prepared from 
E13,5 embryos. Again the difference between the genotypes is apparent (Fig 22A+B). 
Importantly, NS expression decreased significantly with increased passages in both wild-
type and heterozygous cultures. MEFs in culture slowly lose their proliferation potential, 
mostly due to oxidative stress (Campisi et al. 2007), ultimately leading to senescence after 
10 to 12 population doublings. NS-expression in MEFs therefore correlates well with their 
proliferative potential. 
Fig 19: The nucleoli of NS-/- mutants seem intact. Immuno-
staining for NS and fibrillarin (a protein associated with the 
fibrillar regions of nucleoli). 
-/-
+/+
or 
+/- 
FibrillarinDapi Dapi/Fibrillarin NS
-/- 
+/+
or 
+/-
Oct4Dapi NS/Oct4 NS
Fig 20: NS-/- mutants retain pluripotency. Immunostaining for 
NS and Oct4 (a marker for pluripotent ES-cells). 
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Given the severe impact of NS-loss on cell proliferation during early embryogenesis, it 
was tested whether loss of one NS allele is sufficient to cause a decrease in MEF cell 
proliferation. To examine the growth rate of the NS+/- cells at various passages, a modified 
3T3 culturing protocol was carried out. No difference was found in proliferation rate between 
heterozygous and wildtype cultures at early passages. However from passage 4 on, the 
NS+/- cells exhibited a slight but reproducible decrease in growth rate compared to NS+/+ 
cells (Fig 23C). A growth curve of passage-4 MEFs showed a similar reduction in growth 
rate of NS+/- MEFs (Fig 23A). The NS+/- MEFs arrested before they reached the same 
density as the NS+/+ cells. Although these observations varied widely between different 
MEF-clones (compare experiments in Fig 23A & 23B), NS+/- cells appear to be haplo-
insufficient to a certain extent. 
 
 
 
E10,5                         E13,5        E17,5 
+/-    +/+    +/-    +/-     +/-    +/+ +/+                     +/- +/+            +/-
NS 
 
vinc 
A 
B
Fig 21: NS-expression is lower in NS+/- embryos compared to NS+/+ embryos. A) NS-stained 
paraffin sections of E6,5 embryos, resulting from a NS+/- intercross. The genotypes are 
unknown. B) Western blots of whole embryos at different stages. The difference in expression 
between +/+and +/- becomes less pronounced as development progresses. (vinc = vinculin). 
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A B
Fig 22: NS is expressed in low-passage MEFs, with reduced levels in NS+/- cells. A) NS 
immunostaining of passage-3 WT MEFs, prepared from E13,5 embryos.  B) Western blot of 
MEFs at different passages (3, 6 and 9; vinc = vinculin). 
0
5
10
15
20
2 3 4 5 6 7 8 9 10 11
passage
re
la
tiv
e 
gr
ow
th
+/+
+/-
0
1
2
3
4
5
6
7
8
9
10
11
0 2 4 6 8 10 12 14
days
re
le
at
iv
e 
gr
ow
th
   +/+
   +/- 0
1
2
3
4
5
6
7
8
9
10
11
0 2 4 6 8 10 12 14
days
re
le
at
iv
e 
gr
ow
th
+/+
+/-
A B
C 
Fig 23: NS+/- MEFs show a slight growth defect compared to NS+/+ cells.  A) growth curve of 
passage-4 MEFs, experiment 1. B) growth curve of passage-4 MEFs, experiment 2. C) Modified 
3T3 protocol showing cumulative increase in cell number (curve representative for several 
experiments).  
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5.6. The embryonic lethality of nucleostemin-/- mice is not p53-dependent 
Based on transfection studies indicating that NS can bind p53 and modulate its activity 
(Tsai & McKay 2002), NS-depletion is expected to lead to p53 stabilization and/or activation 
of function (Bernardi & Pandolfi 2002). The proliferation defect observed in NS-/- embryos is 
consistent with this possibility. However, indirect evidence that does not support a role for 
NS in regulating p53 levels was obtained. NS+/+ and +/- MEFs showed comparable p53 
levels (Fig 24), and p53WT and p53-/- MEFs contain similar amounts of NS (Fig 25). 
Interestingly, NS expression decreased upon UV-exposure in both genotypes (even though 
the p53-/- cells continued to grow, whereas the p53 WT cells arrested). This observation 
suggests that NS expression is downregulated in response to stress, in a p53-independent 
manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 24: No clear correlation between NS and p53 when comparing NS+/+ 
and NS+/- MEFs.  NS-levels are lower in NS+/- cells, but p53 levels are not 
significantly different.  
MEF NS +/+  #2 
MEF NS +/+  #5 
MEF NS +/-  #7 
DAPI              nucleostemin                      p53 
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To test whether the embryonic lethality associated with NS loss was p53-dependent, 
NS heterozygous mice were crossed with p53-null mice (Jacks et al. 1994). The NS-mutant 
mice were also intercrossed with mice harboring a silent p53 KI allele, which can be 
activated following Cre-mediated excision of a silencing lox-stop-lox (lsl) element (Francoz 
et al. 2006; Ventura et al. 2007). NS+/-; p53-/- were crossed with NS+/-; p53lsl/lsl so all 
animals produced harbor one p53-null allele and one p53lsl allele. These crosses did not 
result in any viable NS-/-;p53lsl/- mice (Table 5). At the blastocysts stage NS-/-; p53lsl/- 
embryos showed an abnormal morphology much like the NS-/-;p53+/+ blastocysts, while 
their NS+/+, p53 lsl/- or NS+/-,p53 lsl/- littermates looked normal (Fig 26A). NS-/- mice 
showed the same reduction in cell number on the p53-null background (p<0.05; Fig 26B). 
Evidently loss of p53 does not delay the phenotype associated with NS loss, suggesting 
that the role of NS during embryogenesis is largely p53-independent.  
Fig 25: NS-protein and mRNA levels are similar in p53 WT and p53-/- MEFs.  NS staining in 
MEFs treated with 30 J UVC; NS protein levels decrease after UV-induced DNA-damage, in 
WT as well as p53-null MEFs.
MEF WT -control 
MEF p53-control 
MEF WT -UV 24h 
MEF p53 -UV 24h 
MEF WT -UV 48h 
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TABLE 5. Genotyping analysis of progeny from NS+/-;p53-/- x NS+/-;p53 lsl/lsl crosses. 
a ND, not determined. 
b As determined by lack of immunoreactivity to the NS antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7. Nucleostemin  is evolutionary conserved between mouse and frog 
NS is conserved during evolution. Alignment of predicted NS amino acid sequences of 
several species showed high degree of similarities between the Xenopus, mouse and 
human orthologs (Fig 27) The very early embryonic lethality associated with NS-loss in the 
mouse makes it difficult to study. Xenopus laevis on the other hand is an ideally suited 
model organism to study early developmental defects. In collaboration with M. Nichane and 
E. Bellefroid from the Unit of Molecular Embryology at the Free University of Brussels 
(ULB), first the expression profile of the Xenopus laevis ortholog NSx was determined. NSx 
transcripts can be detected by RT-PCR analysis both maternally and zygotically (Fig. 28).  
No. of embryos 
Stage  No. of 
litters Total +/+ +/- -/- Abnormal 
E3-3.5 2 23 NDa ND 5b 5 
E9.5-12.5  7 53 18 35 0 0 
F2  17 81 23 58 0 0 
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Fig 26: The embryonic lethality of NS-/- mutants is not rescued on a p53-null background. A) 
NS immunostaining of E3,5 embryos, resulting from a NS+/-,p53-/- intercross. B) Count of 
DAPI-stained nuclei of NS-positive and negative embryos.  
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 hNS    (1) -------------------------------------------------- 
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----MKRPKLKKASKRMTCHKRYKIQKKVREHHRKLRKEAKKQGH--KKP 
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NLESWLNYLKKELPTVVFRASTKPKDKGK--ITKRVKAKKNAAPFRSEVC 
NLENWLNYLNKELPTVVFKASTNLKNR----KTFKIKKKK-VVPFQSKIC 
NLEKWLNYLKKEFPTVAFKSATLLKDRNM--QTFSRRRAR-IDLSRHTES 
MVEKWLQVLSAELPTVPFRCVAQIQDKSE--KKKKKKVPVSADLVTDPKC 
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VPDIENIAKSLLCDWTGAKISYHSEPPA--SQILPPYLTEDKIAEMQAGF 
VPDTEGAGRLLFNDWMGARMKYYCRPPD--SPVCQPHISREVVAAMSSGI 
VADTELAATTFLNDWTGAKLSYYSRVPE--RQGLPSYLSDAIVTELQSDV 
RPDVNAAAKRVLNDWNTGKLRYYTHPPEQGTAKEDIVVPAEVVSQFSKEF 
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          600 
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LVIDE-KEKPAKGRKRKLDEEKEKVDPSLLLEENQSLNKGIKQMQKLKKK 
 
G4 domain 
G1 domain 
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Fig 27. NS is evolutionary conserved. Amino acid sequence alignment of predicted human (hNS), mouse (mNS), chicken (cNS), 
Xenopus (XNS), zebrafish (zNS), C. elegans (ceNS) and drosophila (dNS) nucleostemin proteins. The basic, acidic, coiled-coil 
and the G4 and G1 GTP-binding domains are indicated. 
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Fig 28: Xenopus NS is expressed during early embryogenesis in 
proliferating tissues. A) RT-PCR analysis of XNS expression during 
embryogenesis (H4 = loading control histone H4). XNS is expressed both 
maternally and zygotically. B) Whole-mount in situ hybridization of xNS
expression at the indicated Nieuwkoop-Faber stages. B1,2,6: XNS 
expression is first detected at the neurula stage in the ectodermal cells of 
the sensorial layer, especially at the neural plate and prospective neural 
crest region. in B3,4,5,7: At tailbud stage, xNS is strongly expressed in 
migrating cranial neural crest cells, in the eye and in the posterior 
mesoderm. In tadpoles, XNs staining is detected in the head region (eye, 
otic vesicle) and somites. B8: Within the neural tube, XNS expression is 
restricted to the ventricular zone. (np- neural plate; nc- neural crest; sle-
sensorial layer of the ectoderm; ev- eye vesicle; s- somites; ov- otic vesicle; 
ba- branchial arches. B1+2= dorsal view, B3-5= lateral view; B6-8= 
transversal sections). 
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Whole-mount in situ hybridization shows that the entire neural plate of early neurula 
(stage 13) contains significant amounts of NS RNA, particularly around the anterior neural 
plate (Fig. 28B). Cross-sections reveal that NSx is expressed throughout the ectoderm at 
neurula stage, and is restricted to the sensorial layer. By late neurula to tadpole stage, 
strong staining is observed in the head region in the brain, cranial neural crest cells, eye 
and otic placodes (Fig.28E-F). Weaker staining is observed in the somites. Expression of 
NS in the Xenopus embryos thus correlates with sites of active cell proliferation (Saka & 
Smith 2001) and is therefore consistent with the above-described expression and function 
of NS in the mouse embryo. 
 
5.8. NSx stimulates proliferation during Xenopus embryogenesis 
Given the expression of NS in the neural plates, it was decided to determine if NSx is 
required for proper neural plate formation and neural crest development. Morpholino oligos 
(MO) were designed and shown to effectively block translation in an in vitro 
transcription/translation assay (Fig 29A). The NS and NS mismatch MOs were injected into 
single cells of two-cell stage embryos, together with β-galactosidase mRNA. This way NS 
expression is knocked down on one side of the embryo, with the other side serving as an 
internal control. Injection of the NS MOs significantly decreased the number of proliferating 
cells in the injected side as shown by immunostaining against phosphorylated histone H3, 
while NS mismatch MOs had no effect (Fig 29B+C). Moreover, NS MOs-injected neurula 
stage embryos display increased expression of Sox3, a marker of CNS progenitor cells and 
a decrease in expression of neuronal marker N-tubulin and neural crest marker FoxD3 (Fig 
29D). However, these markers could be detected at later stages of development, implying 
that NSx-depletion does not interfere with neural specification, but only slows down the 
process by decreasing cell proliferation. 
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5.9. Nucleostemin function may contribute to tumorigenesis 
In order to establish a putative role of NS in tumor development, the survival of NS+/+, 
p53lsl/lsl and NS+/-, p53lsl/lsl animals was examined. P53 deficient mice develop tumors 
between 15 and 25 weeks (Donehower et al. 1992) and only few survive past week 35 
(Hursting et al. 1994). In the present study the NS+/- mice survived significantly longer on a 
p53-deficient background than the control NS+/+ controls (log rank test: P=0,003). All 
NS+/+ mice died within 30 weeks (n=6), whereas some NS+/- animals survived past 40 
weeks (4 out of 22 mice). On average the NS heterozygotes lived 10 weeks longer than NS 
WT mice on a p53-deficient background (Fig 30). This result implies that NS depletion 
dramatically slows down in vivo tumorigenesis and therefore suggests that NS could 
become a drug target for cancer therapy. 
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Fig 30: NS function may contribute to tumorigenesis. NS+/-, 
p53lsl/lsl mice live longer than NS+/+, p53lsl/lsl controls. 
Fig 29: Xns depletion affects the pattern of cell division and the expression of neuronal and 
neural crest markers.  A) Western blot using the antibody against NS: The XNS morpholino 
inhibits translation of XNS in vitro, whereas the mismatch-MO does not.  B) Immunostaining 
using an antibody against phosphorylated histone H3 and quantification of the results. Injection 
of the XNS MO, decreases the number of mitotic cells significantly (P= 0.002). (pH3= 
phosphorylated histone 3; n= number of cases analyzed).  C) Dorsal view of embryos injected 
with xNS or mismatch MO, coinjected with LacZ as a lineage tracer. XNS MO causes an 
expansion of Sox3 staining in the neural plate and trigeminal placode area, as well as a 
reduction of neural crest cell marker Fox3D and neuronal marker N-tubulin, compared to 
embryos injected with a control mismatch MO. 
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6. Results Ptprv 
 
6.1. Ptprv is a p53-inducible gene in cultured cells and in vivo  
Since Ptprv was found to be up regulated in Mdm4-deficient embryos, which die due to 
uncontrolled p53 activity, Ptprv was hypothesized to be a new p53-inducible gene 
(Martoriati et al, 2005). To test this, Ptprv expression levels after endogenous p53 activation 
were determined in a series of cellular systems by RNAse protection assays, semi-
quantitative and quantitative RT-PCR. Ptprv mRNA was induced in response to DNA-
damage following doxorubicin treatment (Fig. 30A) or UV-irradiation (Fig. 30B) in wild type, 
but not in the p53-null embryonic stem cells. The doxorubicin-stimulated induction of Ptprv 
mRNA was concomitant with p53 protein stabilization and p21 induction in the p53 WT cells 
(Fig 30A). In addition, Ptprv mRNA was induced in wild type but not p53-null MEFs in 
response to γ-radiation (Fig. 30C) or doxorubicin treatment (Fig. 30D). These results 
demonstrate that activation of p53 leads to up-regulation of Ptprv expression. The kinetic of 
this induction is similar to that of several known p53-inducible target genes, such as p21, 
suggesting that Ptprv is a direct p53 transcriptional target. Additional experiments by others 
in our lab demonstrated the presence of a functional p53 RE element in the promoter region 
of the Ptprv gene. Sequence analysis of the murine Ptprv locus had revealed the presence 
of three conserved putative p53-binding sites (as defined by El-Deiry et al. 1992), but band 
shift assays and chromatin immunoprecipitation studies in pMTArf cells and doxorubicin-
treated ES cells revealed a specific recruitment of p53 to only one of these sites (which is 
situated roughly 800 bp upstream of exon 1). This proved that Ptprv is a direct p53-
transcription target.   
To investigate the role of Ptprv in the p53 pathway in vivo a Ptprv-deficient mouse line 
was used. This mouse line has been kindly provided to us by the Austin Smith and 
colleagues from the Institute for Stem Cell Research at the University of Edinburgh (UK). In 
this mouse line a LacZ cassette was knocked into the Ptprv locus, leading to deletion of the 
majority of the Ptprv coding sequence (Dacquin et al. 2004). Therefore the knock-in mice 
are Ptprv-null but express a β-galactosidase reporter under the control of resident Ptprv 
regulatory elements (Fig 32). These Ptprv-deficient mice are viable, fertile, show no clear 
anatomical defects and are not more tumor-prone. Whole-mount LacZ staining of 
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heterozygote E12.5 embryos under normal circumstances showed low levels of Ptprv in the 
fetal gonadal ridge and in the apical ectodermic ridge of the limb buds (Fig 33A). The Ptprv-
deficient mice were crossed with p53-null mice. After whole-body γ-irradiation of pregnant 
females the Ptprv+/-;p53+/- embryos displayed β-galactosidase activity throughout their 
body (Fig 33B), with the strongest staining observed in the branchial arches, maxillary 
areas, limb buds, and the tail. In Ptprv+/-,p53-/- no induction of the Ptprv reporter was 
observed, implying that Ptprv induction in vivo is also p53-dependent. 
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Fig. 31. Ptprv expression is p53-inducible. A) Western blot (top panel) and 
semiquantitative RT-PCR (lower panel) show levels of p53 protein and Ptprv 
mRNA in p53 WT and p53-deficient ES cells, exposed to doxorubicin (doxo).  B) 
Induction of Ptprv mRNA expression in p53 WT, but not p53-deficient ES cells, 
exposed to UVC (30 J/m2).  C) Q-PCR analysis shows the induction of expression 
of Ptrpv in γ−irradiated (10 Gy) WT MEFs, but not in p53-null MEFs. The data 
represent three independent experiments.  D) Semiquantitative RT-PCR analysis 
shows Ptprv expression in p53 WT and p53-deficient E1A-expressing MEFs, 
exposed to doxorubicin (0.2 mg/ml). β−Tub served as a normalization control. 
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6.2 Ptprv-null MEFs show increased proliferation and partially loose contact 
      inhibition 
P53-deficient MEFs are known to proliferate faster and reach higher cell density before 
arresting in culture, whereas p21-deficient MEFs do not. To determine if Ptprv-activation 
could be partly responsible for phenotype of p53-null MEFs, the growth rates and saturation 
densities of early-passage Ptprv-deficient MEFs were studied. The p53-null MEF cells grew 
more rapidly from the start, whereas the Ptprv-mutant cells started to grow faster than WT 
cells at day 5 (Fig 34).  
A B
           Ptprv+/-                            Ptprv+/+                   Ptprv+/- p53+/-              Ptprv+/- p53-/- 
γ-irradiation
WT 
 
 
mut 
1     5   10           15                 20              25              30            35
ATG       TGA
IRES-lacZ
Fig.32. Schematic representation of the WT and the targeted 
Ptprv loci. An internal ribosome entry site-LacZ casette was 
knocked in the Ptprv locus, leading to deletion of the majority of 
the Ptprv coding sequence (Dacquin et al, 2004). 
Fig 33. Ptprv induction by γ-IR. Whole-mount lacZ staining of E12.5 embryos performed in 
untreated embryos (#1) and 8h after exposure to 5Gy of γ-IR (# 2-4). (GR: gonadal ridge; LB: 
limb bud). 
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By day 9, all 
MEF- lines had 
reached saturation 
density. Ptprv -/- 
MEFs reached a 
much higher satu-
ration density than 
Ptprv WT and 
heterozygous MEFs, 
even higher than the 
p53-null MEFs.  
 
 
 
Subsequently Ptprv expression levels were compared in WT MEFs plated at very high 
density and exponentially growing MEFs. As shown in figure 35A, Ptprv mRNA levels were 
clearly higher in the confluent cultures. Importantly, Ptprv-null MEFs, but not wild-type 
MEFs, continue to proliferate to some extend at high density as assessed using BrdU 
incorporation assay (Fig 35B). Of note, Ptprv-null cells are not fully transformed since they 
do not form foci in soft agar and do undergo senescence like wild-type cells after a few 
more passages in culture. These observations suggest that genetic ablation of Ptprv results 
in increased MEFs proliferation rate and partial loss of contact inhibition but not 
immortalization. 
 
6.3 Loss of Ptprv protects against p53-induced cell cycle arrest 
The increased proliferation rate of Ptprv-null MEFs suggests that the p53-mediated 
growth suppression is impaired in those cells. Wild-type MEFs undergo a well-characterized 
arrest in G1 when treated with γ-irradiation, while p53-null MEFs fail to do so (Kastan et al. 
1992). To decipher the functional importance of Ptprv to this checkpoint, subconfluent 
asynchronously growing MEFs were γ-irradiated and the number of cells in S phase 
evaluated after 24 hrs. As indicated in figure 36A, wild-type cells show a 60% reduction in  
Fig 34. Loss of Ptprv leads to increased proliferation. Passage 2 MEFs 
of different genotypes were counted at 2-day intervals;  The number of 
cells was normalized to that 4h after plating. 
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the number of S phase cells relative to unirradiated samples averaged over several 
experiments. By contrast, both p53- and Ptprv-null cells were almost completely deficient in 
the ability to arrest in G1 (Fig. 36A). Because interpretation of these pulse-labeling results 
on asynchronous cultures is complicated by the ability of the cells to arrest in G1, G2, or M, 
the effect of irradiation was measured more precisely using synchronized cells. MEFs were 
synchronized at G0 by serum starvation (0,1% serum for 96 h), and treated with 0 or 10 Gy 
of γ-radiation. Cells were then stimulated to enter the cell cycle in the presence of BrdU by 
the addition of serum. After 24h FACS analysis revealed that only a small percentage of the 
irradiated Ptprv+/+ and +/- cells had reentered the cell cycle compared to their untreated 
counterparts (Fig. 36B). In contrast to the wild-type MEFs, p53-/- and (to a lesser extent) 
Ptprv-/- cells show a defect in G1 arrest. As p21-null cells are also significantly deficient in 
their ability to arrest in G1 in response to DNA damage (Deng et al. 1995; Brugarolas et al. 
1995), impairment of the G1 checkpoint in Ptprv-null cells may be due to an inability of 
these cells to up-regulate p21 expression. However, p53 stabilization and concomitant 
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Fig 35. Ptprv-null MEFs partially loose contact inhibition. A) RT-PCR analysis showing Ptprv 
and p21 expression in p53 wild-type and p53-deficient MEFs in sparse and dense cultures. 
Cells were seeded at 106 cells or 107 cells/10 cm dish; RNA samples were prepared from cells 
collected after one or seven days (β-tub: normalization control beta-tubulin). B)  Sparse or 
confluent MEF cultures labeled with BrdU and analyzed by FACS. Compared to WT cells more 
Ptprv-null MEFs stay in S-phase (BrdU-positive) at high density. 
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induction of p21 transcription was observed in both wild-type and Ptprv-null cells following 
DNA damage, excluding this possibility (Fig. 36C). In conclusion, these results clearly 
indicate that induction of Ptprv contributes to the p53-mediated G1 arrest response to γ–
radiation.  
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Fig 36: More Ptprv-null cells stay in S-phase after γ-IR. A) Effect of γ-IR (10 Gy) on the cell cycle 
of asynchronously growing MEFs of different genotypes. The percentage of S-phase cells is 
shown relative to the percentage of S-phase cells in untreated (UT) cultures. B) S-phase entry 
following serum stimulation and γ-IR of synchronized MEFs. The percentages of BrdU-positive 
cells immediately after starvation (Starv.), cells grown for 24 h in growth medium (UT), or cells 
that had undergone γ-IR are shown. For A and B three independent experiments were 
performed, and the mean values with standard deviations (error bars) are presented. C) 
Western analysis (top panel) and semi quantitative PCR (lower panel) in p53 WT, p53-deficient, 
and Ptprv-null MEFs after γ-IR. Induction of p21 mRNA was concomitant with p53 protein 
stabilization, and was detected in WT and in Ptprv-null cells (β-Tub = normalization control).
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6.4. Ptprv is dispensable for p53-induced apoptosis 
Aside from cell cycle arrest, p53 activation can also result in apoptosis. MEFs undergo 
p53-dependent cell cycle arrest when exposed to a DNA-damaging agent such as 
doxorubicin, unless otherwise sensitized to apoptosis by expression of the adenovirus E1A 
oncogene (Lowe et al. 1994). Notably, cells expressing E1A showed reduced induction of 
Ptprv expression by doxorubicin (Fig. 31D). Quantitative RT-PCR experiments confirmed 
the more pronounced increase in Ptprv mRNA in E1A-negative cells compared to E1A-
positive cells (27-fold vs. 2.1-fold), suggesting that Ptprv is preferentially up-regulated by 
stimuli inducing p53-mediated cell cycle arrest rather than apoptosis. 
In contrast to p53-null cells, Ptprv-deficient MEFs infected with E1A and exposed to 
doxorubicin or deprived of serum were just as sensitive to apoptosis as WT cells (Fig 
7A+B). Wildtype thymocytes are also susceptible to p53-dependent apoptosis upon DNA 
damage (Clarke et al. 1993; Lowe et al. 1993). Whereas p53-/- thymocytes were resistant 
to γ-IR, WT and Ptprv-deficient cells were equally sensitive to this treatment (Fig 7C). From 
these data it is concluded that p53-dependent apoptosis does not require Ptprv. 
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Fig 37. Ptprv is dispensable for p53-induced apoptosis. A) MEFs with the indicated genotypes 
were infected with a retrovirus expressing E1A and serum deprived. Apoptotic cells were 
measured with annexin V staining and FACS analysis in three independent experiments.  B) 
MEFs with the indicated genotypes were infected with a retrovirus expressing E1A and exposed 
to doxorubicin. Apoptotic cells were measured with annexin V staining and FACS analysis in 
three independent experiments. C) Freshly isolated mouse thymocytes were γ-irradiated (10 
Gy) and apoptosis was measured 10 h later by FACS analysis in two independent experiments. 
0
20
40
60
80
100
24h 48h
%
 a
po
pt
ot
ic
 c
el
ls WT Ptprv-/- p53-/-
0
20
40
60
80
100
24h 48h
%
 a
po
pt
ot
ic
 c
el
ls WT Ptprv-/- p53-/-
0
20
40
60
80
100
120
p53-/- Ptprv+/+ Ptprv+/- Ptprv-/-
%
 v
ia
bl
e 
ce
lls
NT IR
C 
A B
                                                                                                                                          . 
 77 
 
 
 
 
 
 
 
RESULTS 
TCTP 
                                                                                                                    . 
 78 
                                                                                                                  RESULTS TCTP 
 79 
7. Results TCTP 
 
7.1. TCTP is required for cell survival and mouse embryonic development 
In order to study the physiological function of TCTP, a tctp mutant mouse line was 
generated by Alexandra Lespagnol (PhD Thesis) with Drs. Robert Amson and Adam 
Telerman (present address: LBPA École Normale Supérieure, Cachan). To this end, the 
genomic region containing exon 3 to 5 of tctp was amplified, followed by insertion of a loxP 
site at the 5’ end and a neomycin cassette flanked by loxP sites at the 3’ end. After 
electroporation into ES-cells, selected clones showing homologous recombination were 
treated with Cre recombinase, leading to the excision of exons 3 to 5, which encode most of 
the TCTP protein.  
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Fig 38: Generation of a TCTP-deficient mouse-line. A) Representation of the 
mouse wild-type locus and the loxP sites that were inserted (by recombination) 
to generate the mutated tctp allele.  F1, R1 and R2 indicate the positions of the 
primers used to discriminate between the two tctp alleles. B)  PCR analysis on 
genomic DNA from wild type (WT), tctp heterozygous (+/-) and homozygous 
mutant (-/-) embryos, using the primers shown in A. 
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A clone with the correct deletion was used to establish a tctp mutant mouse line (Fig 
38A). A PCR-based strategy was used to genotype the offspring (Fig 38B). Heterozygous 
mice for this mutation are morphologically identical to wild-type and fertile. However, no 
viable homozygous mutant pups were born from heterozygous intercrosses, indicating a 
recessive lethal phenotype (Table 6). 
 
TABLE 6. Genotyping analysis of progeny from tctp heterozygous intercrosses 
No. of embryos Stage  No. of 
litters Total +/+ +/- -/- Abnormal 
E6,5-8,5 5 30 ND ND ND 7 
E9,0-10 2 12 2 7 3 3 
F2 16 99 29 70 0 0 
ND: not determined 
 
 
Closer inspection revealed that most homozygous embryos died between 6.5 and 9.5 
dpc (Fig 39). At E6,5 mutant embryos were slightly smaller than wild-type littermates and at 
E8,0 the mutant embryos appeared largely retarded. At this stage of development, wildtype 
and heterozygous embryos had proceeded to late head fold stage, showing head process 
development and foregut invagination (Fig 39). All mutant embryos lagged behind in 
development as E8,5 and E9,0 mutant embryos resembled wildtype E7,5 and E8,0, 
respectively. At E10,0 all mutant embryos were resorbing. To study the effect of the tctp 
mutation on cellular proliferation, expression levels of a phosphorylated form of histone H3, 
a marker of mitosis, were studied by immuno-histochemistry (IHC). Very little difference was 
seen between TCTP-mutant and control embryos (Fig 40). 
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E9,5              E8,5                              E8,0 
Fig 39: TCTP-null embryos die around E9,0. Left: TCTP WT and mutant embryos at 
E9,5; middle: Hematoxylin/eosin staining of sections of paraffin-embedded E8.5 
embryos;  right: sections of E8.0 embryos. Magnification of sections:4X.  
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WT 
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A B
Fig 40: TCTP mutant embryos die due to increased apoptosis. A) Phosphorylated histone 3 staining 
(H3P) on sections of paraffin-embedded E8,0 embryos. B) Hematoxylin/ eosin staining of E6.5 
embryos (left panels) and immuno-fluorescent TUNEL assay on  sections of the same embryos 
(right planel). Green= H3P-positive mitotic cells, red=TUNEL-positive apoptotic cells, blue= DAPI. 
Magnification:20X 
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        To determine if the lethality of tctp-mutant embryos is due to increased apoptosis, 
sections of E6.5 embryos were analyzed for DNA-fragmentation, using the TUNEL 
technique. In the TCTP-plus embryos very little apoptosis was found, only the surrounding 
membranes showed some staining, whereas extensive cell death was revealed in the 
mutant embryos (Fig 40). Together, the data indicate that TCTP is required for the survival 
and proper proliferation of cells during mouse embryonic development. 
 
7.2. TCTP heterozygosity does not cause haploinsufficiency 
TCTP is highly expressed in all tissues, but a general decrease in TCTP was observed 
in heterozygous MEFs (Fig 42A). To test whether TCTP is haplo-insufficient in the control of 
cell proliferation TCTP WT and heterozygous MEFs were used for growth experiments 
under normal culturing conditions. Growth curves performed on these passage-2 cells 
yielded no significant difference between the two genotypes (Fig 41). The p2 TCTP+/- 
MEFs proliferated at the same rate and underwent senescence similar to wild-type controls.  
 
 
 
 
 
 
 
 
 
 
 
 
Although the reduced levels of TCTP seem sufficient under normal circumstances they 
may not be when cells are stressed. To test this, MEF-cells were subjected to UVC-
radiation and doxorubicin treatment (which both cause DNA strand breaks). Trypan Blue 
exclusion assays showed that both treatments effectively caused an increase in the number 
of nonviable cells, yet the increase was equally strong in heterozygous and WT MEFs (Fig 
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Fig 41: Heterozygous MEFs show no growth defect. Growth 
curve performed on passage-2 MEFs.
                                                                                                                  RESULTS TCTP 
 83 
42D). To confirm this in another cell type, thymocytes freshly prepared from wild-type and 
heterozygous Tctp-mutants were exposed to γ-irradiation and dexamethasone treatment. In 
these cells γ-irradiation causes DNA-damage, leading to p53-dependent apoptosis (Lowe et 
al. 1993; Clarke et al. 1993), whereas glucocorticoids like dexamethasone cause apoptosis 
without damaging DNA, in a p53-independent manner. Again the treatments had a clear 
effect on the number of cells undergoing apoptosis, accompanied by a significant, dose-
dependent decrease in TCTP levels (Fig 42A), however no difference between 
heterozygotes and WT cells was shown. Consistent with the MEF-data, heterozygous 
thymocytes are not more prone to apoptosis than WT controls (Fig 42B+C). Results indicate 
that tctp is required for the survival and proper proliferation of cells during mouse embryonic 
development. Although TCTP levels are reduced in heterozygous mice, this does not cause 
haploinsufficiency in the control of cell proliferation and apoptosis. 
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Fig 42: TCTP heterozygous cells do not show increased sensitivity to stress. A) Radiation 
stress leads to TCTP reduction. TCTP protein levels determined by Western blot in tctp +/+ and 
+/- thymocytes. The cells were untreated (NT) or γ-irradiated with 5Gy or 10 Gy; γ-tub= γ-
tubulin (loading control). B) thymocytes 10h after exposure to γ-irradiation (10Gy), percentage 
of cells in pre-G1 phase, analyzed by PI-staining C) thymocytes exposed to γ-irradiation, 
percentage of apoptotic cells, analyzed by TUNEL-staining. D) MEFs exposed to UVC and 
doxo, trypan blue exclusion assay.  
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DISCUSSION 
 
 
In this thesis the mouse has been used as a model system to assess the physiological 
function of a number of putative modifiers of the p53 pathway. When possible these models 
were used to confirm a genetic and functional link between these molecules and p53. One 
putative upstream modulator of p53 levels and function was studied as well as two putative 
downstream effectors. The findings will be discussed separately in three different sections. 
 
 
 
8. Discussion nucleostemin 
 
8.1. Nucleostemin controls stem/progenitor cell proliferation 
NS was discovered in rat neuronal stem cells (Tsai & McKay 2002) and detected in 
several types of adult stem cell populations as well as embryonic stem cells. Consistent 
with this finding, NS protein is highly expressed in the ICM of E3.5 blastocyst embryos, the 
site of mouse pluripotent stem cells in vivo. The protein was previously used to distinguish 
between undifferentiated and differentiated thyroid cells (Hoshi et al. 2007) and was 
suggested to be a marker of multipotential CNS stem cells (Tsai & McKay 2002). In 
contrast, a later study showed that NS could not serve as a neural stem cell marker (Cai et 
al. 2004) or as a marker of skin stem cells (Lacina et al. 2006). In the present study NS was 
detected in almost all adult mouse tissues, at both the mRNA and protein level, although 
the expression in testis was significantly higher compared to other tissues. In the Xenopus 
embryo, NS was most strongly expressed at sites of intense cell proliferation, for example 
the population of cranial neural crest cells, a population of proliferative, migratory, tissue-
invasive stem cells (Bellmeyer et al. 2003). The low amount of NS detected in adult mouse 
tissues could be due to a small stem cell population present in these tissues. It has been 
estimated that whole bone marrow stromal cell preparations contain primitive stem cells at a 
frequency of 1:10,000 to 1:100,000 (Digirolamo et al. 1999; Pittenger et al. 1999; Jiang et 
al. 2002). Although these cells express NS at high levels, it is not enough to explain the 
relatively high amount detected in the bone marrow, therefore NS was suggested to be 
associated with the more abundant population of committed progenitor cells (Kafienah et al. 
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2005). NS is not required for the maintenance of pluripotency, as NS-/- blastocyst embryos 
retain expression of Oct-4, a marker of pluripotent stem cells in vivo. 
Even some committed cell types have been shown to express NS, for instance 
proliferating T-lymphocytes or fibroblasts (Fan et al. 2006). NS protein is readily detectable 
in early passage MEFs, but not at later passages when cells become senescent. In some 
species committed cells can revert to an earlier multipotential state. A recent study on newt 
lens regeneration showed an accumulation of NS in epithelial cells two days before cell 
cycle re-entry (Maki et al. 2007). The two-day delay between NS accumulation and cell 
cycle re-entry could mean that NS is involved in the de-differentiation process, although the 
state of differentiation in these two days was not monitored. This observation of NS 
activation in de-differentiation is interesting, since it might theoretically play a role in the 
transformation of regular tumor cells into cancer stem cells.  
In addition to stem/progenitor cells, NS is found in cancer cell lines. Therefore NS 
expression was examined in a large panel of human primary tumors and normal matching 
samples using a tissue micro-array approach. Surprisingly the results showed no consistent 
difference in NS expression between tumor and normal tissues. More recently, high NS 
expression was reported in several malignant, benign and hyperplastic tumor tissues (Liu et 
al. 2004). On the other hand, different renal tumors showed varying NS expression levels, 
no different from the matching normal tissues (Fan et al. 2006). The fact that NS-expression 
is not consistently high in all tumor samples could be due to the difference in the 
differentiation state or the oncogenic mutations/cellular events that initiated tumor formation. 
Depending on the affected molecular mechanisms, some cancerous cells would require NS 
to start or maintain proliferation, whereas others could do without it. In summary, NS 
expression is not exclusive to stem/progenitor- and cancer cells, but appears closely 
associated with cellular proliferation potential, regardless of the cell of origin. NS expression 
is high in undifferentiated cells but it is not required for the maintenance of pluripotency.  
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8.2. Nucleostemin requirement in growth and development 
The crucial importance of NS during embryogenesis was demonstrated by our 
observation that NS-/- mouse embryos die very early. Unlike Oct-4 or Nanog-deficiency, 
NS-loss does not lead to differentiation into trophoblast or endoderm lineage, but lack of 
BrdU incorporation of the NS-deficient E3,5 embryos suggests that they fail to enter S-
phase. This also explains why several different attempts to generate NS-/- ES cells proved 
unsuccessful. In Xenopus embryos NS was expressed from the two-cell stage on, yet the 
result of NS knockdown only became apparent during gastrulation. This difference may be 
due to the relatively long presence of maternal mRNA in Xenopus. In mice embryos 90% of 
maternal mRNA is already degraded in 2-cell embryos (Paynton et al. 1988; Schultz 1993), 
while in Xenopus these maternal transcripts only start to degrade after the mid-blastula 
transition (Duval 1990). Therefore maternal NS protein may allow the injected Xenopus 
embryos to develop normally until gastrula stage. After that the depletion of NS protein 
levels resulted in proliferation defects of the neural progenitor cells. Together the data 
suggest an important evolutionary conserved role for NS in the control of cell cycle 
progression.  
NS+/– mice develop apparently normally and are fertile despite reduced NS 
expression levels, suggesting that these animals are capable of either up-regulating the 
expression of the remaining wild-type NS allele or functioning at a 50% reduced NS level 
under physiological conditions. The difference in NS expression between NS+/+ en NS+/- 
embryos became less obvious as NS expression decreased during development. In order 
to rescue the phenotype of the NS-/- mice and further examine the impact of NS loss Zhu 
and colleagues (2006) created a transgenic mouse line using a BAC containing the Ns 
gene including the 5’-regulatory region (so that expression is under the control of the 
endogenous regulatory system). Crossing these BAC transgenic mice with the NS KO 
rescued the lethality of NS-deficient embryos in a dose dependent manner. Most embryos 
survived until E10,5, but at E12,5 the ones with lowest transgenic expression levels had 
died. The ones with higher expression showed no apparent phenotype, except for the 
occurrence of cardiac defects. The NS-/-TG mice with highest transgenic expression 
survived until adulthood, much like the NS+/- mice that also show reduced NS levels 
compared to the wild type.  
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NS is vital for ES-cell proliferation and is likely to be for many stem cells/progenitors 
during early embryonic development. At later stages it is apparently required for proper 
cardiac formation, but it would be interesting to see if NS is critical in all (adult) tissues. A 
conditional knockout mouse model could be used to determine if differentiated cells are 
affected by NS-depletion, and more importantly, if the various stem cell compartments can 
survive in the absence of NS. 
 
MEF cells showed a decrease in NS-levels upon passage, which is consistent with the 
reduction in NS mRNA levels observed in hMSCs in long term cultures (Sawada et al. 
2006). MEFs heterozygote for NS show a roughly 50% decrease in NS expression. This 
difference led to a small difference in growth rate compared to wildtype cells and a slight 
delay of the onset of senescence. ES-cells heterozygote for NS also seemed to have a 
growth disadvantage. So although 50% of the normal amount of NS is sufficient to allow for 
normal embryonic development, it does limit the proliferation ability of MEF or ES- cells in 
vitro. In the study of Zhu and colleagues (2006) this difference was shown only at 
intermediate passages. They showed reduced proliferation in NS+/- MEFs between 
passages 5 and 7, which was accompanied by an increased percentage of senescent and 
apoptotic cells. A model was proposed whereby cells could proliferate normally when NS-
levels were above a certain threshold, which would be the case at early passages for both 
genotypes. At later passages NS levels would fall below this threshold for NS+/- cells but 
not for WT cells, leading to the difference in proliferation, until finally the NS-levels in WT 
cells fall below the threshold as well and both genotypes senesce one passage later. This 
model seems to describe well the dependence on NS for normal development and 
proliferation. Heterozygous cells have a growth disadvantage when cultured ex vivo. It will 
therefore be of interest to study their growth potential and ability to survive in response to 
stress such as DNA-damage. A preliminary experiment showed no difference in the 
percentage of apoptotic cells between low-passage NS heterozygous and wildtype MEFs in 
response to UV-C exposure, suggesting that NS is not haplo-insufficient in apoptotic cell 
death. 
The decrease in proliferation observed upon RNAi knockdown of NS is consistent with 
several, but not all previous studies. In osteosarcoma cell line (U2OS) NS knockdown 
resulted in a decrease in cycling cells (Tsai & McKay 2002). In HeLa cells a similar 
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decrease was observed, as well as decreased tumorigenicity in vivo (Sijin et al. 2004), 
strongly supporting the role of NS as a positive regulator of growth. The link between NS 
and proliferation however is not absolute. A small percentage of U2OS-cells remained in 
the cycle after NS had become undetectable (Tsai & McKay 2002). Similarly knockdown of 
NS abolished the increase in proliferation caused by FGF-2 in bone marrow stromal cells 
(BMSCs), but did not stop these cells from dividing at a basal level. Moreover, RNAi 
knockdown of NS in unstimulated BMSCs had no effect on growth (Kafienah et al. 2006). 
This implies that although NS is indispensable in ES-cells, further differentiated cells can 
proliferate in the absence of NS. As lowering NS levels resulted in decreased proliferation, 
an increase could be expected to stimulate growth. Early experiments showed size 
augmentation and nuclei multiplication upon NS overexpression, but no growth rate 
increase (Han et al. 2005), or even a decrease in proliferation and an increase in apoptotic 
cells (Tsai & McKay 2002). This may have been due to excessive overexpression, which is 
supported by the finding that overexpression of NS GTP-mutants resulted in distortion of 
the nucleoli (Tsai & McKay 2002). Loading the cells with non-physiological levels of NS can 
activate stress-responses and ultimately cause cell cycle arrest or apoptosis (for link with 
p53, see below). Later experiments confirmed this; In both stable U2OS cell lines and MEFs 
prepared from NS+/+TG embryos low overexpression resulted in a clear growth advantage 
over the wild-type cells, whereas high overexpression lines displayed a slower growth rate. 
In the high-expressing transgenic MEFs the reduced growth rate eventually turned into a 
growth advantage at late passages, consistent with the model mentioned before (Zhu et al. 
2006): High exogenous expression will lead to decreased cell growth when endogenous NS 
expression is already high (low-passage MEFs), while the same dose of exogenous NS can 
prove favorable for cell proliferation and longevity in late-passage cultures where NS 
expression is low. 
 
8.3. Nucleostemin function & the nucleolus 
The most obvious function of a nucleolar protein would be a contribution to ribosome 
biogenesis and/or rRNA processing. Early studies highlighted the existence of cross-talks 
between ribosome biogenesis and cell cycle progression (Baserga et al. 1965 ; Singer & 
Johnston 1982). Several of the circularly mutated GTPase family members have been 
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shown to localize to the nucleolus and participate in the processing of the nucleolar pre-
rRNA, ribosomal assembly and nucleolar/nuclear export, including human Ngp-1 and yeast 
Nug1p, Grnp1 and Nug2p/Nog2p (Racevskis et al. 1996; Bassler et al. 2001; Saveanu et al. 
2001). Deletion of Grn1p, the yeast homologue of NS, resulted in a severe growth defect in 
S. pombe. This was explained by a reduction in mature rRNA species, accumulation of the 
35S pre-rRNA transcript and failure to export the ribosomal protein Rpl25a from the 
nucleolus (Du et al. 2006). Gnl3l is the closest homologue of NS in vertebrates, bearing 
39% similarity to NS in mice (Yasumoto et al. 2007). GNL3L is required for proliferation and 
mutations affecting normal GNL3L localization disrupted nucleolar stability and integrity (Du 
et al. 2006; Olson et al. 2004). Although structurally similar, NS and GNL3L are expressed 
in different tissues and GNL3L expression in mice is 4 times higher than NS expression 
(Yasumoto et al. 2007), which suggests a more basic role for GNL3L in cell maintenance. 
Indeed GNL3L was able to complement the rRNA processing- and ribosomal export-
functions of Grn1p in fission yeast, while NS failed to rescue the Grnp1 loss-of-function 
phenotype, implying that NS does not play a role in ribosome biogenesis (Du et al. 2006). 
This is consistent with the high-resolution electron spectroscopic imaging analysis that 
showed NS was localized in the ribosome-sparse regions of the nucleolus (Politz et al. 
2005) and the apparently unperturbed nucleolar integrity observed by immunostaining for 
the nucleolar marker proteins UBF, fibrillarin, and NPM, both in NS-deficient embryos and 
NS-depleted cells.  
A homologue of NS that might have a similar role during embryogenesis is the testis-
specific gene 118 (TSG118). Unlike GNL3L it does not display significant sequence 
homology to NS, but the amino acid compositions are closely related, sharing all structural 
features (Grasberg et al. 2005). The nucleolar TSG118 is downregulated upon induction of 
differentiation and mimics the distribution of NS, meaning that it is expressed in the adult 
testis as well as in stem cells and cancer cell lines (Grasberg et al. 2005). However the 
biological consequences of varying TSG118 expression have not been studied yet. 
 
The fact that its localization can be controlled by GTP makes NS prone to regulation 
by signaling cascades. It is plausible that GTP/GDP exchange factors in the nucleoplasm 
and the nucleolus are responsible for transmitting signals to NS, although the identity of the 
exchange factors for NS is not known. GNL3L distribution was found to be regulated by 
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interacting with the nuclear transport receptor importin-beta (Rao et al. 2006). It would be 
interesting to learn if a similar mechanism exists for nuclear import of NS. Because of its 
function in ribosome processing the nucleolar retention of GNL3L may be due to a direct 
interaction with RNA, possibly requiring bound GTP, but this does not seem likely for NS 
given its distinct localization to virtually rRNA-free regions of the nucleolus. Depletion of 
intracellular GTP levels results in reduced nucleolar accumulation of both NS and GNL3L 
(Tsai & McKay 2005; Rao et al. 2006), which implies that GTP-binding targets these 
proteins to the nucleolus. Some caution may be in place here since it was recently 
suggested that GTP depletion affects nucleolar protein localization through its effect on 
rRNA synthesis, possibly due to limitation of GTP as substrate for Pol I activity. This 
nucleolar disruption results in an efflux of nucleolar proteins into the nucleoplasm (Huang et 
al. 2007). In this scenario NS would exit the nucleolus regardless of its GTP-status. 
Nevertheless, GTP-binding is still required for long-term nucleolar engagement of NS (Tsai 
& McKay 2005; Meng et al. 2006). It is still unknown whether NS exerts its function in the 
nucleolus or whether its retention in the nucleolus is a means of regulating NS 
concentration in the nucleoplasm, and related to that, whether GTP-bound or non-GTP-
bound NS represents the active form. The regulation of NS function by GTP makes it an 
attractive target for small molecules that would mimic or compete for GTP binding. Clearly 
identifying the active form of NS would a crucial step in the development of such therapeutic 
molecules. 
 
8.4. Nucleostemin & p53 
A few experiments were performed to determine if NS is a downstream target of the 
p53-pathway. SiRNA knockdown of p53 did not affect the level of NS in U2OS cells (Ma & 
Pederson 2007), which is not surprising since these cancer cells have found ways to cope 
with low p53-levels. However increasing p53 levels, either by UV-radiation or 
overexpression of ARF, did result in a decrease in NS levels in U2OS cells (Ma & Pederson 
2007). The observation that p53-induction by ARF in unstressed cells can reduce NS levels 
suggests that NS may indeed be a downstream target of the p53 pathway. 
One way in which NS may exert its growth-supportive function is through negative 
regulation of the p53 pathway. NS was shown to exist in a protein complex with p53, and 
DISCUSSION NUCLEOSTEMIN                                                                                                                                      . 
 94 
GST pull-down experiments showed it could directly bind p53 (Tsai & McKay 2002). NS 
might therefore affect p53 localization or function via direct interaction with the p53 protein, 
or alternatively NS may affect the nucleolar retention and function of its modulators. 
Nucleolar disruption was also shown to lead to p53 activation (Rubbi & Milner 2003), but 
since NS-depletion did not seem to affect nucleolar integrity, an alternative way of p53 
regulation would seem more likely, possibly as a modulator of p53 itself. Recent reports on 
the interaction between NS and p53 are not consistent. A siRNA-treatment resulting in 60% 
knockdown of NS led to a threefold elevation of p53, accompanied by increased levels of 
MDM2 (Ma & Pederson 2007). NS knockdown caused a significant decrease in the 
proliferation in U2OS cells but not in p53-null Saos-2 cells. Moreover, knocking down p53 in 
addition to NS in U2OS cells abolished the growth defect, providing evidence that cell cycle 
arrest induced by depletion of NS is dependent on the p53 pathway (Ma & Pederson 2007).  
The data collected in primary cells show a different picture: NS-expressing NSCs 
contained the same amount of p53 as differentiated neurons that have little to no NS (Tsai 
& McKay 2002). Similarly, NS+/- MEFs displaying a 50% reduction in NS levels compared 
to wildtype MEFs showed no significant changes in p53 amount, although they did display a 
proliferation disadvantage (Zhu et al. 2006). It is possible that different cell types show 
different sensitivity to NS depletion and that 50% reduction is not sufficient to stabilize p53 
in MEFs. Possibly because these cells are adapted to low NS-levels, whereas for cancer 
cell lines like U2OS the sudden decrease in NS may cause disruption of the nucleoli, p53 
induction and apoptosis before the cells can adapt. Most importantly, loss of p53 does not 
rescue the embryonic lethality associated with NS inactivation. The double knockout E3 
embryos are distinguishable from their NS positive p53-null littermates, suggesting that loss 
of p53 does not even partly rescue NS-deficiency. These data argue for a p53-independent 
function of NS in the control of cell proliferation, which is crucial during embryonic 
development.  
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8.5. Possible nucleostemin mechanisms 
Recently a comparative screen was carried out between normal and NS silenced Hela 
cells (Liu et al. 2006). This yielded 200 differentially expressed genes, mostly related to 
cancer pathogenesis, cell death, cell growth and proliferation. Both p53 and c-myc 
pathways were implicated to directly or indirectly interact with NS to control the proliferation 
and differentiation switch in cancer cells. C-myc functions are necessary and sufficient for 
the entry of most cells into the DNA synthetic (S) phase of the cell cycle (Eilers et al. 1989; 
de Alboran et al. 2001; Trumpp et al. 2001) and when apoptotic regulators are lost, c-myc 
can induce transformation. In normal cells c-myc activation triggers the apoptotic program 
both directly and by triggering the ARF–Mdm2–p53 pathway (Askew et al. 1991; Evan et al. 
1992). C-myc-null ES-cells exhibit reduced growth potential and impairment in their ability to 
form tumors in immune-compromised mice (Baudino et al. 2002). C-myc plays a key role 
during embryonic development and even though c-myc-null mice survive significantly longer 
than NS-null embryos (up to E10,5; Davis et al. 1993), inhibition of the c-myc pathway may 
contribute to the phenotype of NS-null mice. Hypothetically NS could even act upstream of 
c-myc, but in any case the link between NS and c-myc needs to be investigated further. 
To date, the proteins that NS has been found to interact with are not directly implicated 
in the p53 or c-myc pathways. One of them, an isoform of human protein phosphatase-2 
regulatory subunit B (PPP2R5A) was found to bind NS directly during a yeast two-hybrid 
assay (Yang et al. 2005). PPP2R5A is one of the four major Ser/Thr phosphatases, and 
plays an important role in the negative control of cell growth and cell cycle progress. 
Possibly NS could inhibit PPP2R5A function by altering its conformation, or by sequestering 
the enzyme away from its targets (by transportation of PPP2R5A to the nucleolus). The 
interaction was shown to take place in the cytoplasm, which is the normal site for PPP2R5A 
activity (Martens et al. 2004; McCright et al. 1995 & 1996), but little to none NS is found 
there. It would be interesting to determine the functional relevance of this interaction.  
Another protein able to bind NS directly is RSL1D1, a gene known to be 
downregulated upon cellular senescence, and overexpressed in human trophoblast cells 
and non-small-cell lung cancer (Meng et al. 2006). RSL1D1 colocalizes with NS in the 
nucleolus and binds it at the domains required for nucleolar targeting/retention. Treatment 
with RSL1D1-specific siRNA did not affect the total protein level of NS, but did decrease the 
amount of NS in the nucleolus. Interestingly, the nucleolar p53-regulator NPM 
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(nucleophosmin) was also displaced from the nucleolus, suggesting that either RSL1D1 
regulates the nucleolar distribution of NPM directly, or that it affects NPM localization 
through NS. RSL1D1 was unable to interact with a NS GTP-mutant, implying that the 
interaction is GTP-regulated (Meng et al. 2006). As such RSL1D1 could serve as a docking 
protein, retaining NS in the nucleolus when it is GTP-bound. 
A third protein recently discovered in a protein-complex with NS is telomeric repeat 
factor 1 (TRF1; Zhu 2006). Telomeres play a critical role in maintaining genomic stability 
and their length is maintained within a narrow range by the telomerase complex. This 
ribonucleoprotein is composed of a template RNA sequence (TERC), telomerase reverse 
transcriptase (TERT) and several chaperones. Telomerase activity is regulated by a six-
protein complex (telosome or shelterin) bound along the telomeric tract, one of which is 
TRF1. This protein both mechanically protects the telomere and inhibits telomere elongation 
in a length-dependent manner. This way TRF1 helps protect dividing cells from telomere 
attrition, a process known to play a role in ageing and cancer formation. Interestingly, 
deletion of TRF1 causes early embryonic lethality (E5-6), suggesting that TRF1 has an 
essential function in early embryogenesis as well (Karlseder et al. 2003). NS was found in 
complexes with TRF1 in vivo when TRF1 was not associated with the telomeres. 
Overexpression of NS in HEK293-cells led to accelerated TRF1 protein degradation and NS 
was proposed to stimulate proliferation by reducing the telomerase-inhibition of TRF1. The 
authors did not report an effect of this TRF1-inhibition on telomere length. Interestingly, 
another paper suggested that TRF1 can be inhibited by c-myc, which does result in 
telomere elongation (Kim & Chen 2007). This again links NS with the c-myc pathway. 
NS seems to be involved in two pathways controlling cancer formation and in this 
thesis a first indication was found for a role of NS in tumorigenesis: NS+/- mice on a p53-
deficient background survive significantly longer before succumbing to cancer than NS+/+ 
mice, suggesting that the loss of one NS-allele slows down tumor-formation or growth. The 
putative oncogenic function of NS should be further investigated, for instance by 
transferring the NS mutation into another tumor prone background like the Eµ-myc, Eµ-Ras 
or K5-SOS-F transgenic mouse line. A conditional knockout mouse model would also be 
useful in this context. Primary cells derived from these mice could be co-infected with 
oncogene- and Cre-expressing viruses to determine if NS-/- cells will grow in the presence 
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of these oncogenes, and if NS-loss would affect the (double) oncogene-induced 
transformation of these cells. If so, NS would be a potential target for chemotherapy. 
 
8.6. Summary & future experiments nucleostemin 
NS is expressed at low levels in nearly all tissues. Although it is preferentially expressed in 
proliferative cells like stem/progenitor- and cancer cells, it is not a reliable marker for those 
cell types.  NS is vital for ES-cell proliferation and is likely to be for many stem 
cells/progenitors during early embryonic development. A conditional knockout mouse model 
could be used to determine if differentiated cells are affected by NS-depletion and if the 
various stem cell compartments can survive in the absence of NS. Due to its regulation by 
GTP, NS has potential for regulation by many signaling pathways. It also makes NS a 
potential target for small molecule drugs that would mimic or compete for GTP binding, but 
first it will have to be determined whether the (nucleolar) GTP-bound NS or (nuclear) non-
GTP-bound NS represents the active form. The putative oncogenic function of NS should 
be further investigated by transferring the NS mutation into another tumor prone 
background. Differential expression upon NS-depletion links NS-function to both the p53 
and c-myc pathways. It seems plausible that there are p53-dependent and -independent 
roles of NS in cell proliferation. NS is indispensable during embryonic development, 
whether p53 is present or not, and different levels of NS-expression often do not correlate 
with (inverse) p53 levels. The only real evidence for p53-dependence so far comes from 
knockdown studies in cancer cell lines, which do not always respond the same way primary 
cells do. Even so, the NS-p53 interaction may be important during cellular stress, at which 
time NS may regulate the localization and function of proteins participating in the regulation 
of p53 activity. Further attention should be given to possible interaction with p53 regulators 
known to localize to the nucleoli, like ARF and NPM, in order to determine at which level NS 
could antagonize p53 function. NS is probably not involved in ribosome assembly, given its 
failure to complement the function of its homologue Gnrp1. The molecular basis for the 
requirement of NS for cell cycle progression remains unclear, even after the discovery of 
some new protein interactions (see Fig 43 for an overview). The relevance of the interaction 
with PPP2RA has yet to be determined and little is known about the putative NS-regulator 
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RSL1D1. The interaction with TRF1 is potentially interesting, given the importance of 
telomeres in proliferation and the link with c-myc, and should be examined further.   
 
Fig. 43: Overview of different putative NS interactions. Protein phosphatase-2 regulatory subunit 
B (PPP2R5A) plays an important role in the negative control of cell growth and cell cycle 
progress. NS could inhibit PPP2R5A function by altering its conformation, or by sequestering the 
enzyme away from its targets. RSL1D1, a nucleolar protein associated with lung cancer, could 
serve as a docking protein for NS, keeping the GTP-bound form of NS in the nucleolus. NS 
binds telomeric repeat factor TRF1 when it is not associated with the telomeres. NS causes 
TRF1 degradation and may prevent it from binding the telomeres, thereby possibly reducing the 
telomerase-inhibition by TRF1. TRF1 is also inhibited by c-myc, which causes telomere 
elongation. NS is implicated in the c-myc pathway, but the mechanism is yet unknown. 
Likewise, the interaction between p53 and NS still needs to be elucidated. (Nu = nucleus, No = 
nucleolus, Telo. = telomerase). 
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9. Discussion Ptprv 
 
9.1. Ptprv a key downstream mediator of p53-mediated cell cycle arrest 
Micro array-based gene expression profile analysis performed in our laboratory had 
identified Ptprv as a putative p53-inducible gene (Martoriati et al. 2002). In this follow up 
study, Ptprv is demonstrated to be induced in a p53-dependent manner following DNA 
damage in vitro and in vivo. A similar response was found after ARF-dependent stabilization 
of p53 and after expression of oncogenic Ras. The constitutive basal level of Ptprv 
expression was reported to be very low in most adult tissues (Dacquin et al. 2004). 
Ptprv/LacZ reporter mice showed expression only in the fetal gonadal ridge and the 
ectodermal ridge of the limb buds of E12,5 embryos. After γ-irradiation Ptprv was strongly 
expressed throughout the whole body of p53 WT embryos, whereas on a p53-deficient 
background no lacZ induction was found following γ-irradiation. Even the basal levels of 
Ptprv were lower in p53-null mice. Ptprv WT cells subjected to p53-activating factors in vitro 
and in vivo (intestinal epithelia) showed a strong reduction in proliferation, whereas Ptprv 
mutants were mostly unaffected, suggesting a key role for Ptprv as a mediator of p53-
induced cell cycle arrest in vivo. In all settings tested the induction of Ptprv expression was 
exceptionally high compared to other p53-induced genes. Based on these observations, 
Ptprv can be used as a sensitive marker of p53 activation, and the Ptprv/LacZ mouse model 
described in the “Results” section as a new valuable tool for monitoring p53 transcriptional 
activity in vivo. 
 
Ptprv is only poorly induced in response to apoptotic stimuli or when cells are 
sensitized to death by oncogenes, such as E1A. Ptprv expression was also not induced by 
oxidative stress (H2O2-treatment; experiment performed by others). This poor induction 
suggests that Ptprv is not required for p53-mediated cell death. Consistently, Ptprv was 
shown to be dispensable for p53-mediated apoptosis but necessary for efficient p53-
dependent cell cycle arrest in response to DNA damage. The molecular basis for the 
selective induction of the Ptprv promoter by p53 is currently unknown, but this observation 
makes this promoter unique and therefore worth studying further.  
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The function of Ptprv described here is very similar to that of p21 in p53-dependent G1 
checkpoint control, which has long been established (Brugarolas et al. 1995; Deng et al. 
1995). The biological consequences of Ptprv loss and p21 deficiency in MEF cells are 
virtually identical. Both cell types grow faster and to higher saturation densities than control 
cells, and both are compromised in their G1 cell cycle checkpoint following γ-IR. Ptprv and 
p21-null MEFs both enter replicative senescence only slightly later than WT cells and show 
cell cycle arrest in response to oncogenic Ras (Pantoja & Serrano 1999). Importantly, p21 
induction is still observed in Ptprv-null cells following DNA damage. Thus, Ptprv and p21 
appear to function via independent mechanisms. Loss of either p21 or Ptprv does not fully 
recapitulate the G1 checkpoint defects observed in cells lacking p53. 
 
9.2. Ptprv, contact-inhibition & cancer 
Ptprv expression is induced at high cell densities as exemplified by the striking 
increase in lacZ expression in Ptprv/LacZ heterozygous MEFs at confluence. This increase 
is partly p53-independent since some induction of Ptprv was also detected in p53-/- dense 
cultures. Importantly, Ptprv levels reached in WT cells were much higher than those 
observed in p53-null dense cultures. Possibly p53 influences cell-cell interaction through 
Ptprv, which might explain why p53-null MEFs grow to higher cell densities than wild-type 
cells. Indeed Ptprv-null cells show less contact inhibition, leading to the formation of a 
multilayer that eventually detached from the culture dish. This observation suggests a role 
for Ptprv in tumor suppression as loss of contact inhibition may be an important step in 
cancer formation. The molecular mechanism through which increased Ptprv expression 
inhibits cell proliferation remains to be elucidated. Ptprv is part of the RPTP family, a family 
of trans-membrane proteins often localized at sites of cell-cell contact where they associate 
with catenin and (indirectly) cadherins. RPTP signaling is often coupled to cell contact 
formation and several RPTPs, including RPTPm, DEP-1, RPTPk, and RPTPl were found to 
regulate the tyrosine phosphorylation level of catenins (Fuchs et al. 1996; Cheng et al. 
1997; Zondag et al. 2000; Holsinger et al. 2002). Catenins can promote cell growth by 
inducing the transcription of genes involved in proliferation and cancer progression 
(reviewed in Ben-Ze’ev et al. 2000). Several RPTPs are implicated in contact inhibition. It 
was shown that cells harvested at high density contain on 8 to 10-fold higher membrane 
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protein-tyrosine-phosphatase activity than cells harvested at low or medium densities 
(Pallen & Tong 1991; Gaits et al. 1995), which leads to cell cycle arrest. The levels of 
RPTPk and RPTPm and DEP-1 (density-enhanced protein-tyrosine phosphatase-1) are 
significantly increased at higher cell density and DEP-1 expression indeed results in 
reduced proliferation at high density (Gebbink et al. 1995; Fuchs et al. 1996; Ostman et al. 
1994; Kellie et al. 2003). DEP-1 overexpression causes a relocation of cadherins and β-
catenin from distinct cell adhesion areas to a diffuse distribution throughout the cell 
membrane, leading to loss of stable focal adhesions. DEP-1 is also a negative regulator of 
cell-substratum contacts, motility and chemotaxis in fibroblasts, which may be related to the 
function of DEP-1 as tumor suppressor (Kellie et al. 2003; Jandt et al. 2003).  
 
Several reports support the role of RPTPs in tumor suppression, often by inhibiting 
activation of Erk1/2, Ras and Src kinase (van Inzen et al. 1996; Meng et al. 2000; Anders et 
al. 2006; Perez-Pinera et al. 2007; Kovalenko et al. 2000). The identification of Ptprv as a 
key downstream p53 target suggests that it might be required for tumor suppression by p53. 
Treatment of mouse skin with the DMBA induces benign squamous cell papillomas, nearly 
100% of which have activated Hras (Quintanilla et al. 1986). DMBA treatment causes a 
strong induction of Ptprv expression in the hyperplastic epidermis and in the majority of the 
epithelial tumor cells. Importantly, Ptprv-null mice developed more benign papillomas than 
WT mice when exposed to this carcinogen (experiments performed by others in the lab). 
The observation that Ptprv-null mice are more prone to DMBA-induced tumor formation 
than WT mice suggests that mutated Ras cooperates with Ptprv loss to accelerate tumor 
formation in vivo. p21-deficient mice also display increased tumour formation after exposure 
to carcinogens (Weinberg et al. 1999), yet neither mutant recapitulates the phenotype of 
p53-null mice (Kemp et al. 1993). DMBA-treated p53-null animals primarily develop invasive 
skin carcinomas (Kemp et al. 1993). In contrast, only few DMBA-treated Ptrpv-null mice 
developed aggressive (and eventually lethal) tumors, but those were aggressive 
lymphomas infiltrating the thymus, lymph nodes, and vital organs.  
 
 
DISCUSSION PTPRV                                                                                                                                                       . 
 104
9.3. No human Ptprv ortholog? 
A recent study suggests that Ptprv has no functional ortholog in the human genome. 
Human chromosome 1 was predicted to contain a human ortholog of Ptprv, sharing 75% 
identity with the mouse sequence (Andersen et al. 2004). However, this locus was only 
sparsely covered by fragmentary sequences, making the prediction less convincing. 
Cloning of a human Ptprv cDNA fragments obtained from p53-induced transcripts revealed 
the presence of several stop codons and mutations in the open reading frame, expected to 
result in a truncated protein lacking critical residues necessary for tyrosine phosphatase 
activity (Cousin et al. 2004). In silico analysis also predicted a Ptprv-like fragment at 
chromosome 9, but this transcript was already predicted to harbor several stop codons and 
was classified as a pseudogene (Andersen et al. 2004). It should be noted, however, that 
the human Ptprv transcripts were isolated from two human cancer cell lines harboring wild-
type p53, which may have accumulated mutations in the Ptprv gene as a means to allow 
their expansion in vitro.  
 
9.4. Summary & Future experiments Ptprv 
Ptprv expression was reported to be very low in most adult tissues, but is strongly 
upregulated upon DNA-damage in p53-positive cells. Ptprv is dispensable for p53-mediated 
apoptosis, but induction of Ptprv contributes to the p53-mediated G1 arrest in response to 
stress. A good way to assess the importance of its contribution to p53 signalling would be to 
overexpress Ptprv in p53-deficient cells. This would demonstrate whether cell cycle arrest 
can be achieved by Ptprv alone, or if activation of other p53-targets is required. Ptprv 
expression is induced at high cell densities, an effect that is partly p53-independent. Ptprv-
null cells show less contact inhibition, suggesting a role for Ptprv in tumor suppression. 
Indeed Ptprv-null mice developed more benign papillomas after DMBA treatment . Ptprv 
function is similar to that of p21, yet p21-induction is still observed in Ptprv-null cells. Ptprv 
and p21 are likely to activate non-overlapping pathways, both contributing to the full p53- 
dependent response, although other players may play a role as well. It would interesting to 
investigate the DNA-damage response in cells in which both Ptprv and p21 are inactivated, 
and the ability of these cells to proliferate following Ras expression. This could be followed 
by studying the incidence and malignant conversion of epidermal papillomas in Ptprv/p21 
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double knockout mice, after carcinogens exposure. It should also be tested if Ptprv has any 
potential for triggering tumor-reversion, like DEP1 (Trapasso et al. 2000). Furthermore it 
should be determined if Ptprv interacts with proteins involved in cell-cell contact and 
Wnt/TCF-signaling, as most RPTPs seem to do. Last but not least it should be clarified if 
Ptprv is expressed in humans, if it is to be of value for either cancer therapy or medication 
against obesity and/or diabetes. 
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10. Discussion TCTP 
 
10.1. TCTP & development 
TCTP is implicated in multiple biological processes such as cell growth and 
proliferation, histamine release and apoptosis. Decreasing TCTP levels results in a strong 
increase in apoptosis in cultured cells. It was shown here that loss of TCTP expression 
results in a dramatic increase in apoptotic cell death during embryogenesis, demonstrating 
the importance of TCTP in antagonizing cell death in vivo.  
While the TCTP-project was in progress, a paper was published on a similar TCTP 
knockout mouse (Chen et al. 2007). Here the deletion of exon 3 and 4 also led to lethality 
between E9,5 and E10,5 in homozygous mutant embryos; The TCTP-deficient embryos still 
underwent gastrulation, but died before turning. Additionally, an increase in apoptosis was 
shown in TCTP-null mutants at the E6.5 stage, as well as a decrease in  expression of G1-
specific, but not G2/M-specific cyclins at stage E9.5 (which would indicate that TCTP 
function affects proteins required for S phase entry). These observations are mostly 
consistent with the phenotype presented here. Although cyclin expression levels were not 
examined here, no clear decrease in proliferation was found at E6,5. Since no indication of 
reduced proliferation at E9,5 was given by Chen and colleagues, the relevance of the 
reduction in G1-specific cyclins at E9,5 should be further investigated, especially since the 
mutant embryos are already starting to degrade at this stage. Making use of a conditional 
system, Chen and colleagues generated TCTP-null MEFs and showed that these 
proliferated and responded to stress normally, confirming the observations shown here for 
heterozygous MEFs. Interestingly, Chen and colleagues shortly adressed the observation 
that TCTP upregulates TOR signalling in Drosophila, by positively regulating dRheb activity 
(Hsu et al. 2006). The TOR (target of rapamycin) kinase activates p70s6k and 4E-BP1 
(which directly control the translation initiation machinery), so TCTP-depletion should result 
in less phosphorylated p70s6k. In contradiction, TCTP-deficient mouse embryos did not 
display decreased levels of phosphorylated p70-S6K1 compared to normal embryos, at 
least not at the E9.5 stage. As was pointed out, this does not exclude the possibility of 
TCTP regulating Rheb activity in mice; It may exert such a function in a  tissue- or stage-
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specific manner, therefore more experiments should be performed at stages earlier than 
E9.5 and in tissue-specific TCTP knockout mice, making use of a conditional mouse model. 
 
10.2. TCTP & apoptosis 
TCTP structure also displays partial similarity to members of the Bcl2 family. Bcl2 itself 
is found in the outer membranes of mitochondria and activates Bax (BCL2-associated X 
protein) upon stress. Pro- and anti-apoptotic members of the Bcl2 family have a similar core 
fold and modulate mitochondrial membrane permeability by influencing the opening of 
specialized pores (Antonsson et al. 1997; Matsuyama et al. 1998; Minn et al. 1997; 
Muchmore et al. 1996; Nouraini et al. 2000; Petros et al. 2004; Schendel et al. 1997,1998 & 
1999). In yeast TCTP was found to localize to the mitochondria upon stress, and 
immunofluorescence data in mammalian cells suggests that TCTP co-localizes with BclxL. 
Therefore TCTP likely has a function at the mitochondria, similar to other key regulators of 
apoptosis. TCTP associates with Bcl-xL by means of its Bcl-2 homology domain 3 (Yang et 
al. 2005), which suggests that TCTP might bind other Bcl2- family members as well. Indeed 
TCTP also associates with anti-apoptotic protein Mcl-1 and stabilizes Mcl-1 by interfering 
with its degradation by the ubiquitin-dependent proteasomal pathway (Liu et al. 2005).  
Although only a small fraction of the abundantly present TCTP localizes to the 
mitochondria, it is now found to antagonize the function of Bax (Susini et al, submitted for 
publication). TCTP does not bind the proapototic Bax protein directly (Liu et al. 2005; Yang 
et al. 2005), but the crystal structure of TCTP revealed a pair of helices very similar to those 
found in Bax (which is also a p53 target). While overexpression of Bax caused apoptosis in 
HEK293T cells, this effect was almost completely abolished by co-expression of TCTP 
(Susini et al, submitted). The partial structural similarity to Bax raises the possibility of a 
function in mitochondrial membrane permeability. Indeed TCTP overexpression could 
minimize the mitochondrial damage caused by Bax overexpression, making TCTP part of 
the balance between pro- and anti-apoptotic members of the Bcl2 family that determines 
cell fate (Korsmeyer et al. 1993; Oltvai et al. 1993). TCTP can be hypothesized to bind Bax 
through other antiapoptotic members of the Bcl2 family; therefore it should be tested if Mcl-
1 or Bcl-XL are required for the anti-apoptotic function of TCTP. Possibly Mcl-1 or Bcl-XL 
could be involved in the recruitment of TCTP to the mitochondria. Alternatively the (indirect) 
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interaction of TCTP and Bax could take place in the cytosol. In any case the physiological 
relevance of this interaction should be studied further, since it implies that cells lacking 
TCTP should be hypersensitive to Bax-mediated death, while TCTP-deficient MEFs showed 
no increased sensitivity to stress (Chen et al. 2007). To genetically evaluate the link, 
intercrosses between TCTP and Bax knockout mice are in progress. 
 
10.3. TCTP & p53 
Although TCTP levels were shown to be repressed by p53 (Tuynder et al. 2002), TCTP has 
not been identified as a p53 target gene and the mechanism is still unknown. TCTP is 
selectively secreted through the non-classical exosome pathway (Amzallag et al. 2004), 
making its extracellular levels subject to p53 regulation in response to stress. What part 
TCTP excretion could play in mediating the p53 response is not clear, as the release of an 
anti-apoptotic protein would not seem beneficial to neighboring cells. Possibly enhanced 
TCTP-excretion is just a ‘side-effect’ of p53 activation, or alternatively excretion of TCTP 
could serve as an additional way of reducing intracellular levels (and stop it from 
antagonizing p53-induced Bax-activation). However too small an amount of TCTP is 
excreted to make this a likely scenario. TCTP may link Mcl-1 to the p53-pathway through 
the ARF-binding protein 1 (ARF-BP1), also called Mule. This E3 ubiquitin ligase regulates 
the stability of both p53 and Mcl-1 (Chen et al. 2005; Zhong et al. 2005; Schmueli & Oren 
2005). Because of the mostly opposite functions of these two proteins, it is plausible that 
under most physiological conditions, ARF-BP1/Mule does not downregulate p53 and Mcl-1 
simultaneously. TCTP binds Mcl-1 and prevents its degradation (Liu et al., 2005), possibly 
by shielding it from ubiquitination by ARF-BP1/Mule, or even by direct interaction with this 
E3 ligase to prevent it from promoting Mcl-1 degradation. It was speculated that during a 
strong p53 response, p53-mediated downregulation of TCTP could enable ARF-BP1/Mule 
to preferentially target Mcl-1 while letting go of p53, thus allowing for efficient apoptosis 
(Schmueli & Oren 2005). 
Nevertheless, more research is 
needed to establish a clear link 
between TCTP and the p53 
pathway. 
            Mule    Mcl-1           survival 
 
TCTP  
 
           p53            apoptosis 
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10.4. Summary & future experiments TCTP 
TCTP is implicated in multiple biological processes. Decreasing TCTP levels results in 
apoptosis in cultured cells, as well as during embryogenesis, demonstrating the importance 
of TCTP in antagonizing cell death in vivo. Because of the early lethality of TCTP-null 
embryos, it is not possible to study the impact of the deficiency in different tissues, therefore 
a conditional mouse model is needed. TCTP-null MEFs show no difference in proliferation 
and response to stress compared to wild-type cells. TCTP was found to localize to the 
mitochondria upon stress. The crystal structure of TCTP reveals a pair of helices similar to 
those found in Bax. TCTP overexpression counteracts the mitochondrial damage caused by 
Bax overexpression (not by direct interaction), indicating that TCTP is part of the balance 
between pro- and anti-apoptotic members of the Bcl2 family. It should be tested if Mcl-1 or 
Bcl-XL are required for the anti-apoptotic function of TCTP, possibly by recruiting TCTP to 
the mitochondria. The TCTP-induced increase in TOR signalling observed in Drosophila (by 
upregulating dRheb activity) is less likely to play a role in mice, since no decreased 
activation of the TOR-target p70s6k was observed in TCTP-null embryos. However, this 
needs to investigated at more developmental stages and ideally in tissue-specific TCTP 
knockout mice. More research is also needed to clarify how TCTP is repressed by p53, and 
to establish a putative link between TCTP and ARF-BP1, wich would connect the p53-
pathway to Mcl1. 
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MATERIALS & METHODS 
 
Generation of the nucleostemin-deficient mice 
The mouse line with a single gene trap event in the NS locus was generated by the 
German Gene Trap Consortium in Neuherberg, under supervision of Thomas Floss. The 
mutant ES cell clone was created using the Rosaβ-geo vector, which contains a splicing 
acceptor site (SA), β-geo selection/reporter cassette and a transcriptional stop element.  To 
precisely locate the insertion site of the trapping vector, a PCR-fragment was amplified, 
using the following primers and program: 
REV: 5’ end of the retroviral vector 5’- GGCCAGGATGAAGAGGCCTA-3' 
FW: first exon of the NS locus   5’- GGCCAGGATGAAGAGGCCTA-3' 
Program: 94°C -3:00 + (94°C -0:30 + 60°C -1:00 + 72 °C -2:00) x35 + 72 °C -3:00 
An aliquot of the PCR-product was run on a 2% agarose gel to check for size; The 
remainder of the  285bp PCR-product was directly sequenced by the DMBR sequencing 
core facility, using the same primers it was generated with.  
PCR-reagentia: Qiagen Taq PCR Core Kit (# 201225) 
 
Generation of the TCTP-deficient mice 
The TCTP-deficient mice were generated by Molecular Engines Laboratories, Paris 
(www.molecular-engines-laboratories.info). A 8,8 kb genomic region containing the murine 
tctp gene on chromosome 14 was amplified by PCR and cloned in a pBluescript (pBS) 
vector . One loxP site was cloned 5’ of exon 3 and a neomycin cassette flanked by loxP 
sites was cloned 3’ of exon 5. This construct was injected into C57Bl6 ES cells. Correctly 
targeted ES clones (tctpNeo-R/+) were obtained, as assessed by PCR and Southern blot, 
and Cre-mediated excision of exons 3 to 5, which encodes for most of the TCTP protein, 
was achieved upon electroporation of a Cre-recombinase expression vector in those cells. 
One clone that showed proper deletion of exons 3 to 5 (tctp∆3-5/+), as identified by PCR 
analysis, was used to establish a tctp mutant mouse line.  
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Genotyping of nucleostemin, p53 and TCTP-deficient mice 
Between 10 to 20 days after birth pups were numbered by cutting one or two toes, 
which were subsequently used for genotyping. The toes were lysed in tail lysis buffer 
containing 0,25 µg/µl proteinase K for 2-3 hours in a shaker at 55 °C, followed by 
proteinase K inactivation at 85°C for 45 minutes. After a 3-minute spin at maximum in an 
Eppendorf centrifuge a few µl of the supernatant was used for PCR. For the genotyping of 
embryos the yolk sacs were lysed in yolk sac lysis buffer, using the same procedure. 
Lysis buffer:  Viagen DirectPCR (mouse tail), # 102-T;  Viagen DirectPCR (yolk sac), # 202-Y 
Proteinase K:  Sigma # p6556 
 
For genotyping the nucleostemin mice the following primers were used: 
A = FW in intron 1  5’- AACCGAGCCAGATTTCTGTG    -3' 
B = REV in intron 1  5’- AACCGTCCCTGCAAAGTTATG  -3' 
C = REV in vector  5’- GTCCTCCGATTGACTGAGTC    -3' 
primer A : B : C =  0,5 : 0,35 : 0,15 µl  (in 25 µl) 
Program: 94°C -3:00 + (94°C -0:30 + 59°C -0:45 + 72 °C -0:45) x30 + 72 °C -3:00 
WT = 400 bp;  genetrap = 200bp 
 
Genotyping of the p53-null and LSL alleles: Francoz et al. 2006. 
Primers used for the p53-null allele were: 
A = FW in exon 6   5’- AGCGTGGTGGTACCTTATGAGC   -3' 
B = FW in neomycin cassette 5’- GCTATCAGGACATAGCGTTGG     -3' 
C = REV in exon 7  5’- CCATGCAGGAGCTATTACACAT    -3' 
primer A : B : C =  0,5 : 0,25 : 0,25 µl  (in 25 µl) 
Program: 94°C -3:00 + (94°C -0:30 + 58°C -0:30 + 72 °C -1:00) x35 + 72 °C -5:00 
WT = 490 bp;  null = 700bp 
 
Primers used for the p53-LSL allele were: 
B= FW in STOP-cassette 5’- AGCTAGCCACCATGGCTTGAGTAAGTCTGCA -3' 
A= FW in intron 1  5’- CAACTGTTCTACCTCAAGAGCC  -3' 
C= REV in intron 1 5’- CTTGGAGACATAGCCACACTG  -3' 
primer A : B : C =  0,5 : 0,25 : 0,25 µl  (in 25 µl) 
Program: 94°C -3:00 + (94°C -0:30 + 60°C -1:00 + 72 °C -1:30) x30 + 72 °C -5:00 
Recombined (WT) = 410 bp;  LSL = 270 bp 
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Genotyping of the TCTP mice was done using the following primers:  
A = FW intron 2  5’- GAGTGACCACCTCTCTCAGTCC  -3' 
B = REV exon 3  5’- AACACCGGTGACTACTGTGCTTTCG  -3' 
C = REV 3' UTR  5’- AAGGAACACTGTCTCCACCAGTCCC  -3' 
primer A : B : C =  0,5 : 0,30 : 0,20 µl  (in 25 µl) 
Program: 94°C -3:00 + (94°C -0:30 + 62°C -0:45 + 72 °C -0:45) x30 + 72 °C -3:00 
WT = 300 bp - mut = 423bp 
PCR products were separated on 2% agarose gels and visualized by staining with ethidium 
bromide. 
 
 
Blastocyst collection, culture and BrdU incorporation 
To obtain a large number of blastocysts the females were super-ovulated: 100 µl PMS 
was injected peritoneally, followed by 100 µl hCG two days later. The females were put 
together and checked for plugs the next morning. Three days later females were sacrificed 
and the uteri removed from the female as a whole. The uteri were flushed with ES-cell 
medium using a 30 gauge needle on a 2 ml syringe and the E3.5 blastocysts were either 
cultured overnight in ES-cell medium containing 50 µM BrdU or used for 
immunofluorescence analysis immediately. 
BrdU: BD Pharmingen # 51-7581KZ 
  for 1l medium  (in ml)  HEK293 MEF ES thymoc. 
DMEM Gibco-Life Technologies 52100-047 888 877 874 888 
Heat-Serum (FCS) Gibco-Life Technologies 10500-064 100 100 100 50 
L-glutamin (200mM) Gibco-Life Technologies 25030-081 10 10 10 10 
Penicillin/Streptomycin (1/10) Gibco-Life Technologies 15070-063 2 2 2 2 
MEM Non-Essential Amino Acids Gibco-Life Technologies 11140-050 - 10 10 - 
β-mercaptoethanol  (1/250) Gibco-Life Technologies 21985-023 - 1 1 - 
sodium pyruvate Gibco-Life Technologies 11360-039 - - 1 - 
LIF home-made - - 2 - 
HEPES  (500 mM) Sigma-Aldrich  H3375 - - - 50 
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MEF preparation, culture and stress treatments 
To prepare mouse embryonic fibroblasts (MEF) the uterus was removed from a 
pregnant female at E12,5-13,5, the embryos were dissected free, washed with PBS and 
had their internal organs removed. The remaining carcass was chopped into small pieces, 
and incubated for 20 min at 37°C in 1 ml of 0,025% trypsin/PBS. After passing through a 18 
gauge needle the cell-suspension was put in culture in T25 flasks containing MEF-medium. 
The next day the medium was changed and cells were split 1:3 when confluent, usually 
after 3-4 days. For obtaining the growth curves, several MEF-clones were plated in 
duplicate at 120.000 cells/well in 6-well plates, counted 16h later and after that every 2-3 
days until they reached a growth plateau. The life-span of these MEFs was assayed by 
passaging them on a modified 3T3 protocol (1x106 cells on 90-mm dishes, counted  and 
replated at 1x106 cells every 3 days). 
To synchronize cells in G0 the MEFs were cultured in MEF-medium with serum-
concentration reduced to 0,1%. To cause DNA-damage, MEFs were treated with 
doxorubicin (0.2 mg/ml) overnight, exposed to UV (30-60 J/m2) or γ-IR (10 Gy). For BrdU 
incorporation the MEFs were grown on 12mm coverslips and pulse-labelled with 10mM 
BrdU for 1h. 
PBS:   137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4 
Trypsin:   0.25% Trypsin (Gibco-Life Technologies 25300-54)  (diluted 1/5 in 0.53mm EDTA 
  to give 0,05%) 
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Western-blot analysis 
Cells were washed with PBS, trypsinized, pelleted and homogenized in 1% Triton lysis 
buffer. The lysates were sonicated at 37% power for 7s twice and centrifuged to remove the 
remaining debris from the supernatant. Protein concentration was measured using a Bio-
Rad protein assay according to the manufacturer’s instructions. A sample containing 30-70 
ug protein was boiled for 7 minutes at 95°C in 1x Laemmli buffer and loaded on acrylamide 
gel (7,5% for large proteins, up to 15% for small ones) for SDS-PAGE, along with a 
prestained protein ladder. The proteins were then transferred to a nitrocellulose membrane 
by semi-dry blotting device. The membranes were probed with several antibodies (see 
below) and for the detection, ECL Western Blotting Detection Reagent (Amersham) was 
used.  
1% Triton lysis buffer:  50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 
 1% Triton-100, 1 µl  Phosphatase Inhibitor Cocktail 2 (Sigma)/ml.  
Laemmli buffer:  60 mM Tris-HCl pH 6.8, 6% glycerol, 2% SDS, 
 1% µ-mercapto-ethanol,  0.012% bromophenol blue 
Transfer Buffer:  25 mM Tris, 192 mM glycine, 20% methanol 
protein ladder:  PageRuler™, Fermentas 
protein assay:  Bio-Rad  RC DC Protein Assay  # 500-0114  
PVDF membrane :  Immobilon-P polyvinylidene difluoride (PVDF) membrane, Millipore 
 
Antibodies used: 
Primary Secondary 
anti-β-tubulin (mouse clone GTU-88, 1/7.500, Sigma) anti-mouse-HRP (sheep, 1/10.000, Amersham). 
anti-cleaved caspase-3 (1/200, Cell Signaling) anti-rabbit-HRP (donkey polyclonal, 1/10.000, Amersham) 
anti-NSmouse (rabbit polyclonal, 1/2000, Chemicon)  
anti-NSrabbit (rabbit polyclonal, 1/2000, Chemicon)  
anti-p53 (polyclonal FL-393, 1/1000, Santa Cruz)  
anti-Phosphorylated histone-H3  (1/200, Upstate)  
anti-TCTP (home-made)  
anti-vinculin (1/2000, Sigma)  
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Protocol for 2 1.5mm acrylamide gels for the Bio-Rad Mini-PROTEAN® 3 electrophoresis device: 
Running gel 7.5% 10% 12.5% 15% Stacking Gel 5% 
40% acrylamide ml 3.4 4.5 5.6 6.8 40% acrylamide µl 500 
dH2O ml 10 8.8 7.7 6.5 dH2O ml 2.5 
4x Tris LOWER ml 4.5 4.5 4.5 4.5 4x Tris UPPER ml 1 
APS µl 180 180 180 180 APS µl 40 
TEMED µl 9 9 9 9 TEMED µl 6.5 
final volume ml 18 18 18 18 final volume ml 4 
 
4x Tris LOWER running gel buffer: 150mM Tris, 0,1% SDS, 2mM EDTA, pH 8.8 
4x Tris UPPER stacking gel buffer: 50mM Tris, 0,1% SDS, 2mM  EDTA, pH 6.8 
acrylamide:    Acrylamide-Bis 40% (Serva Electrophoresis GmbH) 
TEMED:    Bio-Rad # 161-0801 
 
Histology, immunodetection and TUNEL assay 
For sectioning, embryos were fixed in 4% paraformaldhehyde/1xPBS overnight, 
paraffin embedded, sectioned and stained in hematoxylin and eosin. For 
immunohistochemistry the sections were probed with anti-cleaved caspase-3 (1/200, Cell 
Signaling) and anti-Phosphorylated histone-H3 (PH3) (1/200, Upstate). For 
immunofluorescence blastocysts or MEFs were fixed in 4% PFA for 15 min, permeabilized 
with 0,1% Triton, blocked with 1% BSA and incubated for 30-90 min with antiserum 
containing 1/100 anti-NSmouse (Chemicon) plus one of the following: anti-BrdU (BU33, 
Sigma); anti-phosphorylated histone-H3 (pHH3; Calbiochem); anti-Oct 3 (BD Transduction 
Labs); anti-fibrillarin (Abcam); anti-cleaved caspase-3 (Cell Signaling). After another 30 min 
incubation with a secondary antibody (anti-mouse/rabbit or goat Alexa-488 or 633; 
Invitrogen/Mol. Probes) the embryos were mounted on slides using DAPI-containing 
Vectashield mounting medium (Vector Laboratories).  
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) 
assay was used to detect apoptotic cells on sections of paraffin-embedded embryos using 
the “In Situ Death Detection Kit” (TmR red, Roche). After TUNEL staining, embryo sections 
were counterstained and mounted using Vectashield with DAPI (Vector H-1200). 
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β-galactosidase assays 
E12.5 embryos were isolated 8 h after exposure to γ-IR (10 Gy). Embryos, frozen 
sections or PBS-washed cultured cells on plates were fixed for 10min in a 0.2% 
gluteraldehyde solution, rinsed in a 0.02% NP40 solution and stained overnight at 37C in a 
X-gal staining solution.  
X-gal staining solution: 1mg/ml X-gal, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6) 
X-Gal: 5-bromo 4-chloro-3-indolyl-b-galactopyranoside (Bioline BIO-37035) 
 
Xenopus embryos and injections 
 (These experiments were performed at the ULB). Xenopus laevis females were 
stimulated to lay eggs by injection of 500-800 units of human chorionic gonadotropin into 
the dorsal lymph sac. The eggs were then mixed with minced testis and cultured in 
0.1xMBS at 16-23°C. Antisense morpholinos for nucleostemin consist of the following 
sequences (sequence complementary to the predicted start codon is underlined): 
Xns MO, 5’-TCCTTAGCTTCGGACGTTTCATGGC-3’ ;  
Xns-mis MO, 5’-TCATTAGCTTGCGACATTTCGTGGC-3’.  
MOs were injected unilaterally at the two-cell stage at 40 ng/ blastomere.  
human chorionic gonadotropin: Sigma # 9002-61-3 
1xMBS   5mM HEPES, 88mM NaCl, 1mM KCl, 0.7mM CaCl2, 
1mM MgSO4, 2.5mM NaHCO3 (pH7.6) 
morpholinos:   Genetools  (http://www.gene-tools.com) 
 
Xenopus histology and in situ hybridization 
Injected embryos were fixed in MEMFA and stained for b-galactosidase activity with X-
Gal. Whole-mount phospho-histone H3 staining was performed as described elsewhere 
(Saka and Smith, 2001). Whole-mount in situ hybridizations were performed using 
digoxygenin-labeled antisense RNA probes. The XNS probe was generated using T7 and 
Sal1-linearized pCMV-Sport6-XNS as template (EST BC045248). Plasmids used for 
generating the other in situ probes were as described previously: FoxD3 (Sasai et al., 
2001), N-tubulin (Chitnis et al., 1995). After completion of the whole-mount procedure the 
embryos were gelatin-embedded and vibratome-sectioned.  
X-Gal: 5-bromo 4-chloro-3-indolyl-b-galactopyranoside (Bioline BIO-37035)
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Semiquantitative RT–PCR expression analysis 
Tissues were shredded using a tissue homogenizer and RNA was isolated using the 
RNeasy® MINI Kit, QIAGEN according to the manufacturer’s protocol.  The RNA was dosed 
by measuring the absorbance at 260nm. And 1 µg of total RNA was reverse transcribed in 
a final volume of 20 µl using a SuperScript kit (Invitrogen). PCR primers were as follows:  
Mouse NSm:  sense      5’  ATTGAAGCCTCAGACATTGTGT   -3’  (exon 6) 
  antisense:  5’  GAATGTCTTTCTGTTCTTTAAGTT  -3’  (exon 7) 
Program:  94°C -2:00 + (94°C -0:45 + 61°C -0:45 + 72 °C -0:45) x30 + 72 °C -5:00 
RT-PCR on Xenopus was carried out using the GeneAmp RNA PCR kit (Perkin-Elmer).  
Xenopus NSx:  sense      5’ CGAGAGACAGCGGCCATGAAA     -3’ 
  antisense   5’ CTTTTCAGAATTGTTATTTTTCTTCT-3’  
 
TaqMan quantitative RT–PCR assays 
These assays were performed following the manufacturer’s specifications (PE Applied 
Biosystems). Primer pairs and TaqMan probes were designed by Applied Biosystems 
(Assays on demand). Each sample was analyzed in triplicate. 
 
Flow cytometry 
Flow cytometry was performed on MEFs and freshly isolated thymocytes. MEFs first 
had to be trypsinized and pooled with floating cells. To assess cell viability 100 µg/ml 
propidium iodide was added to living cells and analyzed within 2 minutes, using a 
FACScalibur cell sorter (Becton Dickinson). To examine the DNA-content, cells were fixed 
and permeabilized with 70% EtOH and incubated with 100 µg/ml propidium iodide for 1h 
prior to FACS analysis. Apoptosis was measured using a TUNEL assay (in situ cell death 
detection kit, Roche Applied Science), according to the manufacturer’s instructions. 
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List of abbreviations 
 
14-3-3σ p53-target gene, negative cell cycle regulator cDNA complementary deoxyribonucleic acid 
3T3 protocol split cells every 3 days, at 3 × 105 cells/60-mm dish cdx2 caudal-related homeobox 2 
aa amino acid CHK1, CHK2 checkpoint kinase 1 or 2 
Akt = protein kinase B; targets Mdm2, GSK3β, TSC1/2 cl-PARP cleaved PARP poly ADP-ribose polymerase 
ALK anaplastic lymphoma kinase c-myc transcription factor; oncogene 
αMSH melanocyte-stimulating hormone CNS central nervous system 
AP-2 activating protein-2 Cop1 constitutive photomorphogenic 1 
APAF1 apoptotic peptidase activating factor 1 Cre Cre recombinase 
ARF alternative reading frame - transcript of CDKN2A gene DAPI 4',6-diamidino-2-phenylindole 
ARF-BP1 ARF-binding protein 1 = Mule Dapk1 death-associated protein kinase 1 
ATM ataxia telangiectasia mutated gene DEP-1 density-enhanced phosphatase 1 
ATP adenosine 5'-triphosphate DIABLO  direct inhibitor of apoptosis (IAP)-binding protein with low pI 
ATR ataxia telangiectasia and Rad3 related gene DMBA 7,12-dimethylbenz[a]anthracene 
ATRA all-trans retinoic acid; induces cell differentiation DMEM  Dulbecco’s minimal essential medium 
BAC bacterial artificial chromosome (large cloning plasmid) DNA deoxyribonucleic acid 
Bad  Bcl-xL/Bcl-2 associated death promoter Doxo doxorubicin; used to induce cell cycle arrest 
Bax Bcl2-associated X protein DSB double strand break 
Bcl2 B-cell leukemia gene 2 dsRNA  double stranded RNA 
Bcl-xL Bcl-2 family member Dss4 dominant suppressor of Sec-4 (yeast) 
β-geo β-galactosidase - neomycin fusion protein DUB  de-ubiquitinase 
BH3  Bcl-2 homology domain 3 Eµ-myc / Ras myc/ras expression driven by Ig enhancer Eµ 
Bid  BH3-interacting domain death agonist E1A early region 1A gene 
BMSC bone marrow stromal cells E3 ligase transfers ubiquitin from E2 ligase to substrate 
bp  base pair EF1A, (1Bα, 1Bβ) elongation factor 1A, Bα, Bβ 
BrdU 5-bromo-2'-deoxyuridine ER endoplasmatic reticulum 
BSA  bovine serum albumin Erk1/2 extracellular signal-regulated kinase 
β-TrCP  beta-transducin repeat containing protein ES cell embryonic stem cell 
C. elegans Caenorhabditis elegans ESP embryonic stem cell phosphatase 
C57Bl6 mouse strain 'black 6' EST  expressed sequence tag 
CABC1 chaperone, ABC1 activity of bc1 complex homolog FACS fluorescence-activated cell sorter 
CAM cell adhesion molecule (neuronal) FADD   Fas-associated death domain 
casp3-cl cleaved caspase 3 Fas = CD95 = apoptosis inducing protein 1 
CDKI cyclin-dependent kinase inhibitor FCS  fetal calf serum 
ABBREVIATIONS                                                                                                                                            . 
 130
 
FGF-2 fibroblast growth factor 2 IRES internal ribosomal entry site 
FoxD3 transcription factor required for pluripotency Jak2 janus kinase 2 
G1 - G6 GTP-binding consensus motif 1 - 6 (based on Ras) JNK jun N-terminal kinase 
GATA transcription factor that bindsthe sequence GATA K5-sos dominant form of son of sevenless, driven by keratin 5 promotor 
gata6 GATA binding protein 6 kb  kilobases 
GDI  GDP dissociation inhibitor KDa  kiloDalton 
GDP guanosine diphosphate Killer/DR5 TRAIL-receptor 
GEF guanine nucleotide-exchange factor KO knockout 
GFP  green fluorescent protein L11, L22 nucleolar proteins 
Gnl2 guanine nucleotide binding protein-like 2 lacZ β- galactosidase gene 
Gnl3l guanine nucleotide binding protein-like 3 -like LEF-1  lymphoid enhancer binding factor-1 
gp130 glycoprotein 130 LIF leukemia inhibitory factor 
GSK-3β glycogen synthase kinase 3 β loxP DNA sequence recognized by Cre rebombinase 
GTP guanosine triphosphate LSL lox-stop-lox 
Gy grey (unit for ionizing radiation) LTEP-a-2 human pulmonary adenocarcinoma cell lines 
h  hours LTR long terminal repeat 
H&E hematoxylin & eosin staining MAPK  mitogen activated protein kinase 
H1299 lung cancer cell line MCF-7  human breast adenocarcinoma cell line 
H4 histone 4 Mcl-1 myeloid cell leukemia sequence 1 
hCG human chorionic gonadotropin Mdm2 mouse double minute 2 
HEK239T  human embryonal kidney cell line with SV40 large T antigen Mdm4 mouse double minute 4 
HeLa cervical adenocarcinoma cell line MEF mouse embryo fibroblast 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid MEM  minimum essential medium 
HepG2 human hepatocellular liver carcinoma cell line miR micro RNA 
hMSC human mesenchymal stem cell MO morpholino oligo 
Hprt hypoxanthine phosphoribosyl-transferase MO mis mismatch morpholino 
HRP  horseradish peroxidase mRNA messenger RNA 
HSC  hematopoietic stem cell Mss4 mammalian suppressor of Sec-4 
HSP  heat shock protein Mule ARF-BP1 
HUVEC   human umbilical vein endothelial cells MW  molecular weight 
ICM inner cell mass Nanog transcription factor required for pluripotency 
Ig  immunoglobulin NCC  neural crest cell 
IGF insulin-like growth factor neo neomycin gene or cDNA 
IGF-BP3 insulin-like growth factor binding protein 3 NES nuclear export signal 
IHC immunohistochemistry NF-κB  nuclear factor-κB 
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Ngp-1 nuclear/nucleolar GTP-binding protein family member 1 PTK protein tyrosine kinase 
NLS nuclear localization signal PTN pleiotrophin 
NO  nitric oxide PTP protein tyrosine phosphatase 
NoLS nucleolar localization signal PUMA p53-upregelated modulator of apoptosis 
Noxa NADPH oxidase a Rab ras-related GTPase 
NPC nuclear pore complex Rab8 ras-related GTPase 8 
NPM nucleophosmin Ras small GTPase, oncogene 
NS nucleostemin RE responsive element in promotor 
NSC neuronal stem cell Rheb ras homolog enriched in brain 
NTR nuclear transport receptor RING  really interesting new gene 
Nug2p / Nog2p nuclear/nucleolar GTPase RNA ribonucleic acid 
Oct3/4 POU transcription factor required for multipotency RNAi  RNA interference 
OS-732 osteosarcoma cell line RNP ribo nucleoprotein particle 
OST-PTP osteoblast PTP = Ptprv ROS  reactive oxygen species 
p19ARF mouse ARF Rpl25A ribosomal protein L25A 
p21/CIP/WAF1 cyclin-dependent kinase inhibitor RPTP receptor protein tyrosine phosphatase 
p53AIP1 p53-regulated apoptosis-inducing protein 1 rRNA ribosomal ribonucleic acid 
PARP poly(ADP-ribose) polymerase RSL1D1 ribosomal L1 domain containing 1 
PBS  phosphate buffer saline RT-PCR reverse transcriptase polymerase chain reaction 
PCD  programmed cell death SA splice-acceptor site 
PCNA  proliferating cell nuclear antigen Saos-2 human osteosarcoma cell line, p53-null 
PCR  polymerase chain reaction SCO2 synthesis of cytochrome c oxidase gene 2 
PERP p53 effector related to PMP-22 SDS-PAGE  sodium-dodecylsulphate poly-acrylamide gel electrophoresis 
P-H3 phosphorylated histone 3 Sec-4 secretory vesicle-ass. Rab GTPase essential for exocytosis 
PI  propidium iodide SGC-7901 human gastric cancer cell line 
PI3K phosphoinositide 3-kinase  siRNA  small interfering RNA 
PIDD  p53-induced protein with a death domain Sox2 transcription factor required for pluripotency 
Plk1 polo-like kinase 1 Src tyrosine kinase, similar to Rous sarcoma virus v-src 
PML promyelocytic leukemia SSB single strand break 
PMP-22 peripheral myelin protein 22 Stat3 signal transducer and activator of transcription 3 
PMS pregnant mare serum SW480 human colon adenocarcinoma cell line 
Pol 1 gene for largest subunit of DNA polymerase alpha TAD  transactivation domain 
POMC pro-opiomelanocortin TCF T cell factor 
PPP2R5A protein phosphatase-2 regulatory subunit A TCTP translationally controlled tumor protein 
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TERT telomerase reverse transcriptase 
TG transgenic 
TGFβ  transforming growth factor β 
TIGAR TP53-induced glycolysis and apoptosis regulator 
TMA tissue micro array 
TOR Torso receptor tyrosine kinase 
TPA  12-O-tetradecanoyl-phorbol 13-acetate 
TPT1 translationally controlled tumor protein 
TRF1 telomeric repeat factor 1 
tRNA transfer ribonucleic acid 
TSAP6 tumor suppressor activated protein 6 
TSC1 tuberous sclerosis complex 1 
TSG118 testis specific gene 118 
TUNEL terminal deoxynucleotidyl transferase-med. dUTP nick end labelling 
U2OS human osteosarcoma cell line 
U937 human histiocytic lymphoma cell line 
UBF upstream binding factor 
UTR untranslated region 
UV  ultraviolet radiation 
WB  westernblot 
Wnt wingless-type MMTV integration site family 
WT  wild type 
XNS Xenopus nucleostemin 
γ-IR gamma-irradiation 
YlqF GTP-binding protein in Bacillus subtilis 
YRG YlqF Related GTP-ase 
                                                                                             FIGURE LIST 
 133 
Figure list
Fig  1: The p53 pathway is triggered by DNA-damaging stress or oncogenic signals 
Fig  2: Structure of the p53 locus and protein. 
Fig  3: Signaling during early embryogenesis. 
Fig  4: Structure of the NS locus and protein. 
Fig  5: Structure of the Ptprv locus and protein 
Fig  6: Different types of cell junctions in mammalian cells. 
Fig  7: Structure of the TCTP locus and protein. 
Fig  8: NS is expressed in various adult tissues. 
Fig  9: NS expression in stem cells, tissue and cancer cell line. 
Fig 10: Some NS remains after differentiation. 
Fig 11: Result of tissue micro-array. 
Fig 12: Generation of NS-deficient mice. 
Fig 13: NS transcription is ubiquitous during early embryonic development. 
Fig 14: NS-loss leads to early embryonic lethality. 
Fig 15: NS -/- mutants have a reduced cell number. 
Fig 16: NS-deficient embryos do not die due to increased apoptosis. 
Fig 17: NS -/- mutants show less cells in S-phase. 
Fig 18: NS -/- mutants show less cells in G2/M-phase. 
Fig 19: The nucleoli of NS -/- mutants seem intact. 
Fig 20: NS -/- mutants retain pluripotency. 
Fig 21: NS-expression is lower in NS+/- embryos compared to NS+/+ embryos. 
Fig 22: NS is expressed in low-passage MEFs, with reduced levels in NS+/- cells. 
Fig 23: NS+/- MEFs show a slight growth defect compared to NS+/+ cells. 
Fig 24: No clear correlation between NS and p53 when comparing NS+/+  and NS+/- MEFs. 
Fig 25: NS-protein and mRNA levels are similar in p53 WT and p53-/- MEFs. 
Fig 26: The embryonic lethality of NS-/- mutants is not rescued on a p53-null background. 
Fig 27. NS is evolutionary conserved. 
Fig 28: Xenopus NS is expressed during early embryogenesis in proliferating tissues. 
Fig 29: Xns depletion affects the pattern of cell division  
Fig 30: NS function may contribute to tumorigenesis. 
Fig 31. Ptprv expression is p53-inducible. 
Fig 32. Schematic representation of the WT and the targeted Ptprv loci. 
Fig 33. Ptprv induction by γ-IR. 
Fig 34. Loss of Ptprv leads to increased proliferation. 
Fig 35. Ptprv-null MEFs partially loose contact inhibition. 
Fig 36: More Ptprv-null cells stay in S-phase after g-IR. 
Fig 37. Ptprv is dispensable for p53-induced apoptosis.  
Fig 38: Generation of a TCTP-deficient mouse-line.  
Fig 39: TCTP-null embryos die around E9,0.  
Fig 40: TCTP mutant embryos die due to increased apoptosis.  
Fig 41: Heterozygous MEFs show no growth defect.  
Fig 42: TCTP heterozygous cells do not show increased sensitivity to stress.  
Fig 43: Overview of different putative NS interactions. 
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SUPPLEMENTS 
 
Supplement 1: Theiler Staging Criteria for Mouse Embryo Development
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Supplement 2: Stages of mouse embryonic development  
              (The House Mouse: Atlas of Mouse Development. Theiler Springer-Verlag, NY (1972, 1989). 
Theiler 
Stage dpc (range) 
Somite 
#  Description 
1 0-0.9  (0 -2.5)   One-cell egg 
2 1  (1 -2.5)   Dividing egg 
3 2  (1-3.5)   Morula 
4 3  (2-4)   Blastocyst, Inner cell mass apparent  
5 4  (3-5.5)   Blastocyst (zona-free)  
6 4.5  (4-5.5)   Attachment of blastocyst, primary endoderm covers blastocoelic surface of inner cell mass  
7 5  (4.5-6)   
Implantation and formation of egg cylinder Ectoplacental cone appears, enlarged epiblast, primary endoderm lines 
mural trophectoderm  
8 6  (5-6.5)   
Differentiation of egg cylinder. Implantation sites 2x3mm. Ectoplacental cone region invaded by maternal blood, 
Reichertís membrane and proamniotic cavity form  
9 6.5  (6.25-7.25 )   
Pre-streak (PS), advanced endometrial reaction, ectoplacental cone invaded by blood, extraembryonic ectoderm, 
embryonic axis visible 
Early streak (ES), gastrulation starts, first evidence of mesoderm  
10 7  (6.5-7.75)   
Mid streak (MS), amniotic fold starts to form  
Late streak, no bud (LSOB), exocoelom  
Late streak, early bud (LSEB), allantoic bud first appears, node, amnion closing  
11 7.5  (7.25-8)   
Neural plate (NP), head process developing, amnion complete  
Late neural plate (LNP), elongated allantoic bud  
Early head fold (EHF)  
Late head fold (LHF), foregut invagination  
12 8  (7.5-8.75 ) 1-4 
1-4 somites, allantois extends, 1st branchial arch, heart starts to form, foregut pocket visible, preotic sulcus (at 2-3 
somite stage)  
12a   5-7 5-7 somites, allantois contacts chorion at the end of TS12   Absent 2nd arch, >7 somites  
13 8.5  (8-9.25) 8-12 
Turning of the embryo, 1st branchial arch has maxillary and mandibular components, 2nd arch present  
Absent 3rd branchial arch 
14 9  (8.5-9.75) 13-20 
Formation & closure of ant. neuropore, otic pit indented but not closed, 3rd branchial arch visible   
Absent forelimb bud  
15 9.5  (9-10.25) 21-29 
Formation of post. neuropore, forelimb bud, forebrain vesicle subdivides  
Absent hindlimb bud, Rathke's pouch  
16 10  (9.5-10.75) 30-34 
Posterior neuropore closes, Formation of hindlimb & tail buds, lens plate, Rathke's pouch; the indented nasal 
processes start to form  
Absent thin & long tail  
17 10.5  (10-11.25) 35-39 
Deep lens indentation, adv. devel. of brain tube, tail elongates and thins, umbilical hernia starts to form   
Absent nasal pits  
18 11  (10.5-11.25) 40-44 
Closure of lens vesicle, nasal pits, cervical somites no longer visible   
Absent auditory hillocks, anterior footplate  
19 11.5  (11-12.25) 45-47 
Lens vesicle completely separated from the surface epithelium. Anterior, but no posterior, footplate. Auditory 
hillocks first visible  
Absent retinal pigmentation and sign of fingers  
20 12  (11.5-13) 48-51 
Earliest sign of fingers (splayed-out), posterior footplate apparent, retina pigmentation apparent, tongue well-defined, 
brain vesicles clear 
Absent 5 rows of whiskers, indented anterior footplate  
21 13  (12.5-14) 52-55 
Anterior footplate indented, elbow and wrist identifiable, 5 rows of whiskers, umbilical hernia now clearly apparent   
Absent hair follicles, fingers separate distally    
22 14  (13.5-15) 56-~ 60 
Fingers separate distally, only indentations between digits of the posterior footplate, long bones of limbs present, hair 
follicles in pectoral, pelvic and trunk regions 
Absent open eyelids, hair follicles in cephalic region  
23 15   Fingers & Toes separate, hair follicles also in cephalic region but not at periphery of vibrissae, eyelids open   Absent nail primordia, fingers 2-5 parallel  
24 16   Reposition of umbilical hernia, eyelids closing, fingers 2-5 are parallel, nail primordia visible on toes   Absent wrinkled skin, fingers & toes joined together  
25 17   Skin is wrinkled, eyelids are closed,umbilical hernia is gone   Absent ear extending over auditory meatus, long whiskers  
26 18   Long whiskers, eyes barely visible through closed eyelids, ear covers auditory meatus  
27 19   Newborn Mouse  
28     Postnatal development  
Excretion by p53 probably not to reduce intracellular level because only a small part is excreted. 
Function of extracellular TCTP aside for histamine release? Uptake by other cells? (p53 kills the bad 
cell but stimulates the healthy neighbour??)
Supplement 3: The PTP family. Ptprv resembles DEP1, only it has an extra ,inactive, phosphatase domain.
(Alonso et al. 2004). 
 
MOLECULAR AND CELLULAR BIOLOGY, Dec. 2006, p. 9291–9301 Vol. 26, No. 24
0270-7306/06/$08.000 doi:10.1128/MCB.01183-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Evolutionarily Conserved Role of Nucleostemin: Controlling
Proliferation of Stem/Progenitor Cells during Early
Vertebrate Development†
Chantal Beekman,1 Massimo Nichane,2 Sarah De Clercq,1 Marion Maetens,1 Thomas Floss,3
Wolfgang Wurst,3 Eric Bellefroid,2 and Jean-Christophe Marine1*
Laboratory for Molecular Cancer Biology, Flanders Interuniversity Institute for Biotechnology (VIB) and University of Gent,
B-9052 Ghent, Belgium1; Unit of Molecular Embryology, Free University of Brussels (ULB-IBMM), Gosselies,
Belgium2; and GSF-Institute of Mammalian Genetics, Neuherberg, Germany3
Received 29 June 2006/Accepted 15 September 2006
Nucleostemin (NS) is a putative GTPase expressed preferentially in the nucleoli of neuronal and embryonic
stem cells and several cancer cell lines. Transfection and knockdown studies indicated that NS controls the
proliferation of these cells by interacting with the p53 tumor suppressor protein and regulating its activity. To
assess the physiological role of NS in vivo, we generated a mutant mouse line with a specific gene trap event
that inactivates the NS allele. The corresponding NS/ embryos died around embryonic day 4. Analyses of NS
mutant blastocysts indicated that NS is not required to maintain pluripotency, nucleolar integrity, or survival
of the embryonic stem cells. However, the homozygous mutant blastocysts failed to enter S phase even in the
absence of functional p53. Haploid insufficiency of NS in mouse embryonic fibroblasts leads to decreased cell
proliferation. NS also functions in early amphibian development to control cell proliferation of neural pro-
genitor cells. Our results show that NS has a unique ability, derived from an ancestral function, to control the
proliferation rate of stem/progenitor cells in vivo independently of p53.
Stem cells are present throughout embryonic development
as well as in several adult organs. They constitute a pool of
undifferentiated cells with the remarkable ability to perpetuate
through self-renewal while remaining able to terminally differ-
entiate into various mature cell types. Coordinated control of
self-renewal and commitment to differentiation is key to main-
taining the homeostasis of the stem cell compartment, and its
deregulation may contribute to cancer pathogenesis (35). The
identification of stem cell-specific proteins and the elucidation
of novel regulatory pathways that ensure the integration of
these processes are therefore of fundamental importance.
Nucleostemin (NS) was identified because it is highly ex-
pressed in rat neuronal stem cells. It is also highly expressed in
expanded neurospheres from the adult subventricular zone, in
mouse embryonic neuronal stem/progenitor cells between em-
bryonic day 8.5 (E8.5) and E14.5, and in adult bone marrow
stem cells (46). Interestingly, NS was markedly down-regulated
during cellular differentiation. NS expression declines consid-
erably after E10.5 in the mouse cerebral cortex and is unde-
tectable in lineage-committed B lymphocytes or granulocytes.
In culture, NS was found in virtually all rat embryonic cortical
stem cells but became undetectable after treatment with ciliary
neurotrophic factor, when most cells turn into astrocytes. Im-
portantly, both during neuronal development in vivo and dif-
ferentiation in vitro, NS protein levels decrease in dividing
neuronal cells, whereas proteins that mark cell cycle exit are
down-regulated at a later phase. These data indicate that NS
down-regulation may lead to cell cycle exit rather than occur as
a consequence of cellular differentiation and cell cycle with-
drawal (46). Thus, NS is predominantly expressed in stem/
progenitor cells and may play an important role in controlling
their proliferation. Importantly, NS may also be involved in
regulating the proliferation of cancer cells. Indeed, NS was
found in a number of human cancer cell lines, such as H1299,
U2OS, Soas-2, U937, SW480, 95D, and HEK293, and in ma-
lignant renal tissues from patients with clear cell renal cell
carcinomas (46, 18, 16). Moreover, NS knockdown experi-
ments in U2OS cancer cells resulted in an increase in non-
cycling cells (46).
The nucleolus is the subnuclear compartment where rRNA
transcription and ribosome assembly occurs. Since NS protein
is predominantly found in the nucleoli of undifferentiated cells
and cancer cells, its involvement in the regulation of cell pro-
liferation may be indirectly linked to a function in ribosome
synthesis. Intuitively, efficient protein synthesis is required to
support growth and proliferation. In agreement, links between
cell proliferation control and ribosome biogenesis have been
demonstrated experimentally (14, 44). However, NS is ex-
cluded from the nucleolar domains in which ribosomes are
born and appears concentrated in rRNA-free sites within the
granular component (33). Alternatively, NS may be associated
with other nucleolar functions. Indeed, the notion that this
subnuclear structure functions as a mere ribosome factory has
recently been challenged. More recent findings showed that
the nucleolus also functions as a storehouse for titrating cer-
tain proteins and consequently modulating their molecular
pathways (30). For instance, mounting evidence highlights a
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Cancer Biology, Flanders Interuniversity Institute for Biotechnology
(VIB), Technologiepark, 927, B-9052 Ghent, Belgium. Phone: 32 9
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critical role for the nucleolus in the regulation of the p53
pathway, the activity of which is essential for controlling cell
proliferation and survival in response to cellular insults (31). In
addition to the key role of nucleolar ARF in the activation of
p53 in response to oncogenic stress (49), recent studies have
shown that deregulation of the expression of a number of
nucleolar proteins, such as ribosomal proteins L5, L11, L23,
and nucleophosmin (NPM or B23) can affect p53 function (8,
24, 10, 11, 22, 21, 7, 9). An attractive model, in which NS acts
to suppress the growth suppressive function of p53 in actively
proliferating stem/progenitor cells and cancer cells, has re-
cently been proposed (5). NS may regulate the localization and
function of proteins participating in the regulation of p53 ac-
tivity. Alternatively, NS may control the activity of the p53
pathway via a key role in the maintenance of nucleolar integ-
rity. Indeed, all types of stress that induce p53 appear to
disrupt nucleolar integrity, and a model in which impair-
ment of nucleolar structure/function was suggested to sta-
bilize p53 by interfering with its degradation was proposed
(36). Finally, regulation of p53 may occur through direct
binding because NS was found to interact with p53 in in vitro
pull-down assays and in coimmunoprecipitation experiments
of endogenous proteins (46). In this scenario, NS would
function in the nucleoplasm, as p53 is not normally found in
the nucleolus. Consistently, NS was found in the nucleo-
plasm at low levels and shown to rapidly shuttle between the
nucleolus and the nucleoplasm (47).
To gain insight into the physiological function of NS, we
generated a mouse line inactivated for NS. We show here that
germ line inactivation of NS results in peri-implantation lethal-
ity between E3.5 and E5.5. Analyses of NS mutant blastocysts
indicated that NS is not required to maintain pluripotency,
nucleolar integrity, or survival of the pluripotent embryonic
stem cells in vivo. However, proliferation of the mutant cells
was decreased even in the absence of functional p53. Our
results show that NS has a unique ability to control the prolif-
eration rate of stem/progenitor cells in vivo independently of
p53. Moreover, we show that this function of NS is evolution-
arily conserved in early amphibian development.
MATERIALS AND METHODS
Generation of NS-deficient mice. An embryonic stem (ES) cell clone with a
single gene trap event in the NS locus was used to generate the NS-deficient
mouse line (50). The vector used to create this particular ES cell clone was
Rosa-geo, containing a splice acceptor site, the -geo selection/reporter cas-
sette, and a transcriptional stop element. To precisely locate the insertion site of
the trapping vector, a PCR fragment was amplified, using primers at the 5 end
of the retroviral vector (5-GGCCAGGATGAAGAGGCCTA-3) and in the
first exon of the NS locus (5-GGCCAGGATGAAGAGGCCTA-3), cloned,
and sequenced. The insertion occurred in the first intron, 285 bp downstream of
the 3 end of exon 1 (Fig. 1A).
PCR genotyping. A PCR-based strategy was developed to distinguish between
the wild-type and NS mutant alleles. The primers are as follows: a, 5-AACCG
AGCCAGATTTCTGTG-3; b, 5-AACCGTCCCTGCAAAGTTATG-3; c, 5-
GTCCTCCGATTGACTGAGTC-3 (Fig. 1A). A 200-bp fragment indicates the
presence of the mutated allele, whereas a 350-bp fragment is amplified from the
wild-type allele (Fig. 1B). Genotyping of the p53-null and LSL alleles were
determined as previously described (19, 17).
MEF preparation, culture, and BrdU incorporation. Mouse embryonic fibro-
blasts (MEF) were prepared from E13.5 embryos and cultured as described
previously (25). The procedure used for growth curves was previously described
(25). The lifespan of MEFs was assayed by plating 1  106 cells on 90-mm dishes
in quadruplicate and passaging them on a 3T3 protocol. For bromodeoxyuridine
(BrdU) incorporation assays, the MEFs were grown on 12-mm coverslips and
pulse labeled with 10 M BrdU for 1 h before fixation with 4% paraformalde-
hyde (PFA). The BrdU-positive cells were identified by indirect immunofluores-
cence.
Western blot analysis. Lysates were prepared as previously described (25).
Fifty micrograms of each sample was fractionated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to a nitrocellulose mem-
brane. The primary antibodies used were anti-NSmouse (rabbit polyclonal,
1/2,000; Chemicon) and -tubulin (mouse clone GTU-88, 1/7,500; Sigma) for
normalization. The secondary antibodies were anti-rabbit-horseradish peroxi-
dase (donkey polyclonal, 1/10,000; Amersham) and anti-mouse-horseradish per-
oxidase (sheep, 1/10,000; Amersham). For the detection, ECL Western blotting
detection reagents (Amersham) were used.
Blastocyst collection, culture, and BrdU incorporation. E3.5 blastocysts were
flushed from the uterus and either used for immunofluorescence analysis or
cultured in ES cell medium-MEF medium with added leukemia inhibitory factor.
For the BrdU incorporation assays, blastocysts were cultured for 16 h in ES cell
medium containing 50 M BrdU (Sigma) before fixation in PFA.
Immunofluorescence. Blastocysts or MEFs were fixed in 4% PFA for 15 min,
permeabilized with 0.1% Triton, blocked with 1% bovine serum albumin (BSA),
and incubated for 30 to 90 min with antiserum containing 1/100 anti-NSmouse
(Chemicon) plus one of the following: anti-BrdU (BU33; Sigma), anti-phosphor-
ylated histone H3 (pHH3; Calbiochem), anti-Oct 3 (BD Transduction Labs),
antifibrillarin (Abcam), or anti-cleaved caspase 3 (Cell Signaling). After another
30-min incubation with a secondary antibody (anti-mouse/rabbit or goat Alexa
488 or 633; Invitrogen/Molecular Probes), the embryos were mounted on slides
using 4,6-diamidino-2-phenylindole (DAPI)-containing Vectashield mounting
medium (Vector Laboratories).
Xenopus embryos and injections, RT-PCR, in situ hybridization, and histology.
Xenopus laevis eggs were obtained from hormone (chorionic gonadotropin; Sigma)-
induced adult female frogs and fertilized using standard methods. Antisense
morpholino oligonucleotides (MOs) for nucleostemin (Genetools) consist of the
following sequences (the sequence complementary to the predicted start codon
is underlined): Xns MO, 5-TCCTTAGCTTCGGACGTTTCATGGC-3; Xns-
mis MO, 5-TCATTAGCTTGCGACATTTCGTGGC-3. MOs were injected at
the two-cell stage unilaterally at 40 ng/blastomere. Injected embryos were fixed
in MEMFA (MOPS [morpholinepropanesulfonic acid], EGTA, MgSO4, form-
aldehyde), stained for -galactosidase activity with 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (Bioline), and stored in ethanol at 20°C. Whole-mount
phospho-histone H3 staining was performed essentially as described elsewhere
(37). Whole-mount in situ hybridizations were performed using digoxigenin-
labeled antisense RNA probes. The XNS probe was generated using T7 and
Sal1-linearized pCMV-Sport6-XNS as templates (expressed sequence tag
BC045248). Plasmids used for generating the other in situ probes were as de-
scribed previously, FoxD3 (38) and N-tubulin (6). After completion of the whole-
mount procedure, embryos were gelatin-embedded and vibratome-sectioned at a
30-m thickness. RNA isolation from embryos was performed using the
QIAGEN RNeasy minikit. RNA preparations were treated with DNase I
(QIAGEN) and checked with 32 cycles of histone H4 for DNA contamination.
Reverse transcription (RT)-PCR was carried out using the Gene Amp RNA
PCR kit (Perkin-Elmer). The following primers were used: histone H4 F,5-CG
GGATAACATTCAGGGTATCACT-3, and R, 5-ATCCATGGCGGTAACT
GTCTTCCT-3 (58°C, 26 cycles); XNS F, 5-CGAGAGACAGCGGCCATGA
AA-3, and R, 5-CTTTTCAGAATTGTTATTTTTCTTCT-3 (58°C, 30 cycles).
PCR products were separated on 2% agarose gels and visualized by staining with
ethidium bromide.
RESULTS
A gene trap event in the mouse NS locus results in peri-
implantation lethality. An ES cell clone (W223E05) with a
specific gene trap event in the NS locus was microinjected into
host blastocysts to produce an NS gene trap mouse line (50).
The insertion gene trap vector integrated into intron 1 (Fig.
1A). This vector (Rosageo) contains a splice acceptor (SA)
site, the -geo selection/reporter cassette, and a transcriptional
stop element. The mutant allele is expected to drive the ex-
pression of a fusion protein that encodes the first four amino
acids of the NS open reading frame and the -galactosidase
reporter. Notably, expression of the fusion transcript is under
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the control of resident NS regulatory element. Heterozygous
mice for this mutation are viable and fertile. The ratio of
wild-type to heterozygous mice indicated that loss of one copy
of the NS gene was unlikely to cause developmental defects.
However, matings between heterozygous animals produced no
viable homozygous mutant offspring, indicating a recessive le-
thal phenotype (Table 1).
No homozygous mutants could be identified at E9.5 or later
stages. We next performed serial sectioning and staining with
hematoxylin and eosin of 11 litters at E5.5 or 7.5. Most em-
bryos were morphologically normal at both stages, but five
lacked any discernible embryonic tissue within the deciduae
and so were considered presumptive NS-null embryos (Ta-
ble 1). These presumptive null embryos showed complete
lack of the development of the embryo proper, suggesting
FIG. 1. A gene trap event into the NS locus leads to a null NS mutation and early embryonic lethality in mice. (A) The structure of the retroviral
construct along with the structures of the wild-type and mutated alleles and the positions of the oligonucleotides used for the PCR-based strategy
are depicted. Exons are indicated by black boxes, and the long terminal repeats (LTR) of the viral vector are represented by light gray boxes. -geo,
lacZ/neomycin reporter/selection cassette. (B) PCR analysis of embryos with the indicated genotypes. The three primers, a, b, and c, are indicated.
(C) Morphology of NS wild-type (/ or /) and homozygous mutant (/) E3.5 to E4.0 embryos. Magnification, 200 (phase-contrast
microscopy). (D) NS is expressed in the nucleoli of blastocysts. Blastocysts were recovered from NS/ intercrosses, fixed, and stained with anti-NS
antibody (red). Nuclei were visualized with DAPI staining (blue). About 25% of the embryos failed to stain for NS. Magnification, 200.
TABLE 1. Genotyping analysis of progeny from NS
heterozygous intercrosses
Stage No. oflitters
No. of embryos
Total / / / Abnormal
E3-3.5 13 151 NDa ND 43b (28) 43 (28)
E3-3.5 7 60 14 30 16 (26) 16 (26)
E5.5-7.5 11 97 ND ND ND (0) 5 (5)
E9.5-10.5 7 45 19 26 0 (0) 0 (0)
E12.5-13.5 6 57 17 40 0 (0) 0 (0)
E15.5-17.5 2 14 8 6 0 (0) 0 (0)
F2 49 342 127 215 0 (0) 0 (0)
a ND, not determined.
b As determined by lack of immunoreactivity to the NS antibody.
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that the longest-surviving NS/ embryos die shortly after
implantation.
At E3.5, blastocyst embryos are composed of an outer layer
of cells that form an epithelium, the trophoectoderm, which
gives rise to the trophoblast components of the placenta. The
cells in the interior, the inner cell mass (ICM), develop into
pluripotent progenitors of nontrophoblast extraembryonic tis-
sues and all fetal cell types, including germ cells. At E3.5 to
E4.5, all homozygous mutants showed various degrees of mor-
phological deterioration and were distinguishable from their
littermates. Whereas the NS/ and NS/ embryos had gone
on to form compact inner cell masses and spreading tropho-
blasts, NS mutants failed to form fully expanded blastocysts
and showed reduced cell masses (Fig. 1C). At this stage of
development, NS mutants could be identified by PCR (Fig. 1B,
representative genotype assay) and a correlation between em-
FIG. 2. Failure of the NS/ blastocyst cells to proliferate normally. (A and B) number of nuclei detected by DAPI staining of blastocysts from
NS/ intercrosses. (A) Mean cell number of wild-type and heterozygous embryos combined and of homozygous NS embryos at E3.0 and E3.5.
Error bars denote standard errors. There is a significant difference between the mean numbers by Student’s t test at both stages of development
(E3.0, P  6.1013; E3.5, P  1.1011). (B) Representative images of E3.5 NS/ or NS/ and NS/ mutant embryos stained with DAPI (blue)
and anti-NS (red) antibodies. Magnification, 200. (C and D) Number of cells positive for phospho-Ser-histone H3 (P-H3, the M-phase specific
marker) among the total number of blastocyst cells (determined by DAPI staining of nuclear DNA). (C) The percentage of P-H3-positive cells in
wild-type and heterozygous embryos combined and in homozygous NS embryos at E3.0. Error bars denote standard errors. There is a significant
difference between the mean numbers by Student’s t test (P  0.03). (D) Representative images of E3.0 NS/ or NS/ and NS/ mutant
embryos stained with DAPI (blue), anti-P-H3 antibody (green), and anti-NS antibody (red). Magnification, 200. (E and F) NS-deficient
blastocysts fail to incorporate BrdU. Blastocysts were collected and cultured for 16 h in ES cell medium containing 50 M BrdU. (E) The
percentage of BrdU-positive cells among the total number of blastocyst cells (determined by DAPI staining of nuclei) in wild-type and
heterozygous embryos combined and in homozygous NS embryos at E4.0. Error bars denote standard errors. There is a significant difference
between the mean numbers by Student’s t test (P  2.1010). (D) Representative images of E4.0 NS/ or NS/ and NS/ mutant embryos
stained with DAPI (blue), anti-BrdU antibody (green), and anti-NS antibody (red). Magnification, 200. n, number of embryos analyzed.
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bryos showing a deteriorating phenotype and the NS/ geno-
type was observed. The mutant embryos could also be identi-
fied by immunofluorescence, which could readily detect NS
protein expression in cells from both the ICM and trophoec-
toderm in wild-type blastocysts. In contrast, NS mutants are
not immunoreactive to the anti-NS polyclonal antibody (Fig.
1D). Thus, this NS gene trap mutation leads to the absence of
detectable levels of NS protein expression and results in peri-
implantation lethality. Moreover, the NS/ embryos never
hatched out of their zona pellucida during the study, but all of
the wild-type and heterozygous embryos hatched at about E4.5
(data not shown).
The proliferation rate of NS/ ES cells is reduced in vivo.
NS mutant embryos appeared smaller than wild-type and het-
erozygous littermates. This could reflect a reduced number of
cells in mutant embryos. To address this in a quantitative
manner, E3 to 3.5 embryos from heterozygous intercrosses
were collected, fixed immediately, stained for NS, and coun-
terstained with DAPI, so that the number of nuclei and their
morphology could be ascertained (Fig. 2A). At E3, NS/
embryos contained about half as many nuclei as the NS/ or
NS/ embryos. Moreover, whereas the number of cells in
NS-immunoreactive embryos almost doubled between E3 and
E3.5, the number of cells in the homozygous mutants showed
no significant increase (Fig. 2A and B).
Notably, all NS/ nuclei were morphologically normal (Fig.
1D and 2B). The formation of micro- or macronuclei is a
morphological signature of mitotic errors and is often associ-
ated with mutations in mitotic checkpoint genes or genes in-
volved in the G2 DNA damage checkpoint (1, 23, 45, 48). The
absence of abnormal mitotic figures in NS mutant embryos
indicates that NS deficiency is not associated with a defect in
mitosis. Alternatively, the reduced cell number in NS mutant
embryos could be due to increased spontaneous cell death.
However, the absence of nuclear condensation and fragmen-
tation in the NS mutants, as judged by fluorescent DNA stains
(Fig. 2B), is not consistent with this possibility. This was further
confirmed by measuring apoptosis directly by cleaved
caspase-3 immunostaining. As shown in Fig. S1 in the supple-
mental material, NS mutant E3.5 to 4.5 embryos contained no
more dying cells (Casp-3*-positive cells) than their wild-type or
heterozygous littermates. Thus, NS deficiency does not cause
loss of cell viability.
We next examined the potential effect of the NS/ muta-
tion on the ability of the embryos to proliferate and progress
properly through the cell cycle. Incorporation of BrdU into the
FIG. 3. NS is not required for nucleolar integrity or to maintain pluripotency. (A) Representative images of E3.5 NS/ or NS/ and NS/
mutant embryos stained with DAPI (blue), antifibrillarin (green), and anti-NS (red) antibodies. Fibrillarin nucleolar localization is not perturbed
in NS-deficient blastocysts. (B) Representative images of E3.5 NS/ or NS/ and NS/ mutant embryos stained with DAPI (blue), anti-Oct3/4
(green), and anti-NS (red) antibodies. NS-deficient blastocysts maintain expression of Oct4, the marker of pluripotent stem cells. Magnification,
200.
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DNA during the S phase of the cell cycle was assessed by
indirect immunofluorescence. Both NS/ and NS/ blasto-
cysts showed strong incorporation of this DNA label, whereas
the NS mutants showed practically no BrdU incorporation
(Fig. 2E and F). This observation suggests that the prolifera-
tion capability of the cells from NS/ mutant embryos is
significantly impaired at E3.0 to 3.5. We next immunostained
E3.0 blastocyst embryos with both antibodies specific for NS
and for histone H3 phosphorylated on serine residue 10 (P-
H3). Phosphorylation of histone H3 at Ser 10 coincides with
the initiation of chromosome condensation and is considered a
specific marker of mitosis (42). Our analysis shows that the
percentage of P-H3-positive cells is significantly lower in blas-
tocyst cells from the NS mutant embryos than that in their
wild-type or heterozygous counterparts (Fig. 2C and D). To-
gether, these observations suggest that the majority of cells
from NS-null blastocysts are arrested at E3.0 to 3.5 because the
mutant cells fail to enter the S phase of the cell cycle.
The requirement of NS for proper cell proliferation might
be linked to a role of this protein in the maintenance of nu-
cleolar morphology and/or function. To test whether NS is
required to maintain nucleolar integrity, blastocysts embryos
were immunostained with antibodies directed against fibrilla-
rin, a specific nucleolar marker. The fibrillarin staining was
comparable in NS-null embryos and control littermates (Fig.
3A), indicating that NS deficiency does not cause nucleolar
disruption.
NS mutant cells might exit from the cell cycle because of
spontaneous differentiation, accompanied with loss of pluripo-
tency in the ICM. To clarify the fate of NS mutant cells, we
immunostained the blastocysts with antibodies directed against
Oct4 (also known as Oct3), a POU family transcription factor
specifically expressed in ES cells, preimplantation embryos,
epiblast, and germ cells (29, 40). Loss of Oct4 in blastocysts
leads to terminal differentiation of the inner cell mass into
trophoblast lineages (26), and precise Oct4 dosage is required
for cell fate decisions (28). As expected, strong Oct4 staining
could be detected in the ICM of wild-type and heterozygous
NS embryos. Similar staining was observed in NS mutant cells
(Fig. 3B), indicating that NS is not required for pluripotency in
ICM.
Loss of p53 does not rescue NS deficiency. NS is reported to
be a p53-interacting protein, and expression of NS in stem cells
was proposed to impose a block on p53 activity (5, 46). We,
therefore, sought to test whether the embryonic lethality asso-
ciated with NS loss depends on the presence of functional p53.
NS heterozygous mice were crossed either with p53-null mice
(19) or with mice homozygous for a p53 knock-in allele
(p53LSL/LSL) harboring a transcriptional stop element, flanked
by LoxP recombination sites, and located in the first intron (A.
Ventura and T. Jacks, unpublished data). This element renders
the p53 locus transcriptionally silent, but p53 expression can be
recovered in cells in vitro or tissues in vivo by expressing the
Cre recombinase. NS/ p53/ mice were crossed with
NS/ p53LSL/LSL mice so that all animals produced had one
p53-null allele and one p53LSL allele. We had shown that this
combination of alleles (p53LSL/) fully rescues the embryonic
lethality associated with mdm2 and/or mdm4 loss (17). In con-
trast, loss of p53 expression did not rescue NS deficiency,
because no viable NS/ p53LSL/ mice were found (Table 2).
Moreover, NS/ p53/ blastocysts were also morphologi-
cally distinguishable from their NS wild-type or heterozygous
counterparts, which indicates that loss of p53 does not even
partly prevent or delay the phenotype associated with NS loss
(Fig. 4 A and B). Thus, this observation suggests that the ability
of NS to control the proliferative potential of embryonic stem
cells in vivo is not dependent on the growth suppressive activity
of p53 and is not consistent with a role for NS upstream of p53.
TABLE 2. Loss of p53 does not rescue NS deficiency a
Stage No. oflitters
No. of embryos
Total NS/ NS/ NS/ Abnormal
E3.5 1 9 NDb ND 2 (22) 2
E9.5 1 8 5 3 0 (0) 0
E12.5 6 45 13 32 0 (0) 0
F2 17 81 23 58 0 (0) 0
a NS/ p53LSL/LSL mice crossed with NS/ p53/ mice.
b ND, not determined.
FIG. 4. p53 loss does not rescue NS deficiency; number of nuclei detected by DAPI staining of blastocysts from NS/ p53/ intercross
matings. (A) Representative images of E3.5, p53-null, NS/ or NS/ and NS/ mutant embryos stained with DAPI (blue) and anti-NS antibody
(red). (B) Mean cell number of wild-type and heterozygous embryos combined and of homozygous NS embryos on a p53-deficient background at
E3.0. Error bars denote standard errors. There is a significant difference between the mean numbers by Student’s t test (P  0.06). n, number of
embryos analyzed. Magnification, 200.
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NS/ MEFs exhibit a reduced proliferative capacity. Even
if NS is found predominantly in undifferentiated cells, NS
expression is not restricted to stem cells. Ubiquitous reporter
(lacZ) expression in E10.5, E12.5, and E14.5 heterozygous
embryos indicates that the NS promoter is active in virtually all
embryonic cells at these stages of development (data not
shown). Consistently, NS protein expression could be detected
at high levels in total extracts from E10.5 embryos and in the
nucleoli of explanted early passage MEFs (Fig. 5A and B).
Interestingly, NS expression diminishes concomitantly with a
decrease in the proliferation potential of the cells upon pas-
sages (Fig. 5A). Strikingly, expression of NS was consistently
and significantly reduced in NS/ cells compared to NS/
cells (Fig. 5A). To further study the implication of NS in the
control of cell proliferation, we examined the proliferative
capacity of the NS/ cells at various passages. We did not
observe significant differences in the proliferation rate between
heterozygous and wild-type cultures at early passages. How-
ever, at later passages, NS/ cells exhibited a slight but re-
producible decrease in their proliferation potential compared
to control cells (Fig. 5C). Together, the data suggest that NS is
haplosufficient in the control of cell proliferation. Wild-type
MEFs undergo 10 to 12 population doublings in culture, after
which they cease to divide and develop a so-called senescent
phenotype. Notably, even if a slight difference in the prolifer-
ation rate between heterozygous and wild-type cultures was
observed on a 3T3 schedule, both NS/ and NS/ cells
underwent senescence at similar passages (Fig. 5C).
NS has an evolutionarily conserved function in the control
of cell proliferation. NS is conserved during the evolution (see
Fig. S2 in the supplemental material, alignment of the pre-
dicted amino acid sequences of NS from Drosophila, Caeno-
rhabditis elegans, zebra fish, Xenopus, chicken, mouse, and hu-
man). We next used Xenopus laevis as a model system to
further examine NS function in early embryos. We first deter-
mined the expression profile of XNS, the ortholog of NS in
Xenopus laevis. XNS transcripts can be detected by RT-PCR
analysis both maternally and zygotically (Fig. 6A-a). Whole-
FIG. 5. Haploid insufficiency of NS in MEFs leads to reduced proliferative potential. (A) NS endogenous protein is detected by Western
blotting analysis in total extracts from E10.5 embryos (top panel) or in MEFs at various passages (lower panel). A significant decrease in NS protein
expression is detected in cells prepared from NS/ heterozygous embryos, and NS expression decreases at late passages. -Tubulin (-tub) serves
as a loading control here. (B) The NS protein (green) is mainly localized in the MEF nucleoli, as assessed by indirect immunofluorescence. Nuclei
are visualized using DAPI staining. (C) Growth curves for NS/ and NS/ MEF cultures at passage 4. Cells (1  105) were plated into six-well
plates. Cultures were harvested at daily intervals, and the total number of cells was determined and normalized to the number of cells at day 1 (20
h after plating). The numbers refer to the mean values of four independently derived MEF cultures of each genotype. (D) Proliferation of NS/
and NS/ MEF cultures on a revisited 3T3 schedule. The accumulated number of population doublings is shown on a linear scale on the y axis.
VOL. 26, 2006 NS IS REQUIRED FOR PROLIFERATION OF STEM CELLS 9297
 at Universiteitsbibliotheek G
ent on Septem
ber 5, 2007 
m
cb.asm
.org
D
ow
nloaded from
 
FIG. 6. XNS is expressed during early embryogenesis in proliferating tissues and its depletion affects the pattern of cell division and the
expression of neuronal and neural crest markers. (A, part a) Expression of XNS during embryogenesis analyzed by RT-PCR. Control RT-PCR of
histone H4 was used as a loading control. Note that XNS is expressed both maternally and zygotically. (A, parts b to i) Whole-mount in situ
hybridization of XNS expression at the indicated stages Nieuwkoop-Faber stages (St) (27). (A, parts b and c) Dorsal views, anterior right. (A, parts
d and i) Transversal sections at the indicated levels of the embryo shown in parts c and h, respectively. (A, parts e, f, and h) Lateral views, anterior
right. (A, part g) Horizontal section of the embryo in part f at the level indicated. Note that XNS expression is first detected at the
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mount in situ hybridization shows that the entire neural plate
of early neurula (stage 13) contains a significant amount of NS
RNA, particularly around the anterior neural plate (Fig. 6A-b
and -c). Cross-sections reveal that XNS is expressed through-
out the ectoderm at the neurula stage and is restricted to the
sensorial layer. By late neurula to tadpole stage, strong staining
is observed in the head region in the brain, cranial neural crest
cells, eye and otic placodes (Fig. 6A-e, -f, and -g). Weaker
staining is observed in the somites. Expression of NS in the
Xenopus embryos thus correlates with sites of active cell pro-
liferation (37) and is therefore consistent with the above-de-
scribed expression and function of NS in the mouse embryo.
We next determined the requirement of XNS for proper
neural plate formation and neural crest development. To this
end, we designed MOs to specifically deplete the NS protein.
We first determined that our NS MOs effectively block trans-
lation in an in vitro transcription/translation assay (Fig. 6B-a).
Next, the NS and NS mismatch MOs were injected, together
with -galactosidase mRNA, into single cells of two-cell-stage
embryos. This strategy allows us to knock down NS in the
neural plate- and neural crest-forming regions of the ectoderm
on one side of the embryo, with the other side serving as an
internal control. Injection of the NS MOs, but not of the NS
mismatch MOs, significantly decreases the number of mitotic
cells in the injected side, as detected using an antibody recog-
nizing phosphorylated histone H3 (Fig. 6B-c and -d). More-
over, NS MO-injected embryos display a decreased expres-
sion at the neurula stage of some neuronal (N-tubulin) and
neural crest markers (FoxD3) (Fig. 6C-b and -d). However,
expression of these markers is not completely abolished,
because they were detected at later stages of development
(data not shown). Together, these observations indicate that
depletion of NS in Xenopus embryos only slows down neu-
rogenesis, due to decreased cell proliferation, rather than
interfering with neural specification. These data, therefore,
further support a role of NS in the control of stem/progen-
itor cell proliferation and suggest that this function is con-
served during the evolution.
DISCUSSION
NS was isolated because it is predominantly expressed in rat
neuronal stem cells (46). It is also expressed in other stem
cell-enriched populations, including embryonic stem cells.
Consistent with this finding, we show herein that NS protein is
detectable in mouse pluripotent stem cells in vivo. NS was
found in E3 to E3.5 embryos both in the ICM and trophoec-
toderm. Interestingly, NS became undetectable when differen-
tiation in CNS rat stem cells was induced (46). This decrease in
expression is likely to reflect a decrease in the cell proliferation
potential rather than being a consequence of cellular differen-
tiation. NS is indeed not exclusively expressed in stem/progen-
itor cells. NS mRNA expression was, for instance, found in
proliferating diploid fibroblasts or T lymphocytes (16). We also
show here that NS protein is readily detectable in early passage
MEFs but not at later passages when cells become senescent.
Moreover, we generated an inactivated NS allele in mice and
showed that NS/ blastocyst embryos retained expression of
Oct-4, a marker of pluripotent stem cells in vivo. NS expression
therefore appears closely associated with cellular proliferation,
regardless of the cell of origin or its differentiation status, and
it is not required for the maintenance of pluripotency. In the
Xenopus embryo, NS expression was also predominant at var-
ious sites of intense cell proliferation. Interestingly, strong
expression was detected in migratory cranial neural crest cells,
a population of proliferative, migratory, tissue-invasive stem
cells in a pattern roughly reminiscent to the one of Myc (4).
Previous observations supported an active role for NS in the
control of cellular proliferation. Upon differentiation of neu-
ronal stem cells, NS expression decreases before cell cycle
withdrawal, suggesting that NS down-regulation leads to cell
cycle exit rather than occurring as a consequence of the cell
proliferation block. Moreover, when bone marrow stem cells
are stimulated with fibroblast growth factor 2 to proliferate, NS
expression increases in a dose-dependent manner, and knock-
down of NS abolishes the proliferative effect of fibroblast
growth factor 2 (20). Finally, NS is also strongly expressed in a
number of cancer cell lines, and NS knockdown in an osteo-
sarcoma cell line (U2OS) increased the number of noncycling
cells (46). The data reported in this paper are consistent with
the above observations. We showed that the NS/ mouse
embryos die very early in development, as the blastocysts fail to
enter S phase. Additionally, several different attempts to gen-
erate NS/ ES cells proved to be unsuccessful (data not
shown). NS/ heterozygote MEFs showed about a 50% de-
crease in NS expression, and their proliferation rate was
slightly less than that of wild-type cells. Finally, NS depletion in
the Xenopus embryos resulted in defective proliferation of
neural progenitor cells. Together, the data suggest an impor-
tant, evolutionarily conserved role for NS in the control of cell
cycle progression at early developmental stages.
The molecular basis for the requirement of NS for cell cycle
progression remains unclear. It was proposed that the ability of
NS to modulate cell proliferation is dependent on a functional
interaction with the p53 pathway (46). This interaction may
occur at several levels. NS might be required for nucleolar
neurula stage in ectodermal cells of the sensorial layer, particularly around the anterior neural plate. At the tailbud and tadpole stages, XNS
staining is observed in migratory cranial neural crests, the eye, and the otic vesicle. (i) Within the neural tube, XNS expression is restricted to the
ventricular zone. np, neural plate; nc, neural crest; sle, sensorial layer of the ectoderm; ev, eye vesicle; s, somites; ov, otic vesicle; ba branchial
arches. (B, part a) The XNS MO inhibits translation of XNS in vitro, whereas the XNSmis MO does not. (B, part b) Injection of the XNS MO,
but not XNSmis, decreases the number of mitotic cells, as revealed using an antibody recognizing phosphorylated histone H3 (	-pH 3). Dorsal view
of XNS MO- and XNSmis MO-injected embryos are shown. LacZ was coinjected as a lineage tracer. Control and injected sides revealed by LacZ
staining are indicated (bottom panel). (d) Quantification of the results (percentage of pH 3-positive cells compared to control embryos). There
is a significant difference between the percentages in control and MO NS-injected embryos by chi-square test (P  0.002). n, number of cases
analyzed. (C, parts a and d) XNS MO, but not XNSmis MO, decreases the expression of the indicated neuronal and neural crest markers at the
neurula stage. The injected side is revealed by LacZ staining.
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integrity and therefore for the regulation of p53 abundance
(36). NS may affect the nucleoplasmic-nucleolar trafficking of
key modulators of the p53 pathway. Alternatively, NS might
affect p53 localization and/or function via direct interaction
(46). However, our data are not consistent with these possibil-
ities. First, nucleoli appeared to be intact in NS-deficient em-
bryos, suggesting that NS loss does not cause nucleolar disrup-
tion. More importantly, loss of p53 does not rescue the
embryonic lethality associated with NS inactivation. Moreover,
like NS/ embryos, NS/ p53/ E3.0 embryos can be dis-
tinguished morphologically from the NS/ p53/ or NS/
p53/ embryos, indicating that loss of p53 does not even
partly rescue NS deficiency. The data therefore argue for a
p53-independent function of NS in the control of cell prolif-
eration.
NS protein is predominantly found in the nucleoli and
thus may be involved in rRNA processing and ribosome
assembly. Early studies highlighted the existence of cross
talk between ribosome biogenesis and cell cycle progression
(2, 41). More recently, perturbation of the activity of BOP1,
a conserved nucleolar protein involved in rRNA processing
and ribosome biogenesis, caused a cell proliferation block in
the G1 phase of the cell cycle (43). Similarly, lack of BrdU
incorporation of the NS-deficient embryos suggests that NS
is required for the G1/S phase transition. Moreover, NS
belongs to a subclass of GTPases characterized by a circular
permutation of their GTPase signature motifs from the C-
terminal side of the protein to the N terminus (12). Several
members of this family, including NGP-1, Nug1p, Nug2p/
Nog2p, and Grn1p/GNL3L (34, 3, 39, 13), have been shown
to localize to the nucleolus and participate in the processing
of the nucleolar pre-rRNA, ribosomal assembly, and nucle-
olar/nuclear export. For instance, deletion of Grn1 resulted
in a severe growth defect, a marked reduction in mature
rRNA species with a concomitant accumulation of the 35S
pre-rRNA transcript, and failure to export the ribosomal
protein Rpl25a from the nucleolus (13). Thus, NS-deficient
cells might therefore undergo cell cycle arrest because of a
defect in ribosome biogenesis/rRNA processing. Mamma-
lian cells quickly adjust the rate of ribosome synthesis based
on the availability of nutrients and growth-promoting mito-
gens, and cells that exit the division cycle into a quiescent
state greatly limit ribosome production and overall protein
synthesis (15, 32). How ribosome biogenesis is ultimately
coordinated with cell growth and proliferation remains un-
clear. Further experiments, using conditional knockout or
knockdown approaches in mice and/or primary cells should
be carried out to formally test the contribution of NS in
these processes.
The observation that loss of NS function and even decreased
NS protein levels impairs cell cycle progression has potential
therapeutic implications. The presence in the protein of two
putative GTP binding sites makes it a very attractive target for
molecules that would mimic or compete for GTP binding. On
the one hand, these molecules could be tested for their ability
to affect cancer cell proliferation. On the other hand, as ex-
pansion of stem cells in culture is a key tool for tissue regen-
eration, drugs that potentiate NS activities may facilitate stem
cell maintenance and propagation.
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G1 checkpoint failure and increased tumor
susceptibility in mice lacking the novel p53
target Ptprv
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In response to DNA damage, p53 activates a G1 cell cycle
checkpoint, in part through induction of the cyclin-depen-
dent kinase inhibitor p21(Waf1/Cip1). Here we report the
identification of a new direct p53 target, Ptprv (or ESP),
encoding a transmembrane tyrosine phosphatase. Ptprv
transcription is dramatically and preferentially increased
in cultured cells undergoing p53-dependent cell cycle
arrest, but not in cells undergoing p53-mediated apoptosis.
This observation was further confirmed in vivo using a
Ptprv null-reporter mouse line. A p53-responsive element
is present in the Ptprv promoter and p53 is recruited to this
site in vivo. Importantly, while p53-dependent apoptosis is
intact in mice lacking Ptprv, Ptprv-null fibroblasts and
epithelial cells of the small intestine are defective in G1
checkpoint control. Thus, Ptprv is a new direct p53 target
and a key mediator of p53-induced cell cycle arrest.
Finally, Ptprv loss enhances the formation of epidermal
papillomas after exposure to chemical carcinogens, sug-
gesting that Ptprv acts to suppress tumor formation
in vivo.
The EMBO Journal advance online publication, 18 August
2005; doi:10.1038/sj.emboj.7600769
Subject Categories: cell cycle; molecular biology of disease
Keywords: DNA damage; growth arrest; p53; Ptprv; skin
carcinogenesis
Introduction
In response to a variety of stressors, the p53 tumor suppres-
sor functions mainly as a sequence-specific DNA-binding
transcription factor to promote antiproliferative responses,
including cell cycle checkpoints, cellular senescence, and
apoptosis (Lane, 1992). A number of proapoptotic genes,
encoding for the mitochondrial proteins Bax, Noxa, Puma,
Apaf-1, or proteins that play a role in death receptor-mediated
apoptosis, such as Fas, KILLER/DR5, and PIDD, are direct
p53 targets (El-Deiry, 1998). Notably, critical importance
in vivo has only been established for few of these genes,
including puma and noxA (Jeffers et al, 2003; Villunger
et al, 2003). p53-mediated cell cycle exit is partly mediated
through induction of the cyclin-dependent kinase inhibitor
p21 (El-Deiry et al, 1993). p21-null fibroblasts are defective
in p53-mediated G1 arrest in response to DNA damage or
nucleotide depletion (Brugarolas et al, 1995; Deng et al,
1995). However, this defect is only partial and, in contrast
to p53-null cells, fibroblasts derived from p21-null mice enter
senescence and have a lifespan similar to wild-type (WT)
cells (Pantoja and Serrano, 1999). In addition, these cells
respond to oncogenic Ras by accumulating p53, and by
decreasing their proliferation rate (Pantoja and Serrano,
1999), suggesting that p21 is not the only critical mediator
of G1 arrest.
Phosphorylation of tyrosine residues is a central feature of
many cellular signalling pathways, including those affecting
apoptosis, growth, differentiation, and cell cycle regulation
(Neel and Tonks, 1997). This phosphorylation is antagonis-
tically controlled by protein tyrosine kinases (PTKs) and
phosphatases (PTPs). In an intriguing symmetry to receptor
tyrosine kinases, many PTPs display a transmembrane topol-
ogy. In all, 21 genes in the mouse and human genomes
encode for members of the receptor PTP family (Alonso
et al, 2004). Identifying physiologically relevant ligands or
substrates for these RPTPs has proven difficult.
Although a variety of PTKs has been directly linked
to tumorigenesis through somatic activating mutations, only
a few PTP genes have been implicated in cancer. Recent
mutational analysis of the tyrosine phosphatome in colorectal
cancers identified multiple inactivating somatic mutations
in several PTPs, including three RPTPs. Expression of
one of them, PTPRT, in human cancer cells inhibited
cell proliferation (Wang et al, 2004). Genetic inactivation
of the DEP-1 induces a vascular phenotype characterized
by enlarged, oversized vessels with abnormally high endo-
thelial cell proliferation (Takahashi et al, 2003). DEP-1 over-
expression in mammary carcinoma cell lines and in thyroid
carcinoma cells suppresses the transformed phenotype
(Keane et al, 1996; Trapasso et al, 2000). The frequent
deletion of the gene in human cancers is another indication
that DEP-1 acts as a tumor suppressor (Ruivenkamp et al,
2002).Received: 18 March 2005; accepted: 13 July 2005
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Here, we report the identification of a new p53 transcrip-
tion target coding for Ptprv (also known as ESP (Lee et al,
1996)), a protein that is structurally highly related to DEP-1.
Both proteins are composed of an extracellular domain con-
taining exclusively multiple type III fibronectin repeats, a
transmembrane segment, and either a single or two intracel-
lular classical PTP domains for DEP-1 and Ptprv, respectively.
The physiological role of Ptprv and its relevance to tumor-
igenesis is currently unknown. We show that, under specific
conditions, p53 directly regulates transcription of Ptprv, and
that Ptprv is a key mediator of p53-mediated cell cycle arrest
following DNA damage. In addition, we provide evidences
suggesting that Ptprv plays a role in tumor suppression.
Results
Ptprv expression is increased in the mdm4-mutant
embryos
We had reported that disruption of the mdm2-related gene,
mdm4, leads to a p53-dependent embryonic lethality, mainly
caused by an arrest of the mutant cells in the G1 phase of the
cell cycle (Migliorini et al, 2002). With the aim to identify
new putative mediators of p53-dependent cell cycle arrest, we
monitored changes in gene expression in mdm4-mutant
embryos using oligonucleotide microarrays (Martoriati et al,
2005). We selected Ptprv for further analysis because it
appeared dramatically upregulated in mdm4 mutants. Real-
time quantitative PCR, and nonradioactive in situ hybridiza-
tion (ISH) confirmed the induction of Ptprv expression in
mdm4-mutant embryos (Supplementary Figure 1). The level
of Ptprv induction (ranging from 70- to 100-fold) is roughly 10
times higher than that of any other known p53-target gene,
including p21.
Ptprv is a p53-inducible gene in cultured cells
We next determined Ptprv expression levels after endogenous
p53 activation in a series of cellular systems by RNAse
protection assays, semiquantitative and quantitative reverse
transcription polymerase chain reaction (RT–PCR).
Activation of p53 by induction of a conditional allele of
p19ARF in NIH-3T3 cells (pMTArf cells; Kuo et al, 2003)
increases Ptprv expression (Figure 1A). Ptprv mRNA was
also induced in response to DNA damage, such as following
doxorubicin treatment (Figure 1B) or UV irradiation
(Figure 1C) in WT, but not in the p53-null embryonic stem
(ES) cells. In addition, Ptprv mRNA was induced in WT
but not p53-null MEFs in response to g-radiation (g-IR)
(Figure 1D), doxorubicin treatment (Figure 1E), and to a
lesser extent UV irradiation (data not shown). Doxorubicin-
treated MEFs undergo p53-dependent cell cycle arrest unless
otherwise sensitized to undergo apoptosis through the ex-
pression of the adenovirus E1A oncogene (Lowe et al, 1994).
Notably, induction of Ptprv expression by doxorubicin was
significantly suppressed in cells expressing E1A (Figure 1E).
Using real-time PCR, we confirmed the more pronounced
increase in Ptprv mRNA in E1A-negative cells (2777.6-fold of
induction) compared to E1A-positive cells (2.170.5-fold of
induction). In addition, Ptprv expression was not induced in
p53 WT MEFs by H2O2, which causes oxidative cell death
(data not shown). These results suggest that Ptprv is prefer-
entially upregulated by stimuli inducing p53-mediated cell
cycle arrest rather than apoptosis. Finally, human Ptprv
mRNA levels are also induced in the p53-null osteosarcoma
SAOS-2, after expression of a conditional p53 allele
(Figure 1F; Nakano and Vousden, 2001). Together, these
results demonstrate that activation of p53 in normal or
tumor cells leads to upregulation of Ptprv expression. The
kinetic of this induction is similar to that of several known
p53-inducible target genes, such as p21 (Figure 1A–C and E),
suggesting that Ptprv is a direct p53 transcriptional target.
p53 binds Ptprv promoter in vivo
Other well-characterized p53-responsive genes contain p53-
binding sites either upstream of the first exon or within the
first intron. Sequence analysis of the murine Ptprv locus
reveals the presence of three conserved putative p53-binding
sites (p53RE1-3), including perfect-match consensus se-
quences as defined by El-Deiry et al, 1992 (Figure 2A). To
determine whether p53 binds to the candidate response
elements in the mouse Ptprv, we carried out band shift
assays, comparing the binding activities of double-stranded
oligonucleotides containing Ptprv-derived sequences and
well-characterized p53-binding sites (PG13) as control. Only
one (p53RE2) of the three sites tested efficiently binds p53
after activation of its DNA-binding function with the p53
antibody PAb421 (data not shown). An oligonucleotide with
mutations in p53RE2 at the positions strictly conserved in the
consensus p53-binding site (positions in bold in Figure 1A)
showed no p53-binding activity. Binding to p53RE2 was
efficiently competed by excess of unlabelled p53RE2, but
not by oligonucleotides harboring mutant p53RE2-binding
sites (Figure 2B). We next tested the ability of p53 to bind
the mouse p53RE2 in vivo, using chromatin immunoprecipi-
tation (ChIP). pMTArf cells were grown for 24 h in the
presence of zinc to induce p19ARF expression and subsequent
p53 stabilization. Chromatin was immunoprecipitated using
either control IgG- or p53-specific polyclonal antibodies (FL-
393), and the Ptprv promoter regions surrounding p53RE2
or p53RE3 as a negative control, amplified by PCR (Figure 2C,
left panels). Amplification of a region containing the p53-
binding sites in the first intron of the Mdm2 gene served
as positive control. Similar experiments were carried out in
doxorubicin-treated ES cells (Figure 2C, right panels). Results
reveal a specific recruitment of p53 to p53RE2, but not to
p53RE3, of the promoter region of Ptprv, thereby proving that
Ptprv is a direct p53-transcription target.
Ptprv is a p53 transcription target in vivo
A Ptprv-null reporter mutant mouse line was generated
(Dacquin et al, 2004) and used to confirm in vivo the p53-
dependent induction of the Ptprv promoter in response to
DNA damage. The knock-in mice express a b-galactosidase
reporter under the control of resident Ptprv regulatory ele-
ments (Figure 3A). To make sure that this reporter is ade-
quate to assay transactivation by p53, induction of lacZ
expression was analyzed in Ptprv-targeted ES cells following
exposure to UV-C irradiation. Like endogenous Ptprv
(Figure 1D), lacZ expression under the control of Ptprv
regulatory elements is detected 8 h after treatment
(Figure 3B). Reporter gene expression was then evaluated
in 12.5 days post-coitus (dpc) embryos after whole-body
g-irradiation of compound pregnant females. In agreement
with the reported histochemical staining of Ptprv-nLacZ
mice, b-galactosidase activity is detectable in the foetal
Ptprv is a key p53-downstream target
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gonadal ridge and in the apical ectodermal ridge of the limb
buds of nontreated Ptprv heterozygotes (Figure 3C; Dacquin
et al, 2004). Following irradiation, b-galactosidase activity
was induced in the majority of the cells of Ptprvþ / p53þ /
embryos, though to various extents (Figure 3C). The bran-
chial arches, the maxillary areas, the limb buds, and the tail
were the sites of strongest expression, whereas no staining
was found in the heart. This lacZ expression profile is very
similar to the pattern observed in irradiated embryos harbor-
ing the p53-dependent promoter of the mdm2 gene, fused to
lacZ (Gottlieb et al, 1997). In contrast, however, lacZ staining
is barely detectable in gelatin sections of the developing
neuroepithelium and in the eye (data not shown), sites
of marked p53-dependent apoptosis in irradiated embryos
(Wubah et al, 1996). This observation is consistent with a
selective upregulation of Ptprv by p53 depending on the
cellular context and/or the cells fate. In order to confirm
that the induction of lacZ expression is p53-dependent, the
Ptprv-null reporter mutation was transferred into a p53-
deficient background. Strikingly, while constitutive basal
transgene expression was still present in the foetal gonadal
ridge and in the apical ectodermal ridge of the limb buds
of Ptprvþ / p53/ embryos, no lacZ induction was found
following g-IR (Figure 3C). Together, these data indicate that
Ptprv expression is induced in vivo following DNA damage in
a strict p53-dependent manner.
Ptprv is not required for p53-mediated apoptosis in vivo
The poor induction of expression in cells undergoing p53-
mediated cell death suggests that Ptprv is dispensable for this
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Figure 1 Ptprv expression is p53-inducible. (A) Semiquantitative PCR analysis shows expression of Ptprv in p19ARF-inducible pMTArf cells
exposed to zinc for 4 and 12 h. Expression of p19ARF, p21, and Ptprv was detected only in the pMTArf cells, not in the NIH-3T3 parental cell line.
b-Tub served here as a normalization control. (B) Western analysis (top panel) and semiquantitative PCR (lower panel) show levels of p53
protein and Ptprv mRNA, respectively, in p53 WT and p53-deficient ES cells, exposed to doxorubicin (Doxo, 0.2mg/ml). Induction of p21 and
Ptprv mRNA was concomitant with p53 protein stabilization, and was detected only in WTcells. b-Tub served here as a normalization control.
(C) RNAse protection assay shows induction of Ptprv expression only in p53 WT and not in p53-deficient ES cells, exposed to UVC (30 J/m2).
(D) Q-PCR analysis shows the induction of expression of Ptrpv in WT and not in p53-null MEFs following g-IR (10 Gy). The data represent the
mean (7the standard deviation) of three independent experiments. (E) Semiquantitative PCR analysis shows Ptprv expression in p53 WT and
p53-deficient E1A-expressing MEFs, exposed to doxorubicin (Doxo, 0.2mg/ml). Induction of Ptprv expression was only detected in WT E1A-
negative cells and not in WT E1A-expressing or p53-deficient cells. b-Tub served here as a normalization control. (F) Western analysis (top
panels) and semiquantitative PCR (lower panels) show expression of p53 protein levels and Ptprv mRNA levels, respectively, in p53-inducible
SAOS-2 cells following doxycycline (Doxy) treatment.
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biological response. To confirm this view, Ptprv-deficient
MEFs were infected with E1A (Lowe et al, 1994) and exposed
to doxorubicin or deprived of serum, conditions known to
trigger p53-dependent apoptosis. In contrast to p53-null cells,
both WT and Ptprv-null MEFs were equally sensitive to
apoptosis (Figure 4A). Moreover, sections through the neu-
roepithelium of irradiated 13.5-day-old embryos were as-
sayed for apoptosis. Consistent with a readily detectable
number of pyknotic nuclei evident by H&E staining, apopto-
sis was widespread in both WT and in Ptprv-deficient em-
bryos, but, as expected, not detected in p53-null embryos
(Figure 4B). We next measured apoptosis in freshly isolated
thymocytes after g-IR. Susceptibility to cell death following
DNA damage in these cells is also p53-dependent (Clarke
et al, 1993; Lowe et al, 1993), and, accordingly, p53/
thymocytes were resistant to g-IR (Figure 4C). In contrast,
WT and Ptprv-deficient cells were equally sensitive to this
treatment. Together, these data indicate that p53-dependent
apoptosis following DNA damage does not require Ptprv.
Ptprv-deficient MEFs proliferate faster in culture
and reach a higher cell density than WT cells
p53-deficient MEFs divide more rapidly and reach a higher
saturation density than WT cells (Harvey et al, 1993). We
therefore studied the growth rates and saturation densities of
early-passage Ptprv-deficient cells (Figure 5A). The Ptprv-null
cells initially did not show any significant differences in
growth rate compared to the WTcells, but differences became
apparent at day 5. The p53 and Ptprv-mutant cells grew more
rapidly than WTcells. By day 9, all cell lines appeared to have
reached saturation density. p53/ and Ptprv/ MEFs
reached a much higher saturation density compared to
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Figure 3 Ptprv induction in vivo. (A) Schematic representation of the WT and the targeted Ptprv loci. An internal robosome entry site-nLacZ
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and exposed to doxorubicin (Doxo; left panel) or serum deprived (right panel). Apoptotic cells were measured with annexin V staining and
FACS analysis. The graphs represent the average percentages7s.e.m. of viable cells in three independent experiments. (B) E13.5 Embryos with
the indicated genotypes were treated in utero with g-IR (10 Gy). Sections through the neuroepithelium were assayed for apoptosis. The sections
were stained with antibody directed against the activated form of caspase-3. (C) Freshly isolated mouse thymocytes were g-irradiated (IR,
10 Gy) and apoptosis was measured 10 h later by FACS analysis. The graph represents the average percentages7s.e.m. of viable cells in two
independent experiments.
Ptprv is a key p53-downstream target
G Doumont et al
&2005 European Molecular Biology Organization The EMBO Journal 5
control genotypes (Figure 5A, right panel). Moreover, flow
cytometry confirmed that, at day 9, a significant percentage
of p53- and Ptprv-null cells continued to synthesize DNA
(Figure 5B). Thus, Ptprv loss gives MEFs a growth advantage
allowing cells to bypass contact inhibition to an extent similar
to p53/ MEFs. It should be noted, however, that absence
of Ptprv does not result in full immortalization of murine
fibroblasts.
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Figure 5 Loss of Ptprv results in defective G1 checkpoint control. (A) To measure cell proliferation, passage 2 MEFs of different genotypes were
plated at day 0. Cultures were harvested at daily intervals, and the total number of cells were determined and normalized to the number of cells
at day 0 (4 h after plating) (relative number of cells). The right panel shows a Hoechst staining (5mg/ml) of WTand Ptprv-null cultures at day 9.
(B) Sparse or confluent MEF cultures were labeled with BrdU and analyzed by FACS. The graph displays the relative reduction in the number of
S-phase cells (BrdU-positive) compared with sparse cultures of the same genotype. FACS analysis also revealed that the WTand Ptprv-null cells
have equivalent cell volumes (data not shown). (C) Effect of g-IR (10 Gy) on the cell cycle of asynchronously growing MEFs of different
genotypes. The percentage of S-phase cells is shown relative to the percentage of S-phase cells in UT cultures. Three independent experiments
were performed, and the mean values with standard deviations (error bars) are presented. (D) S-phase entry following serum stimulation and
g-IR of synchronized MEFs. The percentages of BrdU-positive cells immediately after starvation (Starv.), cells grown for 24 h in growth medium
(UT), or cells that had undergone g-IR are shown. Three independent experiments were performed, and the mean values with standard
deviations (error bars) are presented. (E) Western analysis (top panel) and semiquantitative PCR (lower panel) show expression of p53 protein
levels and p21 mRNA levels, respectively, in p53 WT, p53-deficient, and Ptprv-null MEFs, exposed to g-IR. Induction of p21 mRNA was
concomitant with p53 protein stabilization, and was detected in WT and in Ptprv-null cells. b-Tub served here as a normalization control.
(F) Cell proliferation in the epithelium of small intestine of WT, Ptprv-null and p53-null mice after g-IR (15 Gy). Comparison of BrdU
incorporation in UT mice and irradiated mice (g-IR) 8 h after irradiation.
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DNA-damage-induced G1/S arrest is partly
Ptprv-dependent
WT MEFs undergo a well-characterized arrest in G1 when
treated with g-IR, while p53-null MEFs fail to do so (Kastan
et al, 1992). To decipher the functional importance of Ptprv to
this checkpoint, subconfluent asynchronously growing MEFs
were g-irradiated and the number of cells in S phase after 24 h
evaluated. As indicated in Figure 5C, WT cells show a 60%
reduction in the number of S-phase cells relative to unirra-
diated samples averaged over several experiments. By con-
trast, p53-defective cells were almost completely deficient in
the ability to arrest in G1 (Figure 5C). Ptprv-null cells showed
an intermediate phenotype with, on average, a 30% reduc-
tion in cells entering S phase. As interpretation of these pulse-
labeling results on asynchronous cultures is complicated by
the ability of the cells to arrest in G1, G2, or M, we measured
more precisely the effect of irradiation on the G1- to S-phase
transition using synchronized cells. MEFs were synchronized
at G0 by serum starvation (0.1% serum for 96 h), and treated
with 0 or 10 Gy of g-IR. Cells were then stimulated to enter the
cell cycle in the presence of BrdU by the addition of serum.
Cells were harvested 24 h after irradiation, and the number
of S-phase cells quantified by bivariate FACS analysis
(Figure 5D). p53/ and, to a lesser extent, Ptprv/ cells
show a defect in G1 arrest relative to WT and Ptprv hetero-
zygous cells. As p21-null cells are also significantly deficient
in their ability to arrest in G1 in response to DNA damage
(Brugarolas et al, 1995; Deng et al, 1995), impairment of
the G1 checkpoint in Ptprv-null cells may be due to an in-
ability of these cells to upregulate p21 expression. However,
p53 stabilization and concomitant induction of p21 trans-
cription were observed in both WT and Ptprv-null cells
following DNA damage, excluding this possibility
(Figure 5E). In conclusion, these results clearly indicate
that induction of Ptprv contributes to the p53-mediated G1
arrest response to g-IR.
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Figure 6 Ptprv-deficient mice display increased papilloma yield after chemical carcinogenesis. (A) Expression of Ptprv in the skin of UT or
DMBA-treated Ptprv-null/reporter mice as measured by X-gal staining on cryosections. LacZ expression in UT mice is only detected in hair
follicles, particularly in resting hair follicles (telogen, see 1). Within the hair follicles, expression is confined to the ORS (see 2–4), and is
excluded from the dermal papilla (DP). No expression was detected in the normal epidermis. In contrast, strong staining was observed in the
hyperplastic epidermis (see 6 and 8) of DMBA-treated mice. Two different lesions isolated from DMBA-treated mice are shown (see images 5
and 7, acquired with an  2 objective). Images 6 and 8 are the same lesions showed at higher magnification (acquired with an  10 objective).
Strong expression was evident in most tumor cells of epithelial origin in both lesions (see 5 and 7). (B) Gross morphology of DMBA-induced
skin tumors at 16 weeks of treatment. Two representative WT and Ptprv-null mice are shown. (C) Average number of papillomas (more than
2 mm in diameter) per mouse after 8 and 19 weeks of treatment. (D) Survival curves of DMBA-treated WT (n¼ 10) and Ptprv-null mice (n¼ 10)
with respect to the number of weeks. In (C) and (D), asterisks denote statistical significance.
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Cell proliferation in epithelia of the guts is limited to the
crypts, in which stem cells and early progenitors are located.
WT epithelia block proliferation as early as 8 h after exposure
to a high dose of whole-body irradiation (15 Gy), while in
p53-null mice DNA replication continues (Komarova et al,
2004). We monitored cell proliferation in the epithelium of
the small intestine of Ptprv-null mice after g-IR. As expected,
virtually no BrdU incorporation was seen in the small intes-
tine of irradiated WT animals, while proliferation was largely
unaffected in the crypts of p53-null and Ptprv-deficient ani-
mals (Figure 5F). These results further underline a key role for
Ptprv as a mediator of p53-induced cell cycle arrest in vivo.
Loss of Ptprv enhances papilloma formation
in experimental mouse skin carcinogenesis
In WT MEFs and primary epidermal keratinocytes, constitu-
tive signaling by oncogenic Ras provokes a p19ARF and p53-
dependent cell cycle arrest (Serrano et al, 1997; Palmero et al,
1998; Lin and Lowe, 2001). As Ptprv is a p53 target, its
expression is induced in WT MEFs expressing activated Ras
(not shown). Mutations in endogenous Hras, leading to
constitutively active Ras protein, can be achieved in vivo by
treatment of the mouse skin with the carcinogen 7,12-
dimethylbenzanthracene (DMBA). This treatment induces
benign squamous cell papillomas, nearly 100% of which
have sustained an AT mutation in codon 61 of Hras
(Quintanilla et al, 1986). Interestingly, the expression levels
of both p19ARF and p53 were increased in such papillomas
(Kelly-Spratt et al, 2004), indicating that p19ARF regulates p53
in response to Ras in vivo. Using the Ptprv-nlacZ mice, we
first determined whether Ptprv expression is induced in the
skin of DMBA-treated mice. In untreated (UT) mice, lacZ
staining was only evident in hair follicles and was absent
from the interfollicular epidermis (Figure 6A). The hair
follicle is composed of concentric epithelial layers, an exter-
nal outer root sheath (ORS) attached to the basal lamina, an
internal layer, the inner root sheath (IRS), and the hair shaft
(Panteleyev et al, 2001). Follicles periodically undergo cycles
of growth (anagen), destruction (catagen), and rest (telogen).
The zone between the noncycling and cycling segments is
a stem cell niche, the ORS ‘bulge’ (Alonso and Fuchs, 2003).
Expression of the reporter gene within the hair follicle is
confined to the bulge, which contains infrequently cycling,
label-retaining cells (LRCs) and related keratinocyte progeny
in the basal layer (BL) and ORS, and is absent from the IRS.
LacZ expression was particularly evident in resting hair
follicle, at the end of the telogen (hair club) (Figure 6A).
Expression of the reporter in these structures is p53-indepen-
dent because it is also observed in a p53-null background
(not shown). Strikingly, upon treatment of the Ptprv-null
reporter mice with the tumour-initiating agent DMBA, a
strong induction of expression was observed in the hyper-
plastic epidermis and in the majority of the epithelial tumor
cells (Figure 6A). We next assessed the significance of Ptprv
induction for tumor suppression. Ptprvþ /þ and Ptprv/
littermates were treated with DMBA and scored each week
for papilloma and carcinoma formation. Papillomas began to
appear in both genotypes 8 weeks after the first application of
DMBA, indicating that the latency period for tumor appear-
ance was the same in both groups. By 21 weeks, the average
number of papillomas (more than 2 mm in diameter) was
2.53-fold significantly higher (Po0.025) in mice homozygous
for a null mutation in the Ptprv gene compared with WT
control mice (Figure 6B and C). There seemed to be an
increased mean volume of tumors with decreasing Ptprv
gene dosage (data not shown); however, due to the large-
size variability among tumors, the median tumor size was not
statistically significantly different across genotypes (Kruskal–
Wallis test). Mortality in Ptprv-deficient mice was signifi-
cantly higher (Po0.001; Logrank test) than in age-matched
WT littermates (Figure 6D), and the most common cause of
death in Ptprv/ mice appeared to be lymphoma. Seven out
of the eight mutant mice that died during the course of the
experiment had indeed developed lymphomas, whereas only
one of the two WT mice that died showed signs of lympho-
ma. Other nonepithelial tumors, like hemangiosarcomas,
were also found in mutant mice (two of eight mice), while
none were found in WTanimals. Importantly, the skin tumors
in both groups were exclusively benign squamous tumors,
with no or very few frank carcinomas, indicating that the rate
of malignant conversion of papillomas to carcinomas is not
increased in the absence of Ptprv. Of note, Ptprv-null animals
did not develop tumors spontaneously at an appreciable
frequency in their first year of life (not shown).
Discussion
Our data indicate that Ptprv is a transcriptional target of p53.
Ptprv is induced in a p53-dependent manner following DNA
damage, culture shock, ARF-dependent stabilization of
p53, and expression of oncogenic Ras. Consistent with
these findings, an oligonucleotide microarray-based, gene
expression profile analysis had previously identified Ptprv
as a putative p53-inducible gene (Kannan et al, 2001). We
show here that induction of Ptprv expression is dramatic in
cells undergoing p53-mediated cell cycle arrest, and thus in
all in vitro and in vivo settings tested (see Figures 1A and 2C
for examples). In these conditions, Ptprv induction was
consistently more pronounced than that of p21, which is
widely used as a marker of p53 activation. This is most likely
due to a very low constitutive basal expression level in most
tissues (Dacquin et al, 2004). We therefore propose the use of
Ptprv as a sensitive marker of p53 activation, and the Ptprv-
nLacZ mouse model as a new valuable tool for monitoring
p53 transcriptional activity in vivo.
Notably, Ptprv is only poorly induced in response to
apoptotic stimuli or when cells are sensitized to death by
oncogenes, such as E1A. The molecular basis for the selective
induction of the Ptprv promoter by p53 is currently unknown,
but this observation makes this promoter unique and there-
fore worth studying further.
Consistent with its preferential induction by p53, Ptprv is
dispensable for p53-mediated apoptosis but necessary for
efficient p53-dependent cell cycle arrest in response to DNA
damage. A role of p21 in the p53-dependent G1 checkpoint
had already been clearly established (Brugarolas et al, 1995;
Deng et al, 1995). The similarities between the biological
consequences of p21 loss and Ptprv deficiency are remark-
able. The growth properties of p21/ and Ptprv/ cultured
MEFs are virtually identical. These cells grow faster and to
higher saturation densities than control cells. They are both
compromised, to similar extents, in their G1 cell cycle check-
point following g-IR. However, they both still enter replicative
senescence, even if they do so, with a slight delay as
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compared to WT cells, and decrease their proliferation in
response to overexpression of oncogenic Ras (Pantoja and
Serrano, 1999). In addition, Ptprv- and p21-deficient mice
display an increased predisposition to tumour formation after
exposure to chemical carcinogens (Weinberg et al, 1999).
Loss of both genes indeed enhanced the formation of benign
epidermal papillomas after exposure to DMBA and, thus,
even if slightly different protocols were used. While a classi-
cal DMBA/TPA two-step protocol was used for the p21-null
mice, we did not expose the Ptprv-null mice to TPA. Notably,
none of these mutants recapitulate the increased rate of
malignant conversion of papillomas to carcinomas observed
in the absence of p53 function (Kemp et al, 1993). It therefore
appears that both p21 and Ptprv act as mediators of p53-
induced cell cycle arrest in response to DNA damage or
activated Ras. However, loss of either Ptprv or p21 does not
recapitulate the phenotypes observed in cells and mice lack-
ing p53. Our data raise the possibility that Ptprv and p21
activate nonoverlapping pathways, contributing to a full p53-
dependent response. It would therefore be of interest to
investigate the DNA-damage response in cells in which both
Ptprv and p21 are inactivated, the ability of these cells to
proliferate following Ras expression, and the incidence and
malignant conversion of epidermal papillomas in Ptprv/p21
double knockout mice after carcinogens exposure.
The molecular mechanism through which increased Ptprv
expression triggers a cell proliferation block remains to be
elucidated. Recent experiments have shown that RPTPs can
bind to themselves (homophilic) as well as to other proteins
(heterophilic). Interestingly, several RPTPs, including RPTPm,
DEP-1, RPTPk, and RPTPl, interact with and regulate the
tyrosine phosphorylation level of catenins (Fuchs et al, 1996;
Cheng et al, 1997; Zondag et al, 2000; Holsinger et al, 2002),
which are critical in physiological and pathological events
such as cell proliferation, migration, and adhesion. DEP-1
colocalizes with the junctional protein VE-cadherin at cell
borders in endothelial cells. Interestingly, members of the
cadherin family of cell–cell adhesion molecules function
in the suppression of cell growth and tumor invasion.
Junctional components such catenins, however, can promote
cell growth by inducing the transcription of genes involved in
proliferation and cancer progression (reviewed in Ben-Ze’ev
et al, 2000). The growth-inhibitory effects of the cadherin
complex may involve binding and sequestration of the sig-
naling pool of the catenins. Furthermore, inducible DEP-1
expression in fibroblasts antagonizes platelet-derived growth
factor-stimulated tyrosine phosphorylation of a number of
cellular proteins, including the PDGF receptor itself, compo-
nents of the MAPK pathway (Erk1/2, p21Ras), Src, and
activation of the receptor-associated phosphoinositide-3
kinase (Kellie et al, 2003). Thus, the implication of Ptprv
in the regulation of the cadherin-catenin and MAPK
pathways should therefore be investigated.
Several lines of evidence, albeit preliminary, support the
role of RPTPs in tumor suppression (see introduction). The
data presented herein provide yet another link between
RPTPs and cancer. The identification of Ptprv as a key down-
stream p53 target suggests that it might be required for tumor
suppression by p53. In agreement, we show here that, even if
Ptprv-null animals did not develop tumors spontaneously at
an appreciable frequency in their first year of life, these mice
show a significant acceleration of skin tumour formation
compared to WT littermates when treated with carcinogens
(DMBA). Since, this treatment induces Hras mutations at
high frequency (Quintanilla et al, 1986), it is tempting to
speculate that mutated Ras can cooperate with Ptprv loss to
accelerate tumor formation in vivo. Intriguingly, most of the
lethal tumors found in DMBA-treated Ptrpv-null mice were
aggressive lymphomas that infiltrated thymus, lymph nodes,
and vital organs such as liver and lungs. In contrast, DMBA-
treated ARF-null or p53-null animals primarily develop in-
vasive skin carcinomas (Kemp et al, 1993). Notably, mice
deficient for DMP1, an ARF transcriptional activator, develop
tumors with a spectrum very similar to the one observed in
mice lacking Ptprv when treated with DMBA (Inoue et al,
2000). DMP1 was originally isolated from a T-lymphocyte
cDNA library and DMP1-null T-cells in long-term culture have
a proliferative advantage when stimulated by IL-2 and anti-
body to CD3. By analogy, it will be interesting to assess the
relevance of Ptprv for the development and function of cells
of lymphoid origin.
Materials and methods
Cell culture and cell cycle analysis
MEFs, Saos-2 (p53-inducible), NIH-3T3, or NIH-3T3-derived pMTarf
and phoenix packaging cell lines were prepared and/or grown as
described (Martoriati et al, 2005). p53 activity was induced as
follows: NIH-3T3 or pMTarf cells were treated with ZnSO4 (100mM);
Saos-2 p53-inducible cells were treated with doxycycline (2 mg/ml);
ES cells were treated with doxorubicin (0.2mg/ml); MEFs were
treated with doxorubicin (0.2mg/ml), exposed to UV (30 J/m2),
H2O2 (50 mM), and g-IR (10 Gy). BrdU staining on coverslips and
flow cytometry analysis were as previously described (Migliorini
et al, 2002).
Retroviral infection and apoptosis assays
pBABE(Puro) and pBABE(Puro)-E1A 12S were transfected into
phoenix packaging cells and the supernatants used to infect MEFs
as previously described (Danovi et al, 2004). After 2–4 days of
selection, MEFs were replated for apoptosis assays. We treated
MEFs with 0.2 mg/ml doxorubicin (Sigma) or 0.1% fetal serum for
24 and 48 h. Cells were trypsinized and pooled with floating cells
and apoptosis measured using annexin-V detection kit (Roche
Applied Science #1858777) and FACS analysis or a Trypan blue
exclusion assay. We treated pregnant females at 13.5 dpc with 10 Gy
g-IR, and 8 h later collected the embryos. Embryonic heads were
fixed, paraffin-embedded, and apoptosis assayed using an antibody
recognizing the activated form of caspase 3 (Cell Signaling), as
previously described (Migliorini et al, 2002). Freshly isolated
thymocytes from 4-weeks-old mice were treated with g-IR and
apoptosis assayed by annexin V staining 16 h later.
Semiquantitative RT–PCR expression analysis
Total RNA was prepared using RNeasy miniKit (QIAGEN) according
to the manufacturer’s protocol. In all, 1mg of total RNA was reverse-
transcribed in a final volume of 20 ml using a SuperScript kit
(Invitrogen). PCR primers were as follows:
p19ARF: sense 50-AGGGATCCTTGGTCACTGTGAGGATTC-30;
antisense: 50-GCAAAGCTTGAGGCCGGATTTAGCTCTGCT-30;
p21: sense 50-GGAGCAAAGTGTGCCGTTGTC-30;
antisense 50-GAGGAAGTACTGGGCCTCTTG-30;
Ptprv: sense 50-GTTGATGCCTTACAACCTGTGGCG-30;
antisense 50-AGCTGCTTCACGCGCCTCTGTT-30;
b-tubulin sense: 50-CAACGTCAAGACGGCCGTGTG-30,
antisense: 50-GACAGAGGCAAACTGAGCACC-30.
TaqMan real-time quantitative RT–PCR assays
These assays were performed following the manufacturer’s
specifications (PE Applied Biosystems). Primer pairs and TaqMan
probes were designed by Applied Biosystems (Assays on demand).
Each sample was analyzed in triplicate.
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Electromobility shift assay (EMSA)
Oligonucleotides encoding the p53-binding sites (p53RE2) located
in Ptprv (50-CTGCAAGCCTAGGCTTGTCC-30), and the consensus
p53-binding site (PG13: 50-GGGCAAGCCCGGGCAAGCCC-30) were
32P end-labeled with T4 kinase (10 U/ml, Invitrogen) and hybridized
with the complementary oligonucleotide. Unlabeled p53RE2 and
mutant p53RE2 (50-CTGAAAACCTAGGATTATCC-30) probes were
used as specific competitor and unspecific competitor, respectively.
Probes were incubated with an in vitro transcribed and translated
p53 protein (Promega) and the mouse antibody pAb421 (Onco-
gene). The DNA–protein complexes were separated from the
nonbound probes by electrophoresis.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were carried out as described (Martoriati et al, 2005).
Ptprv p53RE2-, p53RE3-, and mdm2-specific products were ampli-
fied using primers:
50-CTGGGATGCTCTGGGTGGATA-30,
50-TCCGCCTTTGTGCCATGGCTT-30;
50-AAGACGAGTGTCTCAAGCATTG-30,
50-GTGTGCAGAGGATGGAATGG-30, and
50-GGTGCCTGGTCCCGGACTCGCCGGG-30,
50-CCGAGAGGGTCCCCCAGGGGTGTCC-30, respectively.
Western blot analysis
Western analyses were performed as described (Martoriati et al,
2005). The primary antibodies used were: polyclonal anti-p53
(FL-393, Santa Cruz) and monoclonal anti-b-tubulin (Sigma).
RNAse protection assays
32P-labeled antisense probe for Ptprv was generated using T7 and
by a BamHI-linearized pcR2.1-Ptprv plasmid (Invitrogen) contain-
ing a 575 bp fragment of mouse Ptprv ORF. A 249 bp HPRT
probe, obtained using T7 and BamHI-linearized pCR2.1-HPRT con-
taining a 249 bp fragment of mouse HPRT ORF, was used as loading
control.
b-galactosidase assays
E12.5 embryos were isolated 8 h after exposure to g-IR (10 Gy).
Embryos, frozen sections or PBS-washed cultured cells on plates
were fixed for 10 min in a 0.2% gluteraldehyde solution, rinsed
in a 0.02% NP40 solution and stained overnight at 371C in a
X-gal staining solution (1mg/ml X-gal, 5 mM K3Fe(CN)6, and 5 mM
K4Fe(CN)6).
In situ quantitation of BrdU-positive cells in the small
intestine
BrdU (50 mg/kg) was injected intraperitoneally 6 h after irradiation
(15 Gy). At 2 h after injection, mice were killed and a part of small
intestine (ileum) was fixed for 15 h in paraformaldehyde 4% and
paraffin embedded. Sections were prepared, permeabilized, and
DNA was denatured at 371C for 1 h in HCl 2 N. An anti-BrdU rat
monoclonal antibody was used as primary antibody (1 h incubation,
diluted 1/60) and an anti-rat polyclonal antibody, HRP-conjugated,
was used as secondary antibody (10 m incubation, 1/250).
Tumor induction protocol
Skin papillomas were induced as previously described (Capozza
et al, 2003). The backs of 10 WTand Ptprv/ mice were shaved and
treated weekly (for 10 weeks) with a solution of 0.5% DMBA
(Fluka) in acetone. The number and the size of tumors were
evaluated each week. Statistical significance for the difference in the
number of tumors across genotypes was determined using Student’s
t-test, and Po0.05 was defined as significant. When moribund, the
mice were killed and a complete necropsy was performed. Skin
tumors, lymph nodes, lungs, liver, thymus, spleen, and sternum
were collected, fixed in 4% neutral buffered formalin, and further
processed for histopathological evaluation.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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TCTP protects from apoptotic cell death by
antagonizing bax function
L Susini1,6, S Besse1,6, D Duflaut1,6, A Lespagnol1,6, C Beekman2,6, G Fiucci1, AR Atkinson3, D Busso3, P Poussin3, J-C Marine2,
J-C Martinou4, J Cavarelli3, D Moras3, R Amson1,5 and A Telerman*,1,5
Translationally controlled tumor protein (TCTP) is a potential target for cancer therapy. It functions as a growth regulating protein
implicated in the TSC1–TSC2 –mTOR pathway or a guanine nucleotide dissociation inhibitor for the elongation factors EF1A and
EF1Bb. Accumulating evidence indicates that TCTP also functions as an antiapoptotic protein, through a hitherto unknown
mechanism. In keeping with this, we show here that loss of tctp expression in mice leads to increased spontaneous apoptosis
during embryogenesis and causes lethality between E6.5 and E9.5. To gain further mechanistic insights into this apoptotic
function, we solved and refined the crystal structure of human TCTP at 2.0 A˚ resolution. We found a structural similarity between
the H2–H3 helices of TCTP and the H5–H6 helices of Bax, which have been previously implicated in regulating the mitochondrial
membrane permeability during apoptosis. By site-directed mutagenesis we establish the relevance of the H2–H3 helices in
TCTP’s antiapoptotic function. Finally, we show that TCTP antagonizes apoptosis by inserting into the mitochondrial membrane
and inhibiting Bax dimerization. Together, these data therefore further confirm the antiapoptotic role of TCTP in vivo and provide
new mechanistic insights into this key function of TCTP.
Cell Death and Differentiation (2008) 0, 000–000. doi:10.1038/cdd.2008.18
Inhibition of apoptosis plays a key role in permitting and
favoring cell proliferation in malignant tissues.1 The char-
acterization of proteins that promote or inhibit apoptosis, and
the identification of their mechanism of action, constitute an
important step towards the understanding of programmed cell
death as a biological process and its implication in diseases.
Recently, translationally controlled tumor protein (TCTP) has
been suggested to function as an antiapoptotic protein in
cultured cells.2–7 Overexpression of TCTP resulted in an
inhibition of etoposide-induced apoptosis,3 whereas anti-
sense and siRNA knockdown experiments resulted in
increased apoptosis.5,7 It was more recently shown that
TCTP binds to MCL12,4,7 and Bcl-xL,6 both antiapoptotic
members of the Bcl2 family. However, the physiological
relevance of these data in vivo and the molecular mechanisms
through which TCTP protects cells from apoptosis remain
to be established. TCTP shares no sequence homology
with known antiapoptotic molecules nor it exhibits structural
features that could account for such an antiapoptotic
function.
TCTP is highly conserved in all eukaryotes and encodes
for a hydrophilic protein of 18–23 kDa8,9 that show no
sequence similarity with any other known proteins. TCTP
was discovered over 20 years ago in Ehrlich acites tumor
cells.10 Its name originates from the observation that TCTP
transcripts accumulate in resting cells and are rapidly
translated into the protein when the cells require it. The TCTP
protein is expressed at low levels in resting cells, and at
elevated levels in proliferating ones. TCTP expression in
proliferating yeast (Saccharomyces cerevisiae (S.cerevisiae))
rise for instance to 100 000 copies per cell, which is higher
than actin with 60 000 copies per cell.11 These data, in
addition to very recent genetic studies, suggest that beside its
antiapoptotic function TCTP may be required for cell growth
and proliferation. For instance, Drosophila TCTP was shown
to control cell growth and proliferation through regulation of
Rheb-GTPase activity.12 In addition to its role in the control of
cell survival and proliferation, TCTP was also reported to bind
tubulin,13 to serve as a substrate of Polo-like kinase 1 (Plk1),14
and to act as a histamine releasing factor.15
TCTP is overexpressed in most tumor cells and its
downregulation decreases the viability of those cells.5 Under-
standing the molecular mechanisms through which TCTP
acts as a pro-survival factor in normal and cancer cells is
therefore not only an interesting biological issue but it is also
relevant for cancer therapy.16 In the present work, we show
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that tctp functions as an antiapoptotic protein required for
mouse embryonic development. Moreover, we solved the
crystal structure of TCTP and found an interesting structural
similarity to channel-forming helices17 of the pro-apoptotic
protein Bax.18 This led us to explore one of the potential
mechanism by which TCTP exert its antiapoptotic function
and to propose that this is occurring by insertion of TCTP into
the mitochondrial membrane and inhibiting the dimerization of
Bax.
Results
tctp is required for cell survival and mouse embryonic
development. The murine tctp gene is located on
chromosome 14 and contains 6 exons.19 To generate a
tctp mutant mouse line, a loxP site was inserted 50 of exon 3
and two loxP sites flanking a neomycin resistant gene were
inserted 30 of exon 5 by homologous recombination in
embryonic stem (ES) cells (Figure 1a). Correctly targeted ES
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Figure 1 (a) Representation of the mouse wild-type and mutated tctp alleles and the targeting vector used to generate these alleles. F1, R1, F2, and R2 indicate the
positions of the primers used to discriminate between the various tctp alleles (see b and c). (b) PCR analysis on genomic DNA from wild-type (WT) and tctp heterozygous (þ /
D3–5) mice. The various primers used for the different PCRs are indicated (see Materials and Methods for their sequences) (c) PCR analysis on genomic DNA from wild-type
(þ /þ ) and tctp heterozygous (þ /D3–5) and homozygous mutant (D3–5/D3–5) embryos. (d) tctp-wild-type and -mutant embryos at different stages of development.
Hematoxylin–eosin staining of sections of paraffin-embedded E8.5 and E7.5 embryos are shown. Magnification:  4. (e) Hematoxylin–eosin (H&E) staining of sections of
paraffin-embedded E6.5 embryos is shown. Detection of apoptotic cells (red) was performed using TUNEL assay on sections of paraffin-embedded E6.5 embryos; the
sections were counterstained using DAPI (blue). Magnification:  20. (f) Western blot analysis of tctp protein expression in different organs (30 mg protein loaded) from wild-
type (wt) and tctp heterozygous (het) mice; anti-Actin is used as loading control. (g) tctp protein levels as determined by western blotting in freshly isolated thymocytes from
wild-type (wt) and tctp heterozygous (het) mice. The cells were either left untreated (NT) or were g-irradiated with 5 Gy or 10 Gy. Lysates were prepared 12 h after irradiation.
Anti-g-tubulin (g-tub) is used here as loading control
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clones (tctpNeoR/þ ) were obtained, as assessed by PCR
and Southern blot, and Cre-mediated excision of exons 3–5,
which encodes for most of the tctp protein, was achieved
upon electroporation of a Cre-recombinase expression
vector in those cells. One clone that showed proper
deletion of exons 3–5 (tctpD35/þ ), as identified by PCR
analysis, was used to establish a tctp mutant mouse line.
Mice were genotyped using a PCR-based approach using
primers F1, R1, F2, and R2 (Figure 1b and c).
Heterozygous mice for this mutation (tctpD35/þ ) are viable
and fertile. However, matings between heterozygous animals
produced no viable homozygous mutant offspring (F2),
indicating a recessive lethal phenotype (Supplementary Table
1).
Closer inspection revealed that most homozygous embryos
(tctpD35/þ –5) died in utero between 6.5 and 9.5 d.p.c. The
majority of the E6.5 and 100% of the E7.5 tctp-mutants
exhibited an overall growth deficiency, ranging from minor to
extremely severe (Figure 1d and e). No viable mutants were
observed beyond E9.5 (Supplementary Table 1).
To study the effect of the tctp mutation on cellular
proliferation, we measured in situ incorporation of 5-bromo-
20-deoxyuridine and expression levels of phosphorylated form
of histone H3, a marker of mitosis by immunohistochemistry.
The data indicate that the tctp-mutant cells proliferate to a
lesser extent compared to cells of the control embryos (not
shown). To determine if the growth deficit of tctp-mutant
embryos could also be accounted by an excess of apoptosis,
serially sectioned E6.5 embryos were analyzed by immuno-
histochemistry using an antibody specific to the cleaved form
of caspase-3 (not shown) and TUNEL analysis (Figure 1e).
These analyses revealed extensive cell death in the develop-
ing mutant embryos.
Western blot analysis using anti-TCTP antibodies detect
only one band at the expected molecular weight in protein
lysates from mouse embryo fibroblasts (MEFs) (not shown)
and various mouse organs (Figure 1f). In the lysates of
tctpD35/þ (het) animals, the TCTP signal is weaker in
intensity, indicating that the tctp protein is expressed at lower
levels in heterozygous tissues as compared to wildtype (wt)
(Figure 1f).
To test whether tctp is haploinsufficient in the control of cell
proliferation and/or apoptosis, we next measured the cell
proliferation capacity and/or the apoptotic response of MEFs
and thymocytes prepared from wildtype and heterozygous
tctp-mutants to various stress conditions. tctpD35/þ MEFs
proliferated at the same rate in culture and underwent
senescence similarly to wildtype controls (not shown). They
also exhibited a similar cell cycle distribution and apoptotic
response upon UV-C or doxorubicin exposure (not shown).
We next measured apoptosis in freshly isolated thymocytes
after g–irradiation and dexamethasone (Dex) treatment.
Susceptibility to cell death following DNA-damage in these
cells is p53-dependent, whereas apoptosis in response to
glucocorticoids (such as Dex) occurs independently of p53.
Again, wild-type and heterozygous thymocytes were similarly
sensitive to these treatments (not shown). Interestingly,
however, we noticed a significant and dose-dependent
decrease in TCTP levels in these cells following g–irradiation
(Figure 1g). Together, the data indicate that tctp is required for
the survival and proper proliferation of cells during mouse
embryonic development. Even if tctp levels are reduced in
cells from heterozygous mice, tctp is not haploinsufficient in
the control of cell proliferation and apoptosis. Finally, in
response to DNA-damage, tctp steady state protein levels
dramatically decrease in primary thymocytes, concomitantly
with the onset of apoptosis.
The three-dimensional structure of human TCTP. The X-
ray structure of human TCTP has been solved and refined at
2.0 A˚ resolution (Supplementary Table 2). Phases were
obtained by molecular replacement, using the coordinates of
Schizosaccharomyces pombe (S.pombe) TCTP (PDB code:
1H7Y) as a probe. The crystallographic asymmetric unit
contained four TCTP molecules and 508 water molecules.
The X-ray structure of human TCTP confirms a common
TCTP fold described previously for S. pombe TCTP.20 The
structure contains three a-helices (H1, H2, H3) and nine b-
strands arranged in two distorted b-sheets, forming two
hydrophobic cores (Figure 2). A a-helical hairpin is formed by
the two long helices H2 and H3 and protects one face of the
central b-sheet. In each subunit, a polypeptide
encompassing residues 39–66 is not visible in the electron
density map, but certainly protrudes out of the opposite side
of the core b-sheet and is presumed to be disordered. In S.
pombe TCTP, this portion was shown by NMR spectroscopy
to be highly mobile.21 As noted previously, the TCTP fold has
structural similarities with two other proteins: the guanine
nucleotide-free chaperone Mss420 and the methionine
sulfoxide reductase gene B (MsrB).22 However, the
biological significance of these structural similarities
remains unclear.
Comparison of the structure of human TCTP with those of
proteins in the Protein Data Bank using DALI yielded a
number of other interesting similarities. In particular, the pair
of helices H2–H3 bear structural resemblance to the
transmembrane domains of the diphtheria toxin and bacterial
colicins23 and to the pair of helices H5–H6 in Bcl2 family
proteins17,24–27 such as Bax,18 despite negligible amino acid
homology. It should be noted that there is no striking amino
acid homology between the members of the Bcl2 family in the
domain encompassing these H5–H6 (or H6–H7) pore-forming
helices but, only a structural similarity.
Besides these two helices, the rest of the protein structure
of the Bcl2 family members, including the Bcl2 Homology
domains, fit within a common fold, which is not the case for
TCTP.
Mutations in helices H2–H3 of human TCTP modify its
antiapoptotic function. To investigate whether helices H2–
H3 participate in the antiapoptotic function of TCTP, 293T
cells were first incubated in the presence of staurosporine,
and the levels of TUNEL-positive cells and the extent of
PARP cleavage were monitored. TCTP decreases both the
levels of TUNEL-positive cells (Figure 3a) and the extent of
PARP cleavage (Figure 3b) induced by staurosporine.
Strikingly, TCTP also significantly inhibits Bax-induced
apoptosis in 293T cells (Figures 3b and d–f) and in N2A
cells (data not shown).
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We then investigated the effects of mutations of residues
(E109 and K102) close to the turn between the two helices H2
and H3 of TCTP (Figure 4). A mutation of the hairpin residue
E109 to alanine alters slightly the effect of TCTP on
staurosporine-induced apoptosis, while a mutation of K102
to alanine significantly diminishes the effect (Figure 3a and c).
NPG_CDD_4402333
a b
Figure 2 The crystal structure of human TCTP. Two different orientations of the molecule are presented showing the two distorted b-sheets in green and yellow and the
three a-helices in red. Residues 39–66 belong to a highly mobile polypeptide segment and are not visible in the final electron density map
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Figure 3 Mutations in helices H2–H3 of human TCTP decrease its antiapoptotic activity against staurosporine- or Bax-induced apoptosis. (a) TUNEL analysis of 293T
cells incubated with staurosporine alone, with staurosporine and TCTP or with staurosporine and TCTP mutants. TCTP-EK denotes the double mutation of E109 and K102 to
alanine. (b) Western blot analysis of PARP cleavage in 293T cells following staurosporine- or Bax-induced apoptosis in the presence and absence of TCTP. (c) Western blot
analysis of PARP cleavage in 293T cells following staurosporine-induced apoptosis in the presence and absence of TCTP or TCTP mutants. TCTP-E denotes the E109A
mutation; TCTP-K denotes the K102A mutation; TCTP-EK denotes the double mutation of E109 and K102 to alanine. (d) TUNEL analysis of 293T cells incubated with Bax
alone or with Bax and TCTP. (e) Western blot analysis of PARP cleavage in 293T cells following Bax-induced apoptosis in the presence and absence of TCTP. (f) Western blot
analysis of PARP cleavage in 293T cells following Bax-induced apoptosis in the presence and absence of TCTP or TCTP mutants. (Same mutants of TCTP as described in c)
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The effect of the double mutation of E109 and K102 is identical
to the effect of the K102A mutation alone. Both single mutants
and the double mutant diminish the antiapoptotic effect of
TCTP on Bax-induced apoptosis (Figure 3f). Since the helices
H2–H3 of TCTP appear to play a role in the protein’s
antiapoptotic activity, we wished to investigate the effect of
replacing helices H5–H6 of Bax by helices H2–H3 of TCTP on
the induction of apoptosis. The chimeric protein, BTB (Bax/
TCTP H2–H3/Bax), expressed in 293T cells has a strong pro-
apoptotic function, comparable to that of wild-type Bax as
assessed both by levels of TUNEL-positive cells (Supple-
mentary Figure 1a) and the extent of PARP cleavage
(Supplementary Figure 1b). The double mutation in BTB of
both residues (K126 the residue corresponding to K102 in
TCTP and E133 the residue corresponding to E109 in TCTP)
to alanine resulted in a significant reduction in pro-apoptotic
strength.
The antiapoptotic function of TCTP occurs at the
mitochondria where it inhibits Bax-induced
damage. To establish whether or not the antiapoptotic
activity of TCTP takes place at the level of the
mitochondria in the above experiments, we used an
acellular system of purified mitochondria.28 The purified
mitochondria were directly incubated (Figure 5a) with the
in vitro translation (IVT) products of the proteins. The insert in
Figure 5a shows the expression of the proteins added. In
these assays (Figure 5a, Supplementary Figure 2), TCTP
inhibits mitochondrial damage induced by Bax, while the
double mutant of TCTP in which both E109 and K102 are
replaced by alanine is much less efficient in inhibiting Bax-
induced damage. These results agree well with those
obtained by monitoring levels of TUNEL-positive cells and
the extent of PARP cleavage and suggest that the
antiapoptotic function of TCTP takes place, at least in part,
in the mitochondria, with TCTP inhibiting the function of Bax.
TCTP anchors into the mitochondria and inhibits the
dimerization of Bax. We further tried to identify how TCTP
would ‘neutralize’ the apoptotic effect of Bax. We first
investigated whether wild-type or mutant TCTP binds
directly or indirectly Bax. Neither a GST-IVT pull down nor
a coimmunoprecipitation of endogenous or overexpressed
Bax and TCTP yielded any positive results (data not shown),
in agreement with previous reports suggesting that there was
no direct interaction between TCTP and Bax.4,7 To further
evaluate the potential role of TCTP at the level of the
mitochondria, we assessed the anchorage of TCTP into the
mitochondrial membranes. For that purpose, freshly isolated
mitochondria were incubated in the presence of recombinant
TCTP and treated with Na2CO3, which eliminates loosely
bound proteins and spare anchored proteins into the
membranes. Figure 5b shows that approximately 0.25 pmol
TCTP or TCTP-EK (lanes 2, 3) do anchor into 125mg of
mitochondria. This amount represents less than 1% of the
total amount of recombinant TCTP that was allowed to
incubate in the presence of the mitochondria. 0.5–20 pmol
TCTP were also loaded on the same western blot to allow a
NPG_CDD_4402333
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Figure 4 The three-dimensional structures of (a) human TCTP and (b) the pro-apoptotic protein Bax (PDB code: 1F16). The a-helical hairpin (shown in red) common to
the two structures is displayed here in a similar orientation. (c) Alignment of the two helical hairpin residues of TCTP (H2, H3) and BAX (H5, H6). The position of the mutated
residues is indicated (conserved residues are highlighted in pink)
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quantitative comparison. No difference between TCTP and
TCTP-EK could be detected with regard to their anchorage
capacity into the mitochondria. The anchorage of proteins into
the mitochondrial membrane is a well regulated process.29 As
documented in Supplementary Figure 3, Bax anchors into the
mitochondrial membrane only when activated by tBid. tBid
binds loosely, is sensitive to alkali treatment and thus is not
anchored into the mitochondrial membrane.29
We then analyzed whether the anchorage of TCTP could
interfere with pro-apoptotic function of Bax. Figure 5c (left
panel) indicates that increasing amounts of TCTP do not
inhibit the anchorage of Bax monomers but do inhibit the
dimeric form of anchored Bax. On the other hand, TCTP-EK
(Figure 5c right panel) does not inhibit the formation of this
dimeric form indicating that intact helices of TCTP are
necessary to interfere with the dimerization process of Bax
when already anchored into the mitochondrial membranes.
tBid and TCTP (or TCTP-EK) alone do not generate any Bax
signal (data not shown). To consolidate the fact that the 30–
35 kDa band, recognized by the polyclonal rabbit anti-Bax
antibodies, corresponds to a dimeric form of Bax, we
performed a trypsin digestion assay. Trypsin digestion is
highly efficient on a wide variety of proteins among which is
the monomeric form of Bax. In contrast, the dimeric form of
Bax is resistant to complete digestion by trypsin, sparing a
fragment of 15 kDa that is recognized by this antibody which
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Figure 5 TCTP protects the mitochondria against Bax. (a) Analysis of the integrity of the outer mitochondrial membrane (rat liver). The cellular fraction of purified
mitochondria was placed in the presence of the in vitro translation (IVT) products of TCTP, Bax, Bax and TCTP or Bax and TCTP-EK. Mitochondria alone (Mito). Retic. lysate
alone (Retic).The oxidation of cytochrome c was used as a marker of mitochondrial damage. Inset: SDS-PAGE showing IVTs. (b) Anchorage of TCTP into the mitochondria.
Western blot analysis of TCTP (left panel) and TCTP-EK (right panel) anchorage onto the mitochondria. Lane 1: mitochondria (125mg), lanes 2 and 3 mitochondria (125 mg)
incubated in the presence of 100 pmol TCTP (left panel) or TCTP-EK (right panel), washed and treated with Na2CO3. Increasing amounts of TCTP (left panel) or TCTP-EK
(right panel) were loaded to evaluate quantitatively the anchorage. (c) Bax dimerization. Western blot analysis of Bax anchorage into the mitochondria after treatment by
increasing amounts of TCTP (left panel) or TCTP-EK (right panel). Lane 1: no treatment, lanes 2, 3 and 4 respectively treated with 5, 10 and 20 nM of TCTP (left panel) or
TCTP EK (right panel). Arrows indicate Bax monomer (Bax mm) or Bax dimer (Bax dm). (d) Trypsin digestion assay. Western blot analysis of Bax anchorage into the
mitochondria without (lane 1) or after trypsin digestion (lane 2)
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was directed against a synthetic peptide corresponding to
amino acids 43–61 of human Bax (Figure 5d lane 2) (Lucken-
Ardjomande S, Montessuit S, and Martinou JC. Cell Death
Differ (in press)). Monoclonal anti-Bax antibodies directed
against amino acids 3–16 of Bax do not recognize this 15 kDa
undigested peptide, since this region has been digested by
trypsin (data not shown). Nevertheless this assay does not
allow discrimination between a homo- or heterodimeric form of
Bax.
Discussion
Since the discovery of TCTP by Yenofsky, it became clear that
this protein is implicated in multiple biological processes
(Figure 6a) such as cell growth, division, proliferation, and
inhibition of programmed cell death.2–14,16 It also functions as
a histamine releasing factor15 and is secreted through the
non-classical exosome pathway interacting with TSAP6, a
p53-regulated gene.30,31 It seems that all these different
functions of TCTP are related to specific association with
various protein partners. The cell growth regulatory function of
TCTP is related to its guanine nucleotide dissociation inhibitor
activity for the elongation factors EF1A and EF1Bb.32 We
previously suggested that by inhibiting the dissociation of
GDP from these two components of the translational
machinery, TCTP would slow down the elongation process,
this way avoiding ‘skipping’ and finally rendering elongation
more efficient. A second observation implicating TCTP in cell
growth, was recently made through the study of Drosophila
TCTP genetics.12 This study shows that TCTP would regulate
the TSC1 and TSC2 pathway where it would function as a
GEF-like protein for Rheb. Being upstream of the mTOR
pathway, would place TCTP in a strategic position for
regulating cell growth. It is however difficult to reconcile these
Drosophila results with the yeast, where TSC1 and TSC2 do
not exist and where Rheb does not appear to function in
mTOR pathway; despite highly elevated levels of TCTP. It is
interesting to note that TCTP would be implicated in the
processes cell growth, proliferation and survival since this
relates so closely to the TSC1, TSC2, mTOR pathway.
Regardless of the mechanism involved, the data presented
herein confirm an important contribution of TCTP in the control
of cell growth and proliferation. Embryos lacking tctp fail to
grow and mutant cells to proliferate.
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Figure 6 (a) The different functions of TCTP and their potential mechanism of action. (b) Schematic representation of the potential antiapoptotic mechanism of TCTP
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The crystal structure of human TCTP is highly similar to that
of TCTP from S. pombe, confirming the common fold
expected from the sequence homology.20 As noted pre-
viously, TCTP shows structural homology to Mss4, a protein
originally described as guanine nucleotide exchange factor for
Rab proteins but later identified as a guanine nucleotide-free
chaperone.33 Mss4, however, lacks helices H2–H3, contains
a zinc-binding site absent in TCTP and differs in the
topological placement of a small b-sheet and a long mobile
loop.20 Despite a common core fold, these structural
differences and the lack of any clear evidence for functional
similarities weaken the suggestion that TCTP and Mss4
families of proteins are related. Similarly, the structural
homology with MsrB22 does not seem to extend to any
common function, since the catalytic residues of MsrB are
absent in TCTP.
Structural analysis of TCTP and members of the Bcl2 family
yields some insight into possible mechanisms for the control
of apoptotic processes. The structure of Bcl-xL25 revealed a
similarity between its H5–H6 and the channel-forming
domains of diphtheria toxin and bacterial colicins A and
E1.23 With the determination of a number of structures of
proteins from the Bcl2 family,17 it has become clear that pro-
and antiapoptotic members of the family have similar folds
with the central core helices H5–H6 flanked by the other a-
helices and function as regulators of the mitochondrial
membrane permeability where they would influence the
opening of specialized pores.17,24–27 It is presumed today
that the balance between the pro-apoptotic and the anti-
apoptotic will define the level of permeability of those pores
rather than the helices creating the pores. The crystal
structure of TCTP reveals a similar pair of helices and we
have sought here to characterize the role of these helices in
the antiapoptotic function of the protein.
It has been inferred that TCTP is antiapoptotic since
decreasing its protein levels leads to apoptosis or reversion
of malignant phenotypes.2–7 Importantly, TCTP has been
shown to bind to MCL12,4,7 and Bcl-xL,6 both antiapoptotic
members of the Bcl2 family. TCTP is therefore closely
associated with apoptotic processes. We show here that loss
of tctp expression results in a dramatic increase in apoptotic
cell death during embryogenesis. This phenotype, together
with the proliferation defect observed in these mutants, is
sufficient to explain why the tctp-null mice die early during
embryogenesis. Of note, another tctp-mouse model has
recently been generated and the data reported34 are in
keeping with these observations. Together, these genetic
data clearly highlight a critical role for tctp in the control of cell
survival in vivo. Moreover, mutagenesis of residues in helices
H2–H3 of TCTP reduces its antiapoptotic function. The
creation of a chimeric protein, BTB, in which the helices H2–
H3 of TCTP replace helices H5–H6 of Bax, does not disrupt
the pro-apoptotic function of this Bcl2 family protein. Muta-
tions in BTB corresponding to those made in TCTP do
however disrupt this activity. Together these results show that
the pair of helices function equally well in the context of a pro-
or antiapoptotic protein, and that mutations diminish this
activity. It may therefore be that the precise molecular event in
which the pair of helices participates is similar in the context of
TCTP or BTB. Sequence homology for these helices is low
even between members of the Bcl2 family, although the
helices are structurally and functionally conserved.17,24–27 As
a result, the helices are excluded from the definition of the Bcl2
homology domain,1 yet the similarity found here suggests a
structural feature common to a set of proteins involved in
apoptotic processes.
Previous immunofluorescence data suggested that TCTP
colocalizes with Bcl-xL and MCL1 and therefore acts as the
mitochondria, similarly to other key regulators of apoptosis.
However, the high abundance of TCTP in the cytoplasm
renders interpretation of those data rather complicated. For
this reason we used a purified fraction of mitochondria to
perform our experiments. Our data indicate that TCTP
antagonizes the function of Bax and requires its pair of
helices to participate in antiapoptotic activity at the level of the
mitochondria. Nevertheless, it is clear that those H2–H3
helices are not per se required for the binding and anchorage
of the protein into the mitochondria as revealed by the mutant
TCTP-EK, which binds and anchors as efficiently as wild-type
TCTP to the mitochondria. There are at least two possible
interpretations to explain this weakening of mutant TCTP. It is
possible that while the amount of TCTP and TCTP-EK protein
binding and anchoring in the mitochondria remain similar, the
conformation of the protein in the membrane and its binding to
MCL1 and Bcl-xL would be affected. It is also possible that the
mutation of these helices would impair to some extent the
dimerization of TCTP.
The ‘rheostat’ model suggests that the balance between
pro- and antiapoptotic members of the Bcl2 family determines
the fate of a cell. However, this model is not sufficient to
explain our results because TCTP does not bind directly to
Bax (Liu et al., 20054; Zhang et al., 20027; our results). We
therefore propose that TCTP would bind antiapoptotic
members of the Bcl2 family, as described for MCL12,4,7 and
Bcl-xL,6 and possibly arrange them in such a way into the
mitochondrial membranes that their antiapoptotic action
would be more efficient. We suggest that this is the ‘enhancer’
part of the model that would regulate the efficiency of the
‘rheostat’. Furthermore, we suggest that TCTP would anchor
into the mitochondrial membrane and inhibit the formation of
dimeric Bax. One possible interpretation of this would be that
TCTP, following its anchorage into the membrane, would
separate and distance Bax homodimers (Figure 6b), but this
necessitates further investigation.
Materials and Methods
Generation of tctp knockout mice and genotyping. Genomic DNA
was prepared from 129/Svj ES cells using established procedures. PCR was
performed using expand long template (Roche, France) in buffer 1 following
manufacturer’s recommendations.
Three fragments (a, b and c) overlapping 8,8 kb of the genomic region containing
the murine tctp gene on chromosome 14 were amplified using following primers:
F(a) 50-GATGCGGCCGCCTGTCCATTAGAGTACCGG-30,
R(a) 50-CTCGATATCCCTGAAACATCTTAACCTACC-30,
F(b)50-AGGGATATCGAGCTGACTGATCGTTGCCGG-30
R(b) 50-TTCGGATCCCACAGTTATTATACAACCCTT-30
F(c) 50-GTGGGATCCGAAAAAGTCTGTTTGCTGTCT-30
R(c) 50-CTCGTCGACGGGGGCGTTGCTCACTGAGAG-30
These 3 amplicons were cloned in a pBluescript (pBS) vector digested NotI/SalI.
One 46 bp oligonucleotide containing a LoxP site floxed by 2 EcoRV sites and one
neomycin resistance gene with one LoxP site at each end were cloned respectively
NPG_CDD_4402333
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in 50 of exon 3 and in 30 of exon 5. This construct was linearized and injected into
C57Bl6 ES cells to obtain recombinant mice in which the exons 3, 4 and 5 upon Cre-
mediated recombination.
Genotyping was performed on genomic DNA from mouse tails or yolk sacs. A
PCR-based strategy was developed to distinguish between the wild-type and tctp
mutant alleles. The primers are as follows (see Figure 1a):
F1 50-GAGTGACCACCTCTCTCAGTCC–30
R1 50-AACACCGGTGACTACTGTGCTTTCG–30
F2 50-GGGAGTGCAGCAGTGATTCTTTGCC–30
R2 50-AAGGCACTGTCTCCACCAGTCCC-30
When primers F1, R1 and R2 are used in the same reaction (see Figure 1c), a
423 bp fragment indicates the presence of the mutated allele (tctpD3–5), whereas
300 bp fragment is amplified from the wild-type allele (see Figure 1b).
Mouse embryo fibroblasts were prepared from 12.5-days-old embryos using
established procedures. Cells and organs were lysed in hypertonic buffer (50 mM
Tris–HCl pH 7.5, 250 mM NaCl, 10 mM EDTA, 1 mM DTT and 1% NP40).
Histology. For sectioning, embryos were fixed in 4% paraformaldehyde/1
PBS overnight, paraffin embedded, sectioned and stained in hematoxylin and eosin.
Immunohistochemistry and TUNEL assay. The following antisera were
used: anticleaved caspase-3 (1/200, Cell Signaling); antiphosphorylated histone-H3
(PH3) (1/200, Upstate). Avidin-conjugated peroxidase (ABC and DAB kits from
Vector Laboratories) was used for immunodetection. TUNEL assay was used to
detect apoptotic cells on sections of paraffin-embedded embryos using the ‘In Situ
Death Detection Kit’ (TmR red, Roche). After TUNEL staining, embryo sections
were counterstained and mounted using Vectashield with DAPI (Vector H-1200).
Crystallization and data collection. Initial crystallization conditions were
found by screening different precipitating agents. Different crystal forms were
crystallized by the hanging drop vapor-diffusion method at 41C using polyethylene
glycol (PEG) 5000 MME as the crystallization agent. Crystallization trials were set up
using equal volumes of protein (concentrated to 3 mg/ml) and reservoir. The best
crystals were grown against a reservoir containing 25% PEG 5000 MME, 50 mM Bis
Tris (Bis(2-hydroxyethyl) iminotris (hydroxymethyl) methane) buffer pH 6.2, 50 mM
magnesium acetate and 3% 1,6-hexanediol. These crystals diffracted beyond 2.0 A˚
resolution at the European Synchrotron Radiation Facility ID14-1 beam line, and
belong to the monoclinic space group P21, with unit-cell parameters a¼ 63.8,
b¼ 93.7, c¼ 70.4 A˚, ¼ 114.9. A complete data set was obtained from a single
crystal cooled to 140 K from 150 frames of 11 oscillation (wavelength of 0.934 A˚,
crystal-detector distance of 180 mm) using an ADSC Q4R CCD detector. The
estimated Vm of 2.3 A˚
3/Da indicates four molecules of TCTP in the asymmetric unit
and corresponds to a solvent content of 47%, assuming a protein density of 1.22 g/
cm3. Data were processed with the package HKL2000.35
Structure determination. The structure of human TCTP was solved by the
molecular replacement method (Program MOLREP, AMoRe supplemented in
CCP436) using the NMR coordinates of S. pombe TCTP (PDB code: 1H7Y). The
refined model contains four human TCTP molecules of 155 residues (residues 39–
66 are not visible in the final electron density map) and 508 water molecules. The
crystallographic R-factor is 19.1% using all reflections between 25 and 2.0 A˚ with no
sigma cutoff (Rfree¼ 23.8%, using a random sample containing 7.5% of the data).
The models were refined with the CNS program,37 using the Engh and Huber
stereochemical parameter set. All rebuilding and graphics operations were done
with O and related Uppsala programs.38 All crystallographic calculations were
carried out with the CCP4 package.36 The stereochemistry of the model was
inspected using Procheck39 and the quality of the refined structure was assessed
using the Biotech validation suite for protein structures.40 In each monomer, 92.9%
of the residues are in the most favored regions of the Ramachandran plot (7.1% in
additional allowed regions). Data collection statistics and refinement statistics are
presented in Supplementary Table 2.
Coordinates of human TCTP at 2.0 A˚ resolution have been deposited in the
Protein Data Bank (accession code: 1YZ1).
Figures were prepared with PyMOL (Delano Scientific, http://www.pymol.org)
and TeXshade.
Expression constructs and mutagenesis. The coding regions of
human Bax-a and human TCTP were cloned into the EcoRI and XhoI sites of
the plasmid vector pCDNA3.1. (Invitrogen), with a HA tag and a Flag tag
respectively. BTB was obtained by replacing Bax H5 and H6 helices by TCTP H2
and H3 helices.
BTB sequence:
MDGSGEQPRGGGPTSSEQIMKTGALLLQGFIQDRAGRMGGEAPELALDPVP
QDASTKKLS
ECLKRIGDELDSNMELQRMIAAVDTDSPREVFFRVAADMFSDGNFNTGKEAY
KKYIKDYM
KSIKGKLEEQRPERVKPFMTGAAEQIKHILRTGWIQDQGGWDGLLSYFGTPT
WQTVTIFV
AGVLTASLTIWKKMG*
This BTB sequence corresponds to the following construction: BAX1106, TG,
TCTP85126, RT, BAX150192. The TCTP insert has been underlined in the BTB
sequence above.
TCTP mutants TCTP-E109A, TCTP-K102A, TCTP-EK and BTB mutants BTB-
E133A, BTB-EK were obtained using QuickChange site-directed mutagenesis
(Stratagene) following the manufacturer’s protocol. All mutants were confirmed by
automated DNA sequencing.
Purification of recombinant protein. Full-length TCTP cDNA was cloned
in-frame in the pGEX-6P vector (GE Health Care). Expression of the GST-fusion
protein in BL21 (DE3) bacteria strain (Stratagene) was induced by the addition of
0.1 mM IPTG for 16 h at room temperature. Cells were lysed for 30 min in a 1%
Nonidet P-40 buffer (10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 1 mM
EDTA, plus the protease inhibitors 1 mM AEBSF, 1% aprotinin, 1 mM leupeptin, and
2 mM pepstatin (all reagents from ICN)). The lysates were clarified by sonication
and centrifugation (16 000 g) for 30 min at 41C, and the GST-fusion protein was
purified with glutathione-sepharose beads (GE Health Care). The beads were
washed three times with the 1% Nonidet P-40 buffer and TCTP protein was cleaved
from GST tag by Prescission protease (GE Health Care). The quality of the purified
protein was assessed by SDS-PAGE and Coomassie blue staining. The purified
protein was dialyzed and stored at 41C in 50 mM Hepes pH 7 and 100 mM NaCl.
Cell culture. 293T cells were maintained in DMEM containing 10% (v/v) FBS
and 1% (v/v) penicillin–streptomycin–glutamine. 293T cells were transiently
transfected by the calcium phosphate method. In all experiments, carrier DNA
was added to maintain equal plasmid concentrations between different samples.
Antibodies. Rabbit anti-TCTP antibodies were generated against the human
protein TCTP. The corresponding polyclonal antiserum was affinity-purified on a
column coupled with the protein (Agro-Bio). This antibody is used at a 1/4000
dilution in western blot analysis. Goat anti-Actin I19 antibody (Santa Cruz
Biotechnology) or mouse monoclonal anti-g-tubulin (SIGMA) was used at 1/1000 for
equal loading. Secondary antibodies, antigoat, antirat, antirabbit or antimouse HRP-
linked (Calbiochem) were used at a 1/5000 dilution. Anti-cytochrome c (6H2) and
anti-Smac (V17) (Santa Cruz Biotechnology), anti-HA (Babco), anti-Flag (M2,
Sigma), anti-PARP (C2.10, ICN), anti-MTCO1 (ab14705, abcam), anti-Bax
(Pharmingen).
Flow cytometry. The TUNEL assay was performed using an In Situ Cell Death
detection kit (Roche Applied Science) according to the manufacturer’s instructions
and cells were analyzed in a FACScan cell sorter (Becton Dickinson).
Binding of TCTP to the mitochondria and cytochrome c oxydase
assay. Mitochondria were isolated28 from normal rat liver using a mitochondria
isolation kit (Sigma Aldrich). For mitochondrial targeting assays, [35S]Met-labeled
proteins (GE Health Care) were synthesized from cDNAs using the TNT-coupled
Transcription/Translation system (Promega, France). Radio-labeled Bax, TCTP,
TCTP-EK, were incubated with isolated mitochondria (2.5 mg proteins/ml) at 301C
for 1 h in 40ml of standard import buffer (250 mM sucrose, 80 mM KCl, 10 mM
MgCl2, 10 mM malic acid, 8 mM succinic acid, 1 mM ATP-Mg
2þ , 20 mM MOPS, pH
7.5). Where indicated, 35S-Bax was pre-incubated with radiolabeled TCTP or TCTP-
EK for 30 min prior to incubation with mitochondria. The integrity of the outer
membrane was assessed by measuring cytochrome c oxidase activity in
mitochondrial membranes in the presence and absence of a detergent, n-
dodecyl-D-maltoside, one of few detergents that allows the cytochrome c oxidase
dimer to be maintained in solution at low detergent concentrations. The ratio
between activity in the presence and absence of the detergent is a measure of the
integrity of the mitochondrial outer membrane. The assay was performed using a
cytochrome c oxidase assay kit (Sigma), according to the manufacturer’s
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instructions. Alternatively, cytochrome c was detected in the supernatant of the
mitochondria by western blot analysis using anti-cytochrome c antibodies.
Anchorage assay of TCTP into the mitochondrial
membrane. Mitochondria were purified from rat liver by differential
centrifugation. 125mg of freshly prepared mitochondria were incubated in the
presence of 5–20 nM recombinant TCTP or TCTP-EK at 301C for 10 min. Samples
were washed and treated with Na2CO3 followed by centrifugation at 100 000 g for
1 h.29
Bax dimerization assay. Mitochondria preparation and incubation with
TCTP (20 nM) or TCTP-EK (20 nM) were performed as above. Hereafter,
recombinant tBid (5 nM) was added for 5 min at 301C, followed by an incubation
with recombinant Bax (10 nM) for 7 min at 301C. Na2CO3 treatment was performed
as above followed by western blot analysis.
Trypsin digestion assay. 250mg of freshly prepared mitochondria were
incubated in the presence of Bax (100 nM) and tBid (10 nM) for 10 min at 301C and
treated with Na2CO3 as above. Samples were resuspended in 50ml KCl buffer and
10mg of trypsin was added. Digestion occurred for 2 h at 301C and analyzed by
western blot using the polyclonal rabbit antibody directed against the amino acids
43–61 of human Bax (Pharmingen) (Lucken-Ardjomande S, Montessuit S, and
Martinou JC. Cell Death Differ (in press)). This antibody detects the undigested
15 kDa fragment of Bax dimers.
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